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Introduction 
INTRODUCTION 
In the past century treatment and primary prevention of disease has focussed on de-
creasing mortality rates (Wolleswinkel-van den Bosch, 1998). The current challenge is 
directed towards secondary prevention. Screening for disease is becoming increasingly 
part of medical practice in the Western world. Screening for cervical cancer with PAP 
smears and for lung cancer with chest X-rays were the first examples of cancer screen-
ing that were expected to reduce mortality (Boucot, 1948; Papanicoulou and Traut, 
1941; Victor, 1955). Although many in the medical profession had great expectations 
there were also opponents, at least for lung cancer screening (Boucot and Sokoloff, 
1955). The natural course and the screening tools (chest X-rays) available for the detec-
tion of lung cancer seemed not to be able to detect the cancer in a phase where treat-
ment resulted in substantially improved prognosis. The resuits of clinical trials, pub-
lished approximately 30 years later, showed no overall decrease in lung cancer mortal-
ity and screening for lung cancer never became established as a public health service 
(Early Lung Cancer Cooperative Study, 1984). For cervical cancer however, the charac-
teristics of screen test in combination with the natural history of the disease (I.e. the 
long duration of the screen detectable period), is estimated to reduce mortality by 75% 
(100% attendance of screening) (van Ballegooijen, 1998). Evidence about the effective-
ness of cervical cancer screening is provided by historical studies, case-control studies, 
analysis of data from large screening programmes and analysis of the natural history of 
cervical cancer using mathematical models. 
Mammography as a screening tool with acceptable test characteristics was devel-
oped in the sixties (Gershon-Cohen et a/., 1961). At that time, testing new techniques 
in Randomised Clinical Trials had become common practice. This explains why the 
estimates of the effectiveness of breast cancer screening were much more evidence 
based than those of cervical and lung cancer screening. 
In figure 1.1 the conceptual framework of screening is depicted. For lung cancer, 
because the pre-clinical detectable stage (B-C) is so short and lacks a suitable test to 
detect the disease early, no improvement in prognosis can be achieved. For breast and 
cervical cancer, screening by mammography and cervical smears can detect and treat 
the disease, while it is still in the pre-clinical phase. This resuits, on average, in im-
proved prognosis if treated and thus prevents deaths from the disease. 
For breast cancer, national screening programmes have been introduced in the Nether-
lands and in many European countries (Fracheboud et a/., 1998; Shapiro et a/., 1998). 
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disease A B C D process 
----~---.~--------_r~------~-+----
primary prevention secondary prevention tertiary prevention 
patient 
behaviour 
A-B: 
B: 
B-C: 
C: 
D: 
E: 
E T' 
period of increased risk 
first detectable patho-fysiologic change 
pre-clinical detectable stage 
first symptoms andlor signs 
F 
stable outcome (partial or complete recovery or death) 
moment of early detection 
T 
F: 
T: 
moment when patients will seek medical advice because of signs or symptoms 
time of onset of therapy 
Tf: 
E-F: 
onset of therapy after early detection 
lead time 
C-F: "patient delay" 
E-T' and F-T: period of diagnostic procedures and doctors' delay 
Figure 1.1 
Conceptual frame work of screening, the disease process and patient behaviour 
Table 1.1 
Favourable and unfavourable effects of introducing cancer screening 
Favourable effects 
Cancer mortality reduction 
Prevention of advanced disease 
Less intensive treatment1 
Cost savings 
1 in the case of breast cancer 
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Unfavourable effects 
Lead time (years) 
Attending screening (pain, anxiety, false 
positive results) 
Overdiagnosis 
Costs 
Secondary effects of screening (e.g. radiation 
risk1, opportunistic screening) 
Introduction 
Swedish randomised trials have shown that a breast cancer mortality reduction of ap-
proximately 30% can be achieved by mammography for women aged 50-69, of whom 
70% attend the screening (Nystrom et a/., 1993). The favourable outcome of a trial with 
regard to mortality is however not a guarantee of a successful nation-wide screening 
programme. Before the introduction of a screening programme in the total population, 
all positive and negative effects of screening for population health status should be 
quantified. In table 1.1, these favourable and unfavourable effects are summarised. The 
current state of health care relating to the disease, i.e. no available screening pro-
gramme is the baseline for a comparison with a situation where screening is available. 
The advantage of evaluating screening programmes and other health care facilities 
using a uniform outcome measurement (cost per Quality adjusted life year saved) en-
sures that the outcomes of health services can be compared and provides relevant in-
formation for assisting health policy priorities. The consequences for population health 
status can therefore be better assessed. This is currently, especially relevant as technical 
developments are resulting in new diagnostic tools and thus new possibilities for early 
detection. Because of a limited health care budget a uniform outcome is expected to 
facilitate considerations on the introduction of both screening programmes and new 
curative treatments. 
New challenges for cancer screening are in the area of colorectal cancer, mela-
noma and prostate cancer. Screening is, in regard to these diseases still however in a 
process of development. There are many questions that have to be resolved, before 
policy makers can decide about the introduction of these programmes. In this thesis the 
differences in the phase of evaluation between two cancer-screening programmes 
(breast cancer and prostate cancer) are used to illustrate aspects of the evaluation of 
cancer screening programmes. 
EVALUATION OF BREAST CANCER SCREENING 
In the Netherlands a thorough evaluation of all effects and costs in the total female 
population was carried out before the decision to introduce screening as a public 
health service was made, (de Koning, 1993). This cost-effectiveness analysis was also 
used to determine the most appropriate age group and screening interval (de Koning et 
a/., 1991). The MISCAN (Mlcrosimulation SCreening ANalysis) programme takes into 
account all favourable and unfavourable effects of the introduction of screening using 
the situation where no screening programme exists, as a reference (Habbenla et a/., 
1985; van Oortmarssen et a/., 1990). 
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Using the computer simulation package MlsCAN, individual life histories are gen-
erated, representing the demography, mortality of all causes and incidence and mortal-
ity from breast cancer. In the disease part of the programme the relevant stages of breast 
cancer are discerned and the natural history is simulated as a progression through these 
stages. Key parameters in the model of the performance of screening are mean duration 
of screen·detectable preclinical disease, sensitivity and improvement of prognosis for 
screen detected cancers. Changing one of the input parameters, e.g. sensitivity of the 
screening, age group or interval enables the evaluation of the impact of different sce-
narios. 
Some examples of evaluation issues that were (in part) studied in this thesis, in the 
phase after the introduction of screening programme as a national health care service in 
the Netherlands, are described below. An important question in regard to screening 
evaluation is whether the results of cost-effectiveness analyses in one country can be 
extrapolated to other countries with a different health care setting, epidemiology of the 
disease and perhaps other test characteristics of mammography. In a study by van 
Ineveld et al. it was shown that the cost·effectiveness of breast cancer screening might 
differ by a factor of 3-5 between different countries of the European Union (van Ineveld 
et at., 1993). In this thesis factors are explored that determine whether and how results 
of cost-effectiveness analyses and thus evaluation of screening programmes can be ex-
trapolated. This is illustrated using a cost·effectiveness analysis from Germany, in a de-
centralised screening setting and in Spain where there is a centralised screening system, 
but with lower levels of incidence and mortality of breast cancer. 
After screening was introduced in the Netherlands for all women aged 50·69 with an 
interval of 2 years, the National Evaluation Team on Breast cancer screening (NET B) 
analysed the early outcomes of the screening (de Koning et at., 1995; Fracheboud et 
at., 1998). At the end of 1997 all 750.000 women in the target age group had been 
invited at least once to participate in the national screening programme. During the first 
few years the evaluation of the national screening programme focused on the results of 
the first screening examinations. These results were very encouraging. The subsequent 
screens are however also of the most importance for the effectiveness of the screening 
programme (reduction of breast cancer mortality). After implementation of the pro· 
gramme, approximately 90% of all screening examinations consisted of subsequent 
screens. The cancers should be detected so early in their development that the ex-
pected breast cancer mortality reduction should result. This depends however on the 
sensitivity of the screening test and the biological growth of the tumours. The results of 
subsequent screens so far have not been as encouraging as those of the first screens 
(Fracheboud et at., 1998). 
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After the introduction of the Dutch screening programme, the results of a com-
bined analysis of the Swedish screening trials were published (Nystrom et al., 1993). 
These new results were implemented in the MISCAN model in order to make new es-
timates of the expected mortality reduction resulting from the Dutch national screening 
programme (de Koning et aI., 1995). Other issues that require continuous attention are 
new screening techniques such as computed assisted diagnosis (Karssemeijer and 
Hendriks, 1997) and the discussion about screening women in their forties and the ex-
pansion of screening to higher ages (Anonymous, 1997). 
Before the introduction of breast cancer screening in the Netherlands, all effects men-
tioned in table 1 were quantified and used in the cost effectiveness analysis (de Koning; 
1993). The quantification of secondary effects had however been based on assumptions 
that had not yet been studied or were judged to be of minor importance at the time. 
Two of these topics, namely opportunistic screening (screening outside a programme) 
and radiation risk of mammography were further studied in this thesis. 
The effect of introducing breast cancer screening in certain age groups (50-69) 
might change the use of mammography in other age groups and in the target popula-
tion. In the cost-effectiveness analysis a reduction of mammography requests was as-
sumed in the target population. In this thesis the use of mammography as requested by 
general practitioners was analysed before -and after the introduction of the national 
screening programme. 
The radiation dose used in modern mammography was assumed to be negligible 
at the time the decision was made to introduce breast cancer screening (Health Council 
of the Netherlands, 1987). As a result of new techniques (the use of grids to prevent 
scatter radiation) and continuous improvement of image quality, the radiation dose had 
probably increased from 0.5 mGy to about 2 mGy per examination. These develop-
ments had also accelerated, as a result of the introduction of screening programmes. In 
this thesis, the radiation risk of mammography and the implications for screening pro-
grammes with different age groups and intervals is further studied. 
EVALUATION OF PROSTATE CANCER SCREENING 
Screening for prostate cancer is much less developed than for breast cancer. Random-
ised Controlled Trials are now being conducted (Auvinen et a/., 1996; Gahagan et al., 
1994) but to date no country has implemented a national screening programme. In 
Europe, many urologists and policy makers seem to share the opinion that screening 
should only be introduced after it has been proven to save lives. Evidence about the 
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effectiveness of screening in reducing prostate cancer mortality will only be available 
approximately 10 years after the start of the randomised screening trials, i.e. from about 
2005. But for prostate cancer screening, saving lives is not the only issue in a policy 
decision tei introduce screening. All favourable and unfavourable effects of the screen-
ing (see table 1) should be identified and quantified. 
For the evaluation of prostate cancer screening a MISCAN (Micro Simulation 
SCreening ANalysis) disease module for prostate cancer was developed. In this module 
the relevant stages of the disease are integrated and validated with information about 
incidence, mortality, stage distribution and survival of prostate cancer in the situation 
where no screening programme exists. Information about detection rates and stage dis-
tribution of the trial is also a continuous source of clinical input for the model. 
In addition a quality of life study is also conducted alongside the trial. Quality of 
life before and after participating in the screening (Essink-Bot et al., 1998) and before 
and after primary treatment has been studied (Madalinska et a/.). Furthermore, quality 
of life of metastasised prostate cancer will also be studied. 
Another issue concerns the quantification of changes in assessment and therapy as 
a result of screening. The health care costs of diagnosis and treatment of prostate cancer 
have also to be estimated. All the information will be combined resulting in cost-effec-
tiveness ratios for prostate cancer screening. It is expected that, as for breast cancer, this 
analysis will also help to decide about a lower and upper age-limit of the target popula-
tion and the screening interval. Using this information will support a decision about the 
introduction of a nation-wide screening programme for prostate cancer. 
This thesis contains studies on some of the elements in table 1.1. Examples are the 
analysis of the most optimal combination of screening tests and the observation of PSA 
(prostate Specific Antigen) among men before and after participating in the screening 
trial and in the total population as a baseline value for the situation without screening. 
Determination of PSA in serum is a very simple screening test compared to 
mammography and a cervical smear. A widespread use of the screen test in the control 
arm of the trial (opportunistic screening) might affect the mortality reduction achieved 
in the trial. If large numbers of opportunistic screening occur this might be taken into 
account separately in the cost·effectiveness analysis. With the introduction of a 
screening programme this 'opportunistic' screening is (in part) replaced by an organised 
screening. Thus part of costs of screening is compensated for by abolishing 
opportunistic screening (which is generally less efficient). 
From the evaluation of breast cancer screening it was obvious that many of the 
extra costs (approximately 40%) induced by screening could be compensated for by 
prevention of advanced disease and its costs (de Koning et a/., 1992). Similarly for pros-
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tate cancer, quantification of advanced disease and its costs is also one of the aspects 
for consideration in the screening evaluation. Therefore in this thesis the course, care 
and costs of advanced prostate cancer were studied. 
RESEARCH PURPOSES 
The goal of this thesis is to elucidate some aspects of evaluation of screening pro-
grammes. The evaluations of breast cancer and of prostate cancer screening are in vel)' 
different phases. The differences are used to illustrate the challenges for the evaluation 
of both screening programmes. Especially the experience of the evaluation of breast 
cancer screening can be applied to prostate cancer. 
The following research purposes will be addressed in this thesis: 
• To identify and quantify factors that influence the cost-effectiveness of (breast) cancer 
screening programmes in different countries and thus health care settings (Part I) 
• To quantify secondary effects (racliation risk of mammography and opportunistic 
screening) of the introduction of a national breast cancer screen'ing programme (part 
II) 
• To quantify factors influencing the performance of a prostate cancer screening trial or 
a future programme (Part III) 
STRUCTURE OF THIS THESIS 
Chapter 2 presents the costs and effects of breast-cancer screening in Germany where 
health care is decentra[ised. The effect of sensitivity, specificity and attendance rate on 
the effects and costs is quantified. [n chapter 3, breast cancer screening programmes are 
evaluated to compare extension of screening of the age group 50-64 to higher or lower 
ages in a country with a lower leve[ of incidence and mortality (Spain; Catalonia). 
In chapter 4, the possible effects of radiation exposure in a breast cancer-screening 
programme are explored for different scenarios. Racliation risk is age-dependent and the 
effectiveness of screening is also age-dependent. Furthermore, radiation risk is propor-
tional to the total dose and thus dependent on the age-borders and interval. The effects 
of both factors combined, on the balance between breast cancer deaths induced and 
prevented is investigated. In chapter 5 we evaluate breast cancer screening outside an 
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organised screening programme by the general practitioner in the target age group of 
the national screening programme and in adjacent age groups. 
In part III the screening tests as used in the Rotterdam part of the European Ran-
domised Study on Screening for Prostate Cancer (ERSPC) are evaluated (chapter 6). We 
look at different scenarios by weighing screening procedures, biopsies and cancers de-
tected. In chapter 7 the use of 'screening tools', especially PSA (prostate Specific Anti-
gen) of the trial population before randomisation and during the study is quantified. 
Additionally the base line (situation without screening) with regard to the assessment 
of prostate disease is established. In chapter 8 the course of advanced prostate cancer is 
described, including the care given and the costs involved. 
In chapter 9 the most important aspects of both screening programmes are dis-
cussed to establish their relevance for the evaluation. It is obvious that the evaluation of 
the screening programmes is in totally different phases. For prostate cancer the evalua-
tion will be used to decide about whether a prostate cancer-screening programme 
should be introduced and if so, how. For breast cancer the issue is how to monitor and 
optimise an already established national screening programme. 
References 
Anonymous, National Institutes of Health Consensus Development Conference Statement: Breast 
Cancer Screening for Women Ages 40-49, January 21-23, 1997. National Institutes of Health 
Consensus Development Panel. J Nat! Cancer l/lst, 89, 1015-26 (1997). 
Auvinen, A., Rietbergen, J.B., Denis, L.J., Schroder, F.H. and Prorokt P.C, Prospective evaluation 
plan for randomised trials of prostate cancer screening. The International Prostate Cancer 
Screening Trial Evaluation Group. J Med Screen, 3, 97-104 (1996). 
Boueot, K.R" Mass surveys in case-finding techniques for pulmonary neoplasms. J Am Med WaHl 
Assoc, 3, 485-492 (1948). 
Boucot, K.R. and Sokoloff, M.J., Is survey cancer of the lung curable? Dis Chest, 27, 369-388 
(1955). 
de Koning, H.J., The effects and costs of breast cancer screening, Dept. of Public Health, Erasmus 
University Rotterdam, Rotterdam (1993). 
de Koning, H.J., Boer, R., Warmerdam, P.G., Beemsterboer, P.M.M. and van der Maas, P.J., 
Quantitative interpretation of age-specific mortality reductions from the Swedish breast can-
cer-screening trials. J Nat! Cancer Inst, 87, 1217-23 (1995). 
de Koning, H.J., Fracheboud, J., Boer, R., Verbeek, A.L., Collette, H.J., Hendriks, J.H., van 
Ineveld, B.M., de Bruyn, A.E. and van der Maas, P.J., Nation-wide breast cancer screening in 
The Netherlands: support for breast-cancer mortality reduction. National Evaluation Team for 
Breast Cancer Screening (NETB). Int J Cancer, 60, 777-80 (1995). 
10 
Introduction 
de Koning, H.J., van Ineveld, B.M., de Haes, J.C, van Oortmarssen, G.J., KJijn, J.G. and van der 
Maas, P.J., Advanced breast cancer and its prevention by screening. Br J Cancer, 65, 950-5 
(1992). 
de Koning, H.J., van Ineveld, B.M., van Oortmarssen, G.}., de Haes, J.C, Collette, H.J., Hendriks, 
J.H. and van der Maas, P.}., Breast cancer screening and cost-effectiveness; policy alterna-
tives, quality of life considerations and the possible impact of uncertain factors. fnt J Cancer, 
49,531-7 (1991). 
Early lung Cancer Cooperative Study, Early lung cancer detection: summary and conclusions. 
Am Rev Respir Dis, 130,565-570 (1984). 
Essink-Bot, M.l., de Koning, H.J., Nijs, H.G., Kirkels, Vv.J., van der Maas, P.J. and Schroder, F.H., 
Short-term effects of population-based screening for prostate cancer on health-related quality 
of life. I Natl Cancer !nst, 90, 925-31 (1998). 
Fracheboud, J., de Koning, H.J., Beemsterboer, P.M.M., Boer, R., Hendriks, J.H.Cl., Verbeek, 
A.l.M., de Bruyn, AE. and P.}., v.d.M., Nation-wide breast cancer screening in the Nether-
lands: results of initial and subsequent screening 1990-1995. lilt J Cancer, 75, 694-698 
(1998). 
Gershon-Cohen, J., Hermel, H.B. and Berger, S.M., Detection of breast cancer by periodic X-ray 
examination: A five-year sUIVey.IAMA, 176, 1114-1116 (1961). 
Gohagan, J.K., Prorok, P.C, Kramer, B.S. and Cornett, J.E., Prostate cancer screening in the pros-
tate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute [see 
commentsJ.1 Ural, 152, 1905-9 (1994). 
Habbema, ).0., van Oortmarssen, G.)., Lubbe, ).T. and van der Maas, P.)., The MISCAN simula-
tion program for the evaluation of screening for disease. Comput Methods Programs Biomed, 
20, 79-93 (1985). 
Health Couneil of the Netherlands, The early detection of breast cancer (in Dutch), Health Coun-
eil of the Netherlands, The Hague (1987). 
Karssemeijer, N. and Hendriks, J.H., Computer-assisted reading of mammograms. Eur Radial, 7, 
743-8 (1997). 
Madalinska, ).B., Essink-Bot, M.L., de Koning, H.)., Schroder, F.H. and van der Maas, P.)., Health 
related quality of life in patients with either screen-detected or clinically diagnosed prostate 
cancer before undergoing primary treatment. (in preparation). 
Nystrom, L., Rutqvist, L.E., Wall,S., lindgren, A, Lindqvist, M., Ryden,S., Andersson, I., 
Bjurstam, N., Fagerberg, G., Frisell, J. and et, a., Breast cancer screening with mammogra-
phy: overview of Swedish randomised trials [see comments] [published erratum appears in 
Lancet 1993 Nov 27;342(8883):1372J. Lancet, 341, 973-8 (1993). 
Papankoulou, C.N. and Traut, H.F., The diagnostic vallie of vaginal smears in carcinoma of the 
uterus. Am I Obstet Gyneco!, 42, 193 (1941). 
Shapiro,S., Coleman, E.A, Broeders, M., Codd, M., de Koning, H.J., Fracheboud, J., Moss,S., 
Paci, E., Stachenko, s. and Ballard-Barbash, R., Breast cancer screening programs in 22 coun-
tries: current policies, administration, and guidel ines. lilt J Epidemiology, in press (1998). 
van Ballegooijen, M., Effects and costs of cervical cancer screening [Thesis], Department of Pub--
lic Health, Erasmus University Rotterdam, Rotterdam (1998). 
van Ineveld, B.M., van Oortmarssen, G.J., de Koning, H.J., Boer, R. and van der Maas, P.J., How 
cost-effective is breast cancer screening in different EC countries? Eur J Cancer, 12, 1663-8 
(1993). 
11 
Chapter I 
van Oortmarssen, G.L Habbema, J.D., van def Maas, P.}., de Koning, H.j., Collette, H.J., 
Verbeek, A.L., Geerts, A.T. and Lubbe, K.T., A model for breast cancer screening. Cancer, 
66,1601-12 (1990). 
Victor, A.B., The early diagnosis of primary lung cancer. Dis Chest, 27, 389-409 (1955). 
Wolleswinkel-van den Bosch, J.H., The epidemiological transition in The Netherlands [Thesis], 
Department of Public Health, Erasmus University Rotterdam, Rotterdam (1998). 
12 
• Part I • 
Identification and quantifying factors 
that infl uence the cost effectiveness of 
(breast) cancer-screening programmes 
in different health care settings 

2 
PREDICTION OF THE 
EFFECTS AN D COSTS OF 
BREAST CANCER SCREENING 
IN GERMANY 
Summary 
Although breast cancer screening programmes are now being introduced it is still de-
bated whether tllis is an appropriate policy for all European countries. Taking into ac-
count empirical data from 2 regional pilot screening projects, this sWdy has evaluated 
the effects and costs of a nation-wide breast cancer screening programme in Germany. 
Special attention was paid to the decentralised German health-care system and to the 
influence of attendance, interval and age group. The recent results of the analysis of 
the Swedish randomised screening trials were used to estimate the improvement in 
prognosis after early detection of breast cancer. 
Our analysis shows that a programme providing for the screening of women aged 
50-69 at 2-year intervals might be expected to result in a decrease in mortality from 
breast cancer estimated at 11 % for the total German population, representing 2,100 
deaths from breast cancer prevented each year. The cost per life-year gained was as-
sessed at between OM 18,800 and OM 25,300 for tflis scenario; 2 to 3 times less fa-
vourable than in the UK and The Netherlands. The sensitivity of mammography was 
estimated to be 12% lower than in The Netherlands and the attendance rate was calcu-
lated at 47% on average. A greater effort to ensure the quality of the screening pro-
gramme and to improve the invitation system might finally lead to much bettcr results. 
The mortality reduction might be as much as 18% if the attendance and the sensitivity 
of the screening could be improved to the Dutch level. 
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Prediction of the effects and costs of breast cancer screening in Germany 
INTRODUCTION 
Mammographic screening has been shown to be effective in reducing breast-cancer 
mortality for women aged 50 to 69 in several West European countries (Nystrom et al., 
1993; UK Trial of Early Detection of Breast Cancer Group, 1993). Still, it is not evident 
that a decision for screening would be appropriate for all European countries since they 
might show large differences regarding epidemiology, screening and health care in 
general (van Ineveld et ai., 1993). in The Netherlands a detailed cost-effectiveness 
analysis was carried out to predict the favourable and unfavourable effects of breast-
cancer screening (de Koning, 1993; de Koning et al., 1991). These predictions led to 
the decision to introduce a national screening programme, the results of which ap-
peared to prove that the predictions had been accurate (NETB (National Evaluation 
Team for Breast cancer screening), 1993). 
We used the same approach to make predictions about the main consequences of 
breast cancer screening in one of the largest West European countries, Germany. Since 
1971 the opportunity has been afforded for regular cancer-related health check-ups 
each year, with mammography for high-risk groups only and if symptoms or complaints 
were present (Robra, 1993). In recent years experimental mammography screening has 
been carried out in 2 regions (OMS (Deutsche Mammographie-Studie), 1991, 1992, 
1993), which served as the basis for this analysis. 
The specific influence of a more decentralised screening organisation, including private 
practices, was taken into account. Another important issue was the influence of atten-
dance rates, which are likely to be lower in screening programmes without strict invita-
tion systems. Results are presented on the main favourable and unfavourable effects of 
screening women aged 50 to 69 at 2-year intervals and on quality of life and cost-effec-
tiveness. Because it is still debated whether younger women should also be screened, 
we considered alternative scenarios including women under 50 andlor different screen-
ing intervals. We also examined the country-specific characteristics of screening for 
breast cancer in Germany and the requirements for obtaining the largest possible bene-
fit from breast-cancer screening. 
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MATERIAL AND METHODS 
Cost effectiveness analysis and baseline assumptions 
The design of an analysis of the effects and costs of breast cancer screening has been 
described by de Koning et al. (de Koning et al., 1991). In short, the effects and costs of 
different policies are compared with a situation in which mass screening is not applied. 
The description of the latter situation is based on national data on assessment and 
treatment. Cost and effect estimates for screening are derived form the results of screen-
ing trials. The estimate of improvement in prognosis after early detection is based on 
resuits from the recent analysis of the Swedish randomised trials (Nystrom et a/., 1993). 
For the baseline assumptions on screening and the natural history of breast cancer 
we used the cost effectiveness approach and MISCAN model, which were also used to 
evaluate screening in The Netherlands (de Koning, 1993; van Oortmarssen et al., 
1990). All factors were adjusted for the German situation where available data allowed. 
This method has been shown to be useful for predicting the effects and cost of screen-
ing in Australia, done with the same base-line assumptions adjusted as required (Carter 
et al., 1993). The disease model is based on a 3-stage division of the development of 
invasive breast cancer (stages reflect the size of the tumour). A proportion of the inva-
sive breast cancers was assumed to be preceded by a screen-detectable ductal carci-
noma in situ (dClS). No changes were made regarding the impact on the quality of life 
in the different phases (de Haes et a/., 1991). Only the extent to which these states 
would be prevented or induced by screening in the German setting was taken into ac-
count. 
For the analysis it was assumed that screening would start in 1994, with a build-up pe-
riod of 5 years, based on the experience in The Netherlands and the UK. After this 
build-up period it was assumed that the programme would be carried out in the whole 
of Germany for a total period of 27 years. 
Demography and epidemiology of breast cancer in Germany 
The 1989 (5-year) age-specific distribution of the total German female population was 
used and the death rates from other causes than breast cancer were based on the 1990 
(5-year) age-specific rates from the former Federal Republic of Germany. Detailed data 
were lacking the former German Democratic Republic. Breast-cancer mortality rates for 
the total German population were calculated on the basis of 1990 data from the former 
FRG and 25% lower rales were used for the former GDR (Statistisches Bundesamt, 
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1992; Statistisches Bundesamt, 1991). The "onset" of disease (or preclinical incidence) 
could be assessed by using the clinical age-specific incidence figures from the Saarland 
cancer registry and the expected duration of preclinical breast cancer as estimated in 
detail in earlier analysis with empirical data on screening from the Dutch trials. The 
mean duration of preclinical disease was estimated in detail in earlier analyses with 
empirical data on screening from the Dutch trials. The mean duration of preclinical dis-
ease was estimated to range from 2.7 (age 50) to 6.2 (age 70) years (Statistisches Amt 
des Saarlandes, 1987, 1988, 1989, 1990; van Oortmarssen et al., 1990). Stage distribu-
tion of breast cancer was assumed to be the same as in The Netherlands, although it 
was difficult to make an accurate comparison on account of the diversity of sources 
(Netherlands Cancer registry, 1992; Leonhardt, 1988; Paterok et aI., 1992). 
Since data on the incidence of breast cancer in the whole of Germany were lack-
ing, the Saarland registry was used to determine breast-cancer incidence at the national 
level. Regional differences in incidence were assumed to be negligible on the basis of 
the regional mortality data for breast cancer (Smans et al., 1992). First, the Saarland 
incidence data were used to predict the mortality from breast cancer in Saarland 
(Statistisches Amt des Saarlandes, 1987, 1988, 1989, 1990). Since the predicted mortal-
ity was too high, the relative survival rates of breast cancer patients had to be adjusted 
slightly downwards for all ages and specifically for the younger age group to make the 
simulated breast-cancer mortality fit the data observed in Saarland. With the mortality 
incidence distribution from Saarland, it was possible to estimate national clinical inci-
dence form the national mortality data. The mortality rates predicted by MISCAN and 
those of the German national data were comparable. 
Screening in Germany 
In 2 pilot regions, Aurich and Braunschweigh, the Deutsche Mammographie-Studie 
(DMS) has been carried out since 1990 (DMS (Deutsche Mammographie-Studie), 1991, 
1992, 1993). The DMS study is part of the Krebs-Fruherkennungsuntersuchungen (KFU) 
programme, which affords women the opportunity to see a doctor for regular yearly 
examinations. The expected age-specific attendance rates were based on attendance 
rates observed in the KFU programme in 1985-1986 and on rates obtained from a re-
cent telephone survey (Berghof and Robra, 1988; Robra, personal communication). 
Because it was likely that these 2 sources of data would respectively underrate and 
overrate attendance, we decided to use the average. Moreover, as attendance rates ob-
tained form the telephone survey only concerned women aged 55 to 74, those for 
women age 40 to 54 were extrapolated from the data of the KFU. On the basis of the 
data thus obtained, the attendance rates for women attending breast cancer screening 
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Different attendance patterns for screening programmes with average values for women 
aged 50-69 (depicted by *l 
programmes at least every other year (2-year attendance) or every year (l-year atten-
dance) were calculated. The 1-year attendance rate of the KFU, considered at least a 
reasonable one, was used as a lower boundary. Attendance showed a steep decrease 
with increasing age, so relatively more younger women attend the programme (figure 
2.1). 
In the DMS study women were asked by their general practitioner or specialist to 
participate and undergo a 2-view mammography. Women with suspicious lesions were 
either directly for biopsy or received additional examinations first. The sensitivity and 
the positive predictive values (PPV) of screening were derived from the experience ob-
tained in the first years of the pilot project, including 31,000 first screening examina-
tions and 16,000 subsequent ones until the first quarter of 1993 (DMS (Deutsche 
Mammographie-Studie), 1991, 1992, 1993; Swart, 1992; Swart, personal communica-
tion). On the basis of these data the sensitivity for all stages was lowered by 12% com-
pared to the Dutch sensitivity. The sensitivity of the screening test was 0.73 on average 
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depending on the stage in which the breast cancer was detected, ranging from 0.35 for 
dClS to 0.62 for tumours < 1 COl and 0.84 for tumour ~ 1 cm. In the MISCAN model 
the sensitivity of a screening examination is defined as the probability of detecting a 
preclinical breast cancer. No data were available on the assessment or biopsy of breast 
cancer in normal medical practice in Germany, so data applicable to The Netherlands 
were used. As a consequence the PPV of a biopsy in a situation without screening was 
higher for tumours < 1 cm than in the screening programme and almost the same for 
tumours larger than 1 cm. 
Cost of screening, assessment and treatment 
In Germany screening will be attached to a decentralised health-care system. While in 
The Netherlands special screening units have been built, screening in Germany is car-
ried out in the private practices of gynaecologists and radiologists. The existing mam-
mographic centres often have too high a capacity for an efficient programme to be car-
ried out, and this is the most important reason for the higher cost of screening in such a 
system. The cost estimates of screening were different according to 2 calculations. In 
the first case, the amount of DM 121 per screening was reached by taking the tariff of 
DM 110 quoted in the DMS study and raising it by DM 11 for the cost of external qual-
ity assurance, double reading and training (DMS (Deutsche Mammographie-Studie), 
1991,1992,1993). As a variant the Dutch cost structure of screening was used. It was 
not changed, but applied to a decentralised system by a correction of 1.6 based on data 
from a French decentralised screening system (lancry and Fagnani, 1989; van Ineveld 
et al., 1993). 
The cost and use of all procedures concerning the assessment and treatment of 
breast cancer have been studied extensively for The Netherlands (de Koning, 1993). 
The evaluation of the use of different therapeutic procedures in Germany was based on 
published data, since national data and registries were lacking. The available informa-
tion was comparable with that from Dutch medical practice (Granetzny et al., 1991; 
leonhardt, 1988; Paterok et al., 1992). The tariffs of different additional examinations 
and treatments covered by sickness funds in The Netherlands were related to the tariffs 
in Germany and minor adjustments were made (Mundenbruch, 1990). Because the 
structure of care was based on the Dutch situation, all costs were corrected for the pur-
chasing power parities (PPP) of the cost of health care (OECD (Organization for Eco-
nomic Co-operation and Development), 1991). This PPP was 1.19, which means that 
health care in Germany is 19% more expensive. [Costs are presented in "Deutsch 
Mark"(DM) in this study.] 
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Yearly number of breast cancer deaths prevented by screening women aged 50-69 with a 2-
year interval, 1994-2020 
Table 2.1 
Stage distribution in a situation with and without screening and of the screen detected cancers 
in Germany in the year 2000 
without screening with screening (incl. screen-detected 
screen--detected) 
N (%) N (%) N (%) 
dClS 1,840 (4.6) 2,630 (6.2) 930 (14.0) 
Invasive < 1 em 3,430 (8.5) 4,690 (11.1 ) 1,390 (21.0) 
Invasive 1-2 em 9,970 (24.7) 11,680 (27.7) 2,760 (41.7) 
Invasive C: 2 em 25,070 (72.2) 23,100 (54.9) 1,540 (23.3) 
Total 40,310 42,100 6,620 
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RESULTS 
Effects on incidence and mortality 
In the year 2000 breast cancer will be diagnosed in about 40,310 women if no screen-
ing is available. When a screening programme is implemented in Germany the number 
of newly diagnosed breast-cancer cases will eventually increase by about 2-3%. In a 
situation where women aged 50-69 are screened every 2 years, 42,100 cases will be 
diagnosed each year, 6,620 of them being detected by screening, that is 16% of all 
breast cancers diagnosed each year. To assist with these diagnoses, about 5.2 million 
women have received an invitation and about 2.4 million women have had a mam-
mography (0.6 million first screens and 1.8 million subsequent screens). Ultimately a 
total of 2,100 deaths from breast cancer will thus be prevented each year, and the re-
duction of mortality from breast cancer is expected to be 11 % in the total German 
population by the year 2020 (figure 2.2). 
A comparison between the stage distribution for 1 year in a situation with and 
without screening and of the screen-detected cases (50-69) is summarised in table 2.1. 
The stage distribution is much more favourable for screen-detected cancers. Since only 
16% of all breast cancers are detected by screening, the effect on the overall stage dis-
tribution is relatively small. 
Effects on health care 
With the introduction of a screening programme the use of health-care services for di-
agnosis and treatment will increase. In a programme form women aged 50-69 at 2-year 
intervals, 2.6% of all women screened will have additional examinations. After the first 
screen this proportion will be 4.5%, because of a prevalence screen. A biopsy will be 
carried out in 0.6% of all women screened. The number of diagnostic procedures out-
side screening will decrease, because some women will be diagnosed with breast can-
cer in the screening programme. The proportion of diagnostic procedures for non-pal-
pable breast cancers « 1 em) will increase, however, because smaller cancers will be 
detected by screening. 
Although the absolute number of treatments for breast cancer will rise si nce more 
breast cancers will be detected, the proportions between the various therapies used will 
change (figure 2.3), because the implementation of a screening programme will result 
in a more favourable stage distribution. In comparison with a situation without 
screening, the use of breast conserving therapy will increase by about 15% after the 
build-up period while 8% fewer mastectomies will be carried out. The treatment of 
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dCIS will increase by 36% and the treatment of advanced disease will decrease by 
11 %. 
Cost effectiveness and quality of life 
In table 2.2 a situation with screening and one without are compared for all costs over 
a period of 27 years. The largest extra cost is caused by the screening procedure itself 
(OM 4,010 million). The costs of assessment or biopsy, primary therapy and follow-up 
are all higher in a situation with screening. The increase in costs of assessment and bi-
opsy is almost as great as the increase in costs due to treatment (OM 290 million and 
OM 320 million respectively). On account of the relatively large number of false posi-
tives, the additional cost of assessment and biopsy is high in a situation with screening. 
Moreover, a greater number of procedures for non-palpable breast cancers are carried 
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out and this also involves a higher cost. In a situation with screening the overall costs 
for breast-cancer diagnoses and treatment is 11 % higher than in a situation without 
screening. The cost of advanced disease is OM 890 million lower in a situation with 
screening. This reduction is proportional to the decline in mortality since all women 
prevented from dying of breast cancer would have had p~lIiative treatment. In total, the 
savings are so small that, when a screening programme is implemented in Germany, 
the overall extra costs will be only 2.5% lower than the costs incurred by the pro-
gramme itself (OM 3,890 million and OM 4,010 million respectively). The mean num-
ber of life-years gained by the earlier detection of breast cancer was estimated at 15.8 
years per breast-cancer death prevented (no discounting). The costs per life-year gained 
for screening women aged 50-69 at a 2-year interval were OM 18,800 (5% discounted). 
When the costs of screening were assllmed to be higher than in the basic scenario, 
as in all likelihood they will be when a national decentralised screening programme is 
implemented, the balance between costs and effects was even worse (OM 25,300 per 
life-year gained). 
Table 2.2 
Effects on mortality, costs and cost-effectiveness of breast cancer screening of women 50-69 
with a 2-year interval in Germany during 27 years. Cost amounts are expected differences 
between a situation with and without screening (in Million DEM), 5% discounting, cost per 
screen DEM 121. 
Breast cancer deaths prevented 1 
life-years gained 1 
Cost of screening 
Cost of assessment/biopsy 
Cost of primary therapy 
Cost of follow-up 
Cost of advanced disease 
Difference in cost 
Breast cancer deaths prevented 
life-years gained 
Cost per life-year gained (CE-ratio, DEM)' 
Quality adjusted life-years gained 
Cost per quality adjusted life-year gained (OEM) 
Ina discounting 
20nly cost of follow~up of women after 1992 are included 
screening versus 
no screening 
54321 
860273 
+4,010 
+290 
+320 
+ 170 
-890 
+3,890 
19,600 
206,500 
18,800 
197,000 
19,800 
no screening 
o 
7,350 
;:~~~ 2 
15,860 
34,830 
(total cost) 
3DEM 25,300 if cost of screening based on Dutch cost~structure and decentralized health care system 
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Difference in extra costs and life-years gained for different interval and age group scenarios 
To assess the quality of life a comparison was made between a situation with 
screening and one without. The largest gain in quality-adjusted life-years is caused by 
the less frequent use of palliative therapy in a situation with screening. On the other 
hand, many quality-adjusted life-years are lost, since a screening situation results in a 
greater number of life-years after disease. Overall, 500 quality-adjusted life-years are 
lost with screening, so a small correction of 4.8% was carried out on the total number 
of life-years gained (table 2.2). The costs per quality-adjusted life-year gained amount to 
DM 19,800 for the basic scenario and DM 26,500 for the variant with the higher costs 
of screening (in both cases 5% discounted). 
Influence of screening interval 
If the screening interval is shortened and screening is carried out more frequently, a 
greater number of life-years are gained. The curved line in figure 2.4 shows that addi-
tional costs will be incurred while proportionally less life-years will be gained. This can 
be seen in the scenario involving age group 50-69, with intervals of 3, 2, 1.5 and 1 
years. If the screening interval is reduced frol11 3 to 2 years, the extra costs per extra life-
year are DM 29,400. If the interval is reduced from 2 to 1.5 years the extra costs are 
even higher (DM 69,900). The figure also shows that the costs of implementing screen-
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ing policies for women aged 45+ or 40+ are relatively high compared to the benefits 
in terms of mortality reduction. For the variants with a lower starting age the extra costs 
are very high, with a maximum of DM 96,200 per extra life-year gained when the in-
terval is shortened from 2 years to 1 in the age group 40-69. Is has to be taken into ac-
count that according to the average values of the KFU programme and the telephone 
survey (figure 2.1), the attendance rates vary proportionally to the changing interval. 
Influence of attendance rates on breast-cancer-induced mortality 
Attendance rates in the Dutch screening trials were 70% on average, while in the Ger-
man basic scenario they were 47% and in the KFU programme approximately 26% 
(figure 2.1). On the basic of these rates, the mortality reduction is 17%, 11 % and 7% 
respectively and the number of breast-cancer deaths prevented about 30,200, 19,600 
and 11,600 respectively for the basic scenario. In Germany a steep decrease in 
attendance is observed starting from age 55, while in The Netherlands proportionately 
more older women attend the screening. There are however only slight differences in 
the CE (cost-effectiveness) ratios. 
DISCUSSION 
The predicted balance between the effects and costs of breast-cancer screening in Ger-
many for women aged 50-69 at 2-year intervals is less favourable than in other Euro-
pean countries. In Germany the CE ratio is between DM 18,800 and DM 25,300 per 
life-year gained for this basic scenario if the costs of a decentralised health-care system 
are taken into account. This figure is DFL 7,650 (Dutch florins) for the same programme 
in The Netherlands (exchange rate 1994, 1 DFL ~ 0.89 DM) (de Koning et al., 1991). 
The predicted reduction in mortality from breast cancer was 11 % in the total female 
population for this programme and less than the 16% predicted for The Netherlands. 
The effects and cost effectiveness of screening for breast cancer are determined by 
different factor. Firstly, the CE ratio depends on the epidemiology of the disease, inci-
dence and mortality. If the incidence is high, more cases can be detected and the ef-
fects of screening for disease might be greater, thus preventing more women from dy-
ing of breast cancer. In Germany, since national data on the incidence of breast cancer 
were lacking we predicted the national incidence using the survival rates for Saarland 
and the national mortality rates. We may have underestimated or overestimated the 
effects if the survival rates for Saarland are not representative of all of Germany. How-
ever, because of the absence of data, this problem cannot be addressed. We nonethe-
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less anticipate minor differences in survival deriving also from minor regional differ-
ences in breast-cancer mortality (Smans et a/., 1992). The extrapolation is not likely to 
have influenced the results of the CE analysis very much. 
Another factor that influences the effects of screening is the quality of the screen-
ing test, its sensitivity and specificity. A third one is the behaviour of the target popula-
tion with respect to attendance. All these aspects are negatively related to the CE ratio. 
In Germany the incidence of breast cancer and the mortality incurred by this disease 
are about 20 tot 25% lower than in The Netherlands, so the detection rates will be 
lower and relatively fewer cancers will be found at the same cost. Sensitivity and atten-
dance rates also have lower values than in The Netherlands, with the difference that 
these aspects can be influenced. 
On the basis of the German pilot regions, the sensitivity of screening for breast 
cancer is estimated to be 12% lower than in The Netherlands. Improving sensitivity 
would have a positive effect by increasing the number of early-detected breast cancers 
and thus reducing mortality. In Germany only 16% of all breast cancers are screen-de-
tected while in The Netherlands, where sensitivity is higher, the proportion is 24%. 
Two factors to be taken into account are the higher proportion of older women living in 
Germany and their relatively low attendance. If more older women attended the pro-
gramme the effect of an improvement of sensitivity on reducing mortality would be 
more than proportional. 
Specificity affects the induced costs of the screening programme. In Germany a 
considerable number of additional examinations (2.6% of all screens) is carried out, 
although the percentage of biopsies (0.6% of all screens) is at the same level as in The 
Netherlands. Incidence is about 20 to 25% lower, so more women have to undergo a 
biopsy without having breast cancer. In The Netherlands, a very efficient referral system 
after screening (0.8% of all screened women are referred) reduces the costs of diagnos-
ing breast cancer in a situation with screening. In Germany the costs of diagnosing 
breast cancer are much higher when screening is carried out than when it is not. 
The attendance rate has a large impact on reducing mortality from breast cancer. 
The attendance assumed for this analysis in Germany was low compared to attendance 
in other European countries. The largest difference regarding the invitation system of 
the KFU programme is that women are not actively invited to participate. If a screening 
programme for breast cancer is implemented in Germany a personal invitation is ex-
pected to lead to much higher attendance rates. However, it is impossible to predict 
attendance in this situation since the health-care system is different. One way to in-
crease the overall attendance might be to use population registers or registers of the 
sickness funds (Krankenkassen) or of family practices and to promote health education. 
In the national programmes of both The Netherlands and the UK, this approach results 
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in an attendance of 70% or more (Chamberlain el al., 1993; de Koning, 1993). Our 
results show that with an average attendance rate of 70% the mortality reduction would 
increase to 17%. Finally, the cost of the screening procedure is high. If it were possible 
to save money on the screening examination the cost-effectiveness of this programme 
could be influenced. 
Our results also show that in Germany it is advisable to have an extensive system 
to ensure the quality of screening, as in other European countries. The predictive values 
of different procedures must be improved, thereby reducing the absolute number of 
additional examinations through increased sensitivity. This can be achieved by the ex-
tensive training of all people involved in screening and by using equipment of high 
quality. The decentralised health-care system in Germany presents a difficulty in this 
respect. One solution might be to introduce referral centres to which all women with 
an abnormality on mammography would be sent. Specialised doctors would have to be 
involved to advise for additional examinations and biopsy. 
The KFU programme, in which a general check-up is offered to all inhabitants to 
screen for different kinds of cancer, has been carried out in Germany for about 20 
years. However, no favourable effect on breast cancer mortality has yet been demon-
strated (Robra, 1993). A better option might be to introduce a specially organised na-
tional screening programme for breast cancer, which would replace the breast-cancer 
"screening" in the KFU programme. It would be strongly advisable to carry out this 
screening programme in Germany only when the quality of screening is improved and 
attendance is heightened, especially among older women. Performing a cost-effective-
ness analysis would provide much information relevant to policy decisions before a 
national screening programme is implemented. This study has demonstrated that the 
results of a cost-effectiveness analysis are dependent on the country and the health serv-
ice system for which the analysis is carried out. Without the use of a model it is ex-
tremely difficult to predict the overall effects of breast-cancer screening. 
If sensitivity, specificity and attendance have the same value as in The Netherlands 
the mortality reduction in Germany will be even higher than in The Netherlands (18%) 
on account of the age structure of the German population. The CE ratio will improve as 
well (OM 15,700 per life gained). If all aspects of the Dutch screening programme ex-
cept the demography and epidemiology of breast cancer were applied to Germany 
(costs included), the costs per life-year gained would be DFL 8,900. This finding shows 
that because of differences in demography and epidemiology the CE ratio would 
probably not be as favourable as in The Netherlands. 
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SCREENING FOR BREAST CANCER 
IN CATALONIA: 
WHICH POLICY IS TO BE PREFERRED? 
Summary 
Background: the effects and costs of different policies for breast cancer screening in 
Catalonia (Spain) were analysed, to give a basis for selling priorities and deciding on 
the introduction of a screening programme. 
Methods: tIle MISCAN (Mlcrosimulation SCreening ANalysis) model of the natural his-
tory of breast cancer was used. The epidemiology of breast cancer in Catalonia and the 
demography of the Catalan population was taken into account as well as the results on 
mortality reduction from a Swedish overview of breast cancer screening trials. 
Results: the reduction in breast cancer mortality in the total female population due to a 
screening programme for the age group 50-64 years would be 16, 12 and 9%, with 
screening intervals of 1, 2 and 3 years respectively. The cost-effectiveness ratios (CE 
ratios) for these scenarios were 924,000, 730,000 and 719,000 pesetas (Pts) per life-
year gained respectively (5% discounting). The most cost-effective screening scenario is 
the one in which women aged 50-69 years are screened with an interval of 3 years 
with a mortality reduction of approximately 12% in the total female population (CE 
ratio ~ 694,000 Pts). Screening until the age of 69 years (2-year interval) was almost as 
cost-effective as screening the age group 50-64 years with a 2-year interval, with a re-
duction in breast cancer mortality of 15%. ExtelJSion to under the age of 50 years re-
sulted in diverging results depending on the assumptions for improvement in prognosis 
for younger women (40-49 years). 
Conclusion: if the extension of a 2 yearly screening programme for women aged 50-64 
years is considered (mortality reduction of 12 %), extension to older women would be 
more advisable, based on proven benefits and costs, tllan extension to younger ag~ 
groups. 
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INTRODUCTION 
The cost effectiveness of breast cancer screening can vary substantially between coun-
tries, depending on, for example health care system, costs of health care, the screening 
programme and epidemiology of the disease. In Europe and the USA different screen-
ing policies exist and in the UK and The Netherlands these policies were in part based 
on cost-effectiveness analyses (de Koning el al., 1991; Forrest, 1987). 
In this study a detailed cost-effectiveness analysis was carried out for one region of 
Spain, Catalonia, where all relevant aspects were taken into account in as much detail 
as possible. In Spain, breast cancer screening activities are organised according to the 
regional health care organisation. Pilot projects on breast cancer screening have been 
started in different parts of Spain (Ascunce el a/., 1994; Servei de programmes espe-
cials, 1993). In Catalonia, a pilot project on breast cancer screening was started for 
women aged 50-64 years in Molins de Rei in the metropolitan area of Barcelona in 
1992 (Marzo, 1995). The upper age limit in all pilot projects in Spain is 64 years, while 
the starting age is 45 or 50 years. The screening interval in these pilot projects is 2 
years for the age group 50-64 years and 1 or 2 years for the age group 45-49 years. 
In this study we show the reduction in breast cancer mortality and the cost-effec-
tiveness ratio (CE ratio) of different screening intervals and age groups to be screened in 
Spain, taking into account the age-specific reductions in breast cancer mortality from a 
Swedish overview of screening trials (Nystrom el a/., 1993). Additional scenarios are 
examined in which screening women under the age of 50 years is as effective as for 
women aged 50-69 years. 
METHODS 
The MISCAN model approach to assessing the benefits of screening 
To predict the number of breast cancer deaths prevented for all separate screening poli-
cies, the computer simulation MISCAN (Mlcrosimulation SCreening ANalysis) model of 
the natural history of breast cancer was used. A detailed description of the earlier MIS-
CAN model is given by van Oortmarssen et al (van Oortmarssen et a/., 1990). In the 
present model, breast cancer has four invasive, screen-detectable, pre-clinical states 
(SO.5 cm, 0.5-1 cm, 1-2 cm and >2 cm) and one non-invasive state, Ductal Carcinoma 
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In Situ (DClS). The MISCAN model has been validated with data from the Dutch pilot 
screening projects from Utrecht en Nijmegen, which started in 1974 and 1975 (Collette 
et al., 1984; Verbeek et al., 1984). These data allowed an estimation of the sensitivity 
of mammography in the different states and the mean duration of the screen-detectable, 
pre-clinical period by age (van Oortmarssen et al., 1990). 
The level of mortality, underlying incidence and survival of breast cancer are im-
portant for the proportion of favourable and unfavourable effects of breast cancer 
screening. With the MISCAN model it is possible to take into account the demography 
and epidemiology of breast cancer. By generating individual life histories a dynamic 
population is simulated. The characteristics of the screening programme (attendance, 
interval and age groups) and the screening test (sensitivity) and assessment procedures 
(e.g. biopsy) are considered (see table 3.1). The value of the improvement in prognosis 
by stage after detection of breast cancer by screening was determined in a separate an-
alysis (de Koning et al., 1995). Based on the breast cancer mortality reduction reported 
in a Swedish overview of randomised breast cancer screening trials, the improvement 
Table 3.1 
Demography, incidence, mortality, survival and clinical stage distribution of breast cancer in 
Catalonia as used in the MISCAN model 
Population 1991 (female) 
Total 
Age 40-44 years 
Age 45-49 years 
Age 50-64 years 
Age 65-69 years 
Breast cancer incidence (per 100,000 person-years) 
Crude rate 
Age standardized (European) 
Mortality from breast cancer (per 100,000 persoll-years) 
Crude rate 
Age standardized (European) 
Five year relative survival rate 
Age < 65 years 
Age;?: 65 years 
Clinical stage distribution (%) 
DClS 
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'50.5 em (Tla) 
0.5-1 em (Tlb) 
1-2 em (fle) 
>2 em (T2+) 
3,096,552 
205,716 
184,291 
522,638 
160,973 
75.4 
66.4 
32.8 
27.3 
0.721 
0.693 
3.7 
1.4 
6.2 
32.4 
56.3 
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Characteristics of the screening for first and subsequent screenings or different age groups 
Attendance rate (average) 
Age 40-49 years 
Age 50-64 years 
Age 50-69 years 
Referral rare 
Age 50-64 years (2 year interval) 
Age 50-69 years (2 year inlelVa!) 
Positive predictive value (PPV) of advice for biopsy 
Age 40-49 years 
Age 50-64 years 
Age 50-69 years 
Detection rate (per 1000 examinations at 2 year interva1J4 
Age 40-44 years 
Age 45-49 years 
Age 50-54 years 
Age 55-59 years 
Age 60-64 years 
Age 65-69 years 
Age 50-64 years 5 
Age 50-69 years 5 
First screening 
(%) 
75 
70 
69 
6.2 
6.3 
21 
35 
37 
0.7 
1.7 
2.4 
2.9 
4.5 
6.5 
3.3 
4.1 
Subsequent 
screening 
(%) 
75 
70 
69 
3.6 
3.6 
33 
55 
58 
0.7 
1.4 
1.6 
1.8 
2.7 
3.6 
2.2 
2.6 
Age 45-49 years2 Age 50-69 years 
Sensitivity of screen rest' 
DCIS 
s 0.5 em (T1 a) 
0.5-1 em (fl b) 
1·2 em (fle) 
>2 em (T2+) 
Improvement in prognosis due to screen detection] 
DClS 
S 0.5 em (fla) 
0.5-1 em (flb) 
1·2 em (1le) 
>2 em (12+) 
0.32 
0.52 
0.64 
0.72 
0.76 
1.000 
0.310 
0.230 
0.070 
0.050 
0.40 
0.65 
0.80 
0.90 
0.95 
1.000 
0.892 
0.814 
0.567 
0.395 
1 Sensitivity of screen test is the probability of a positive screen result when screening a woman with 
screen-detectable pre-clinical cancer. 
2 For the age group 40·44 years the values for sensitivity were 60% of those for the age group 50-69 years. 
3 Improvement in prognosis is the reduction in risk of dying from breast cancer compared to a situation 
without screening, detected in that stage. 
4 Note: the possibility of an increase in underlying incidence over time, as seen in some parts of Spain, is 
not taken into account, due to lack of data. 
5 During the first 5 years of the programme. 
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---0- incidence -----+--- mortality 
Breast cancer incidence and mortality in Catalonia (the MISCAN model) 
in prognosis was estimated much higher in age groups over 50 years than for women 
aged 40-49 years (see table 3.2) (de Koning et al., 1995; Nystrom et al., 1993). 
With the use of this model we were able to predict many changes resulting from 
the introduction of a screening programme in a population in detail. The estimates we 
present for the screening programmes with different age groups and intervals are for a 
programme starting in 1995 and carried out over a period of 27 years. This long period 
was chosen because of the gradual introduction of screening and the time lag between 
the introduction of screening and its effect on breast cancer mortality. The effects result· 
ing from the screening programme that extend beyond the 27 years screening pro· 
gramme were also accounted for. 
Demography and epidemiology of breast cancer in Catalonia 
We used the life table and female population structure to simulate the demography of 
the female population in Catalonia (Servei d'informacio Sanitaria, 1993). The incidence 
of breast cancer was used from the cancer registries in Girona and Tarragona for the 
years 1985-1989 (figure 3.1) (Borras and Galceran, 1993; Viladiu et a/., 1994). Because 
of small differences between rural and urban areas, the overall incidence was used. The 
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mortality from breast cancer was based on the vital health statistics of Catalonia (figure 
3.1) (Servei d'informacio Sanitaria, 1993). 
The clinical stage distribution was used to estimate the mean duration of the 
screen-detectable, pre-clinical phase of the different states in the model. Data on the 
tumour size, lymph nodes and distant metastasis (TNM stage) were available for all 
women hospitalised for breast cancer in Girona. These data were compared to less de-
tailed data (local, regional and distant) of all incident cases in the Cancer Registry of 
Girona (Viladiu et a/., 1994). We used the TNM stage information of all patients that 
were hospitalised during 1989, because the differences were small. The age- and stage-
specific survival from breast cancer as used in the model was in accordance with the 5 
year relative survival rate from Girona for the years 1985-1989 (Viladiu et al., 1994). 
With the incidence and survival of breast cancer, the mortality of breast cancer, as 
found in the vital statistics, was predicted by the MISCAN model. The parameters used 
in the MISCAN model are shown in table 3.1. 
The screening process 
With regard to the screening process, we used the data of the small pilot project in Mo-
lins de Rei and the published results of a breast cancer screening programme in Na-
varra (Ascunce et al., 1994). We assumed two-view mammography for the first screen-
ing and one-view screening for subsequent examinations. The number of women re-
ferred to the hospital for additional examinations after the first screen was 6% in Na-
varra, which was similar to the percentage of referrals found in Molins de Rei after a 
two-view examination (Marzo, 1995). We used a referral rate of 6.2% for the first 
screening and 3.6% for subsequent screening for women aged 50-64 years. The values 
for referral after subsequent screens and for the other age groups (50-69 and 40/45-64 
years) were extrapolated using proportions of the Dutch situation, because no data for 
Catalonia and Navarra were available. All referred women received a clinical mam-
mography and 12% of them also needed a biopsy. The attendance rate in Molins de 
Rei was 68% (Marzo, 1995) and in Navarra 86% (Ascunce et aI., 1994). In the scenario 
of screening women aged 50-69 years with a 2-year interval we used an attendance rate 
of 70% on average. The attendance showed a slight decrease with increasing age, from 
75% at age 50 years to 65% at age 70 years. The attendance rate for women aged 40-
49 years was 75% for all ages. We took into account that not all women will attend the 
screening every round. The percentage of attenders that will attend the next screening 
is estimated at 88% and the percentage of women that did not attend but will attend 
next time is estimated at 24% for each screening round, based on the pilot project and 
the national screening programme in The Netherlands (de Koning et al., 1995). 
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The positive predictive values of an advice for biopsy were estimated to be 0.35 
for the first screening and approximately 0.55 for subsequent screening examinations. 
The sensitivity was assumed to be as high as in The Netherlands and was dependent on 
the size of the tumour (T stage). The characteristics of the screening programme in Cata-
lonia as used in the MISCAN model are summarized in the upper part of table 2. The 
age-specific detection rates were predicted by the MISCAN model given the input pa-
rameters clinical stage distribution, incidence of breast cancer and sensitivity of screen-
ing (lower part of table 3.2). 
(Sensitivity) analyses 
The basic scenario was screening with an interval of 2 years for women aged 50-64 
years. In the sensitivity analyses, the age groups and intervals were changed to deter-
mine the impact on mortality reduction of breast cancer in the total female population 
and on the CE ratio. The intervals were varied from 1 to 3 years for the age groups 50-
64 and 50-69 years. For the age groups 40-64 and 45-64 years only scenarios with a 2-
year interval were analysed; because of the shorter pre-clinical phase for the age group 
40-49 years a 3-year interval was assumed to be too long. We also studied the impact 
of a 12% lower sensitivity and an average attendance rate of 50% for women aged 50-
69 years. 
Recently, an updated analysis of Swedish results showed a reduction in breast 
cancer mortality of 23% (95% CI 0.59-1.01) in women of 40-49 years of age at entry 
invited for screening compared to women not invited, which was much higher than the 
relative risk (RR) of 0.90 (95% CI 0.65-1.24) in 1993 (Nystrom, 1996; Nystrom el al., 
1993). As an optimistic variant we used an improvement in prognosis for women aged 
40-49 years as high as for women aged 50 years and over (de Koning el a/., 1995). 
Costs 
For this analysis, the Dutch cost structure was used, because extensive research on this 
aspect has been carried out in The Netherlands (de Koning el al., 1992; de Koning et 
al., 1991). All costs due to the screening, assessment and treatment of breast cancer 
were considered (de Koning el al., 1991). We adapted this to the Spanish situation by 
using the gross domestic product-purchasing power parities (GDP-PPP) of 1991(OECD 
(Organisation for Economic Co-operation and Development), 1992) and the most re-
cently published correction factor for health care PPP of 1990 (OECD (Organisation for 
Economic Co-operation and Development), 1993). All costs are presented in pesetas 
(pts, exchange rate in 1991 100 Pts - $ ~ 1) (OECD (Organisation for Economic Co-
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Table 3.3 
Costs due to breast cancer for the total programme (1995-2021) of screening women aged 50-64 years at an 
interval of 2 years (5% discounting) 
Average Screening 
cost (Pts) 
Screening1 4,000 12,237 
Assessmenf 
- Screening 454,530 3,236 
- Outside screening 324,620 21,211 
Primary treatment plus follow-up) 599,300 31,737 
Pall iative treatment 1,808,960 41,355 
Total 109,776 
(%) 
(11 ) 
(3) 
(19) 
(29) 
(38) 
(100) 
Costs (' 1 0' Pt,) 
No screening 
22,861 
30,511 
43,953 
97,324 
(%) 
(23) 
(31) 
(45) 
(100) 
Difference 
(total cost) 
12,237 
3,236 
-1,650 
1,226 
-2,598 
12,451 
!ncl uded invitations, two-view mammography on first screening.. one-view at subsequent screens and double reading by 
radiologists. 
:2 Included clinical mammography and biopsy for' 2% of referred women, taking into account difference in cost for biopsy of 
palpable and non-palpable breast cancer. 
) Consisted of breast- conserving therapy plus radiation, mastedomy, adjuvant therapy, treatment of stage !liB/IV and cost of 
follow~up v"lsits after treatment. 
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operation and Development), 1992). The categories of costs for the total programme 
with a duration of 27 years are listed for the basic scenario in table 3.3. 
The costs and effects were presented using a discounting rate of 5%, representing 
a time preference. Based on all effects and costs in a screening situation compared to a 
non-screening situation, CE ratios were calculated. For policy decisions the differences 
between scenarios are often expressed in marginal CE ratios. This ratio represents the 
extra costs to gain one extra life-year compared to the reference scenario. 
RESULTS 
Screening policies for women aged 50-64 years 
In Catalonia screening programme for women aged 50-64 years with an interval of 2 
years (eight invitations), the detection rates predicted by the model were 3.3 per 1,000 
examinations for the first screening and 2.2 per 1,000 for subsequent screening during 
the first 5 years (lower part of table 3.2). The mortality from breast cancer in the total fe-
male population is eventually expected to be reduced by 12%, which would mean that 
157 deaths from breast cancer per year would be prevented in this scenario (table 3.4). 
The costs per life-year gained were estimated to be 730,000 Pts (table 3.4). If the 
screening is carried out with a 1 or 3 year interval, the mortality reductions would be 
Table 3.4 
Effects and costs of screening women aged 50-64 years, different policies 
Breast cancer mortality Costs and cost-effectiveness 
reduction (5% discounted) 
Scenario (age group, (no discounting)i 
interval and number of % N (per Life-years rotal cost Life-years CE ratio (Pts) invitations per woman) year) gained (' 1 0' Pts)' gained 
50(1)64 (15 invitations)' 15.8 207 104,505 21,121 22,864 923,800 
50(2)64 (eight invitations) 12.0 157 78,593 12,451 17,049 730,300 
50(3)64 (five invitations) 8.6 112 55,088 8,627 11,991 719,500 
50(2)64 (sensitivity -12%) 10.9 143 71,107 12,395 15,479 800,700 
50(2)64 (attendance 50%) 8.9 116 57,854 9,637 12,570 766,700 
I Steady state after approximately 25 years from the start of the screening programme. 
2 50(1)64 is a screening programme carried out for women aged 50·64 years with a 1 year interval. 
J Refers to all costs due to breast cancer with screening minus all costs due to breast cancer without 
screening (see table 3). 
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16 and 9% and the CE ratios would be 924,000 and 719,000 Pts respectively. Intensify-
ing the programme from a 2 year to a 1 year interval would result in an extra mortality 
reduction of only 33% [(16%-12%)/12%]. 
The scenarios were analysed with a 12% lower sensitivity or an attendance rate of 
50% on average. The mortality reductions for these scenarios were 11 and 9% respec-
tively and the CE ratios were 801,000 and 767,000 Pts respectively (table 3.4). These 
estimates show that a lower attendance rate would result in a proportionally lower re-
duction in mortality from breast cancer, but did not much influence the CE ratio. 
Other screening policies 
The estimates if the less intensive programme (age 50-64 years, interval 3 years and CE 
ratio 719,000 Pts) were to be extended to other age groups and/or intervals are summa-
rized in table 3.5. A programme for women aged 50-69 years and a 3 yearly interval 
would have a CE ratio of 694,000 Pts and the marginal CE ratio would be 614,000 Pts 
indicating that the costs per life-year gained for women aged 65-69 years are less than 
for women of 50-64 years of age. Screening with a higher frequency (50-64 years and 2 
year interval) would result in a marginal CE ratio of 756,000 Pts. Saving an extra life-
year will cost almost the same amount of money if the screening interval for the age 
group 50-64 years is 2 years instead of 3 years (table 3.5). A comparison of the 
screening scenarios 50-64 years with an interval of 2 years and 50-69 years with an 
interval of 3 years showed an almost equal effectiveness (mortality reductions 12 and 
12.3% respectively). The marginal CE ratio for the scenario 50-64 years with an interval 
of 2 years is, however, much higher; to save an extra life-year will cost over 1 million 
Pts (table 3.5). 
Screening with an interval of 2 years until the age of 69 years would result in a 
mortality reduction of 15% and the costs per life-year gained would be 744,000 Pts, 
with a marginal CE ratio of only 844,000 Pts per life-year gained (table 3.5). 
The first variant of the improvement in prognosis was based on the RR of dying 
from breast cancer of 0.90 (95% CI 0.65-1.24) from the Swedish overview by Nystrom 
et al (Nystrom et a/., 1993). In this scenario an extension to younger ages (45-64 years) 
did not much influence the mortality reduction (12.2% instead of 12.0%) and resulted 
in a higher CE ratio of 868,000 Pts. The marginal cost-effectiveness with the scenario 
50-64 years with a 2 year interval as a reference shows that the costs per extra life-year 
saved are much less for an extension to the age group 65-69 years than for an extension 
to the age group 45-49 years (table 3.5). Screening from the age of 40 years would 
result in a high CE ratio of over 1 million Pts per life-year gained. 
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Table 3.5 
Cost-effectiveness and marginal cost-effectiveness for an extension to other age groups 
Breast cancer 
mortality Costs and cost-effectiveness (5% discounted) 
Scenario (age group, interval reduction
1 
and number of invitations per % N (per Total costs life-years CE-ratio MarginalCE 
woman) year) (* 1 0' Pts) gained (Pts) ratio (Pts) 
50(3)64 (five invitations)' 8.6 112 8,627 11,991 719,500 
50(3)69 (seven invitations) 12.3 161 10,926 15,734 694,400 614,200' 
50(2)64 (eight invitations) 12.0 157 12,451 17,049 730,300 756,000' 
50(3)69 (seven invitations) 12.3 161 10,926 15,734 694,400 
50(2)64 (eight invitations) 12.0 157 12,451 17,049 730,300 1,159,7004 
50(2)64 (eight invitations) 12.0 157 12,451 17,049 730,300 
50(2)69 (ten invitations) 14.9 195 14,477 19,447 744,400 844,500' 
45(2)64 (ten invitations) 12.2 159 15,240 17,559 867,900 5,468,600s 
40(2)64 (13 invitations) 12.7 167 19,512 18,566 1,050,900 4,654,600' 
Improvement in prognosis for women aged 40-49 years as high as for women aged 50-69 years (optimistic variant) 
45(2)64 (ten invitations) 13.8 180 14,947 20,438 
40(2)64 (13 invitations) 15.1 198 19,198 23,127 
1 Steady state after approximately 25 years from the start of the screening programme. 
2 50(3)64 is a screening programme carr"led out for women aged 50-64 years with a 3 year interval. 
3 With 50 (3) 64 as a reference. 
4 With 50 (3) 69 as a reference. 
s With 50 (2) 64 as a reference. 
731,400 736,500' 
830,100 1,110,100' 
Policies for breast cancer screening 
In the other variant, women aged 40A9 years had the same improvement in prog-
nosis after screen detection as women aged 50-69 years (table 3.5). The CE ratio of 
screening women aged 45-64 will be 731,000 Pts, which is almost the same value as 
for the age group 50-64 years (both with 2 year intervals). This is also represented by 
the marginal CE ratio (the difference is only 6000 Pts). For a screening programme for 
women aged 40-64 years the CE ratio becomes less favourable (830,000 Pts) which is 
also shown by the marginal CE ratio. The effectiveness based on mortality reduction 
would be 13.8 and 15.1 % for both these programmes, which is more favourable when 
compared to 12.2 and 12.7% with the pessimistic assumptions in improvement in 
prognosis. 
DISCUSSION 
Due to uncertainty about the effectiveness of screening women aged 40-49 years result-
ing in controversy about introducing screening in that age group, we have carried out 
an optimistic and pessimistic scenario for the effectiveness under the age of 50 years. 
Extension to the age of 40 years resulted even with the high improvement in prognosis 
in a high CE ratio, because of a lower incidence rate of breast cancer and a lower as-
sumed sensitivity of mammography in the younger ages. 
The CE ratios for screening started at the age of 45 years are not so unfavourable 
compared to the CE ratio of a 50-64 years programme with an interval of 2 years. These 
relatively favourable CE ratios are, however, partially explained by the high incidence 
peak at ages 45-49 years in Catalonia (see figure 3.1), which is preceded by a high 
onset of pre-clinical disease and, thus, a high pre-clinical prevalence. Introducing 
screening for this age group would result in relatively many screen·detected cancers, 
although the sensitivity of mammography is lower for younger women. At age 50 years 
the incidence in Catalonia was relatively low, which is rather unfavourable for 
screening and the increase in incidence after the age of 50 years is less steep than in 
other European countries. These combined effects resulted in a CE ratio favourable for 
screening the age group 45-49 years in comparison with 50-64 years. 
Under the optimistic assumptions of effectiveness under the age of 50, extending a 
50-64 years programme and a 2-year interval to younger ages (45 years) is comparable 
to extending to olcler ages. Extension to older or younger ages was almost equally cost-
effective, but the reduction in mortality from breast cancer is higher for extending to the 
age of 69 years (15 versus 14%). The number of life-years is, however, higher for an 
extension to younger ages implying that more years per life will be gained. 
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Women aged 64-69 years still have a long life expectancy and screening has been 
proven to be effective in the age group 60-69 years (Nystrom et al., 1993). Due to the 
uncertainty of the effectiveness of screening younger women and the proven benefit for 
older women with a relatively favourable CE ratio an extension to higher ages should 
be preferred rather than an extension to ages under 50 years. 
The mortality reductions we predicted should be regarded as estimates and some 
factors not taken into account in this analysis could affect these estimates. Future 
changes in the mortality or incidence in breast cancer were not accounted for. In the 
UK a decrease in mortality was shown before the screening could have had its effect on 
mortality (Quinn and Allen, 1995). The widespread use of tamoxifen during this period 
in the UK may be important. Another aspect not considered in this analysis is 
opportunistic screening, before introducing screening in the target population. These 
processes might also playa role in Catalonia and would probably result in less 
potential effectiveness of screening, although it is very difficult to quantify these effects. 
The numbers of the Catalonian pilot project were much too small to derive the quality 
of the screening programme. However, the prevalence:incidence ratio in Navarra was 
approximately 3.7 for the age group 45-64 years and the stage-distribution was as 
favourable as in the Dutch national screening (Ascunce et a/., 1994; de Koning et a/., 
1995; van den Akker-van Marie et a/., 1997). The early indicators of efficacy in the 
Spanish setting seem not unfavourable. 
The method used with regard to the costs may not represent the true val ue of re-
source use in the Spanish situation. Using the GDP-PPP and a correction for health care 
might be too approximate for the specialised field of breast cancer screening. Another 
aspect is that no correction was made for quality of life. From other analyses it is clear 
that the number of quality adjusted life-years (QAL Ys) lost due to screening on a na-
tional level was almost equal to the number of QAL Ys saved by screening 
(Beemsterboer et al., 1994; de Koning et al., 1991). Correction for quality of life would 
not change the conclusions of this analysis. 
In countries where mortality from breast cancer is increasing (La Vecchia et al., 
1992; Sanchez et a/., 1994) and the introduction of breast cancer screening is a policy 
priority, the diffusion of opportunistic screening is usually rapid in younger age groups 
where the effectiveness is less clear (Almazan et al., 1995). In that situation, the impor-
tance of the benefits of breast cancer screening in the older age group should be the 
incentive for policy making. 
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RADIATION RISK OF 
MAMMOGRAPHY 
RELATED TO BENEFIT 
IN SCREENING PROGRAMMES: 
A FAVOURABLE BALANCE? 
Summary 
Objectives: To estimate the number of breast-cancer deaths induced by low dose ra-
diation in breast-cancer screening programmes compared to numbers prevented. 
Methods: A computer simulation-model on Ole natural history of breast cancer was 
combined with a model from BEIR-Von induced breast-cancer mortality from low lev-
els of radiation. The improvement in prognosis due to screening was based on the re-
sults of the Swedish overview of the randomised screening trials for breast cancer and 
the performance of screening in the Netherlands. Different scenarios (ages and inter-
vals) were used to explore the objectives. Sensitivity analyses were carried out for la-
tency period, dose of mammography, sensitivity of the screening test, early detection 
by screening of induced breast tumours and new 1996-risk estimates by Howe and 
McLaughlin. 
Results: For a screening programme, age group 50-69, 2-year interval, 2 mCy·per view, 
the balance between the number of deaths induced versus those prevented was fa-
vourable; 1:242. When screening is expanded to the age group 40-49 with a 1- or 2-
year interval the results may be less favourable, i.e. 1 :66 and 1:97. According to these 
scenarios and with O,e Dutch scenario as reference, 1 breast-cancer death from radia-
tion may be expected to occur in order to save 8 extra deaths from breast cancer. If 
screening was equally effective in young women as in women aged 50-69, the mar-
ginal value was 1 :ct30. Assuming detection of induced cancers by screening could in-
fluence the ratios by about 30%, but did not substantially alter the cone/usions. The 
new risk estimates by /-lowe and McLaughlin resulted in 5-8 times favourable ratios 
breast-cancer deaths induced to prevented. Besides age group of screening, dose of 
mammography is the other determinant of risk. 
Cone/usions: For screening under the age of 50, the balance between the number of 
breast-cancer deaths prevented by screening versus the number induced by radiatioll 
seems less favourable. Credibility-intervals were however wide, because of many un-
certainties of radiation risk at very low doses. 
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Radiation risk and benefit in breast screening 
INTRODUCTION 
Different studies have demonstrated the risk of inducing breast-cancer deaths through 
high doses of radiation. In atomic bomb survivors the Relative Risk of dying from breast 
cancer for an organ-absorbed dose of 1 Gy was estimated at 2.19 (90%CI; 1.56-3.09) 
during the period following the explosion (1950 to 1985)(Shimizu et a/., 1990). 
Women treated for tuberculosis by fluoroscopy in Sweden and Canada as well as 
women treated for benign breast disease by radiation in the United States were found 
to have developed more breast cancers than expected (Hrubec el a/., 1989; Miller et 
al., 1989; Shore et al., 1986). long term follow-up of radiation therapy for benign 
breast disease in Sweden has shown a statistically significant increase of breast cancer 
among women 40 years of age and older at first treatment (Rate Ratio 3.58 (9S%CI; 
2.77-4.63)(Mattsson et aI., 1993). The average breast dose for the total group of women 
was 5.8 Gy in that study. 
These studies have shown a statistically significant effect of total dose, age at ex-
p'osure and in some studies, time since exposure, on breast-cancer incidence and/or 
mortality. Radiation induced breast-cancer (death) at lower levels is a controversial is-
sue ever since. A major problem with estimates of the effects of low-dose radiation (1 
mGy-100 mGy) is that a very large follow-up study is required to show a statistically 
significant effect. The studies on the effects of low dose radiation that have so far been 
carried out are not yet conclusive (Anonymous, 1994; Boice el a/., 1995), so for the 
time being risk estimates are based on extrapolations of high doses. In a large case-con-
lrol study among radiologic technologists (Boice et a/., 1995) it was concluded that the 
contribution to the risk of developing breast cancer of prolonged exposure to relatively 
low doses of ionising agents was too small to be detectable (RR~1.13; 9S%CI: 0.79-
1.64). 
In a screening programme for women aged 50-69 with a screening-interval of 2 
years, women having mammography would receive an expected lifetime dose of 100-
300 times less than the doses for which a relation with breast-cancer risk was shown. In 
a screening programme, however, many women are exposed to very low doses of ra-
diation. Radiation risks were assumed to be negligible in the national screening pro-
grammes in the Netherlands and the UK (Netherlands, 1987; Vessey, 1991). It ap-
peared however that in the Netherlands larger doses were being administered (1-2 mGy 
per film) (Law, 1991; Young and Ramsdale, 1993) than previously assumed (0.5 mGy 
per examination). In the UK a study was conducted in which the number of cancers 
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induced was compared to the number of cancers detected, taking into account breast 
thickness and number of films needed (Law, 1995). 
In this study the number of breast-cancer deaths induced by radiation due to' 
mammography in a screening programme was directly related to the number of breast-
cancer deaths prevented by that programme. Different scenarios (ages and intervals) 
within a breast-cancer screening programme might account for a different balance be-
tween the number of breast-cancer deaths induced and breast-cancer deaths prevented 
by the programme. The risk of induced breast-cancer deaths has been shown to be de-
pendent on the age at exposure, the time since exposure and on the total accumulated 
dose that might become especially important if screening programmes are extended to 
women under the age of 50. 
METHODS 
Risk estimate 
The model developed for breast cancer in the BEIR-V-report was used to estimate the 
risk of dying from breast cancer due to low dose mammography (BEIR(V), 1990). The 
BEIR-V Committee is a committee of the National Research Council that carried out 
extensive research to advise the US-government on the health consequences of radia-
tion exposure. The BEIR-model is based on parallel analysis of mortality data of two 
cohorts: the Canadian Tuberculosis Fluoroscopy study and a subcohort of the Radiation 
Effects Research Foundation (RERF) Life Span Study for which doses based on the most 
up to date dosimetry system (DS86) were available (Miller et a/., 1989; Shimizu et a/., 
1987). We gave preference to the BEIR-model, firstly because the effect estimates were 
based on two data sets with different ethnic populations and secondly because the data-
set of the patients treated for tuberculosis included older women who had received 
fractionated doses which is more applicable in the quantification of the effects of 
screening. The BEIR-model is a Relative Risk model, in which the extra breast-cancer 
mortality is a percentage of the level of the underlying breast-cancer mortality. The im-
portant modifying factors are "time since exposure" and "age at exposure". In the 
model, the excess risk decreases with increasing age at exposure and also varies with 
time since exposure, with a maximum of approximately 20 years after exposure 
(BEIR(V), 1990). The latency period used was 10 years. Therefore the excess risk y(d) of 
dying from breast cancer after a single exposure to dose dis: 
J{d) ~ 1"( 1 + aT d g(jJ)) 
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with )tJ, age-specific risk of dying from breast cancer without radiation 
and 
g(jJ) ~ expl fJi/ll( T/20) + fJ2ln'( T/20) + fJJ I E-15 )) for E > 15 
with E, age at exposure 
T, years since exposure and for T < 1 0, g(jJ) ~ 0 
d, absorbed glandular dose in Sievert (Sv) 
The estimated parameters (with standard errors between brackets) are: w ~ 1.220 
(0.610), p, ~-0.104 (0.804), p, ~-2.212 (1.376), PJ ~-0.0628 (0.0321). The unit of the 
dose is Sievert (Sv), but for Roentgen, which is the type of radiation in mammography, 
the weight factor equals 1 and thus 1 Sv ~ 1 Gy. 
Benefit of screening programmes 
The computer simulation MISCAN-model (MJcrosimulating SCreening ANalysis) on the 
natural history of breast cancer was used to predict the number of breast-cancer deaths 
prevented (van Gartmarssen, 1995; van GDrtmarssen ct a/., 1990). In the model, breast 
cancer has 4 invasive screen-detectable preclinical stages according to T-stage Df the 
TNM classification of breast cancer and one non-invasive stage (,,0. Scm, 0.5-1 cm, 
1-2cm, > 2cm and dClS). The natural history of breast cancer is modelled as a progres-
sion through these stages. The duration in the different stages follows an exponential 
distribution. Key parameters of the performance of screening are the duration of the 
screen-detectable preclinical disease, sensitivity of mammography and improvement in 
prognosis. The model-assumption Dn sensitivity and mean duration of the screen-de-
tectable preclinical stages had been validated with data from the Dutch pilot screening-
projects in Utrecht and Nijmegen (Collette et a/., 1984; Verbeek ef a/., 1984). Further-
more the model had been shown to adequately predict the early effects of national 
breast-cancer screening in the Netherlands, e.g. age-specific detection rates and stage 
distribution (de Koning et a/., 1995). Demography in the Netherlands and the epide-
miology of breast cancer (clinical stage-distribution, incidence, mortality, survival) and 
the characteristics of the screening programme (attendance, interval, age groups) were 
taken into aCCDunt (table 4.1). 
The improvement in prognosis fDr screen-detected cases in the model was based 
Dn the results of the Swedish overview of the randomised trials. Based Dn the Relative 
Risks (RR) this was estimated to be less fDr WDmen aged 40-49 than for women 50 years 
and older (table 4.1 )(de Koning et a/., 1995). The mDrtality reductiDn fDr screening 
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women aged 40-49 at entry was 10% (RR~0.90 (95%CI;0.65-1.24). For women aged 
50-59 and 60-69 at entry, respectively it was 28% (RR~0.72 (95%CI;0.58-0.90) and 
31 % RR ~0.69 (95%CI;0.54-0.88)) (Nystrom et al., 1993). We also made predictions 
for women 40-49 years, assuming the same effect of breast-cancer screening on mortal-
ity from breast cancer as for older women (50-69), since there is controversy over 
screening younger women and the CI in the Swedish overview was wide. 
Dose 
As part of an extensive quality control system in the Netherlands, the dose of the 40 
mammography devices used in the national screening-programme was assessed daily 
with a Plexiglas phantom of 5 em thickness. The average surface dose was 13.88 mGy 
for 28 kV (kiioVoltage) (Thijssen, 1993) which is the usual power for a mammography 
in the Netherlands. With the power (kV), the Half Value Layer (HVl) and the surface 
Table 4.1 
Incidence, mortality of breast cancer and characteristics of screening in the Netherlands 
Crude Incidence (per 100.000) 
European Standardized Incidence (per 100.000) 
European Standardized Mortality (per 100.000) 
Attendance age 50-69 
age 40-49 
Sensitivity of screening (50-69y4 
DCIS 
invasive tumor:S; 0.5 em 
invasive tumor 0.5-1 em 
invasive tumor 1-2clll 
invasive tumor> 2cm 
Improvement of prognosiS due to screen detections 
DClS 
invasive tumor ::; 0.5 em 
invasive tumor 0.5-1 em 
invasive tumor 1-2cm 
invasive tumor> 2cIll 
106,1 I 
100,6 I 
39,0 2 
70% (decreasing from 75% to 65%) 
75% 
age 40-49 
1.000 
0.310 
0.230 
0.070 
0.050 
0.40 
0.65 
0.80 
0.90 
0.95 
age 50-69 
1.000 
0.892 
0.814 
0.567 
0.395 
1 Source: Incidence of cancer in the Netherlands, 1989 (first report of the Netherlands cancer registry) 
1 Source: Central Bureau of Statistics, 1989 
) Sensitivity: probability of positive screen result when screening a woman with screen-detectable 
preclinical cancer 
4 For women aged 40-44 and 45-59 these values were 60% and 80% of the values for women aged 50-
69, resp_ 
5 Reduction in risk of dying from breast cancer compared to a situation without screening, detected in that 
stage 
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dose (in Roentgen), the absorbed glandular dose (in mGy) in the breast can be calcu-
lated using values for the Normalized Glandular Dose (Dgn, in mGy/Roentgen). The 
Dutch national guidelines for the HVL recommend values between 280101 and 38mm. 
The accompanying Dgn values established by Wu et al. were 1.12 to 1.48 for a mam-
mograph with power of 27-29 kV (Wu et al., 1991). The average dose per one-view 
mammography was calculated as being between 13.88/8.73* 1.12 ~ 1.78 mGy and 
13.88/8.73*1.48~2.35 mGy in the Netherlands (1 Roentgen ~ 8.73 mGy in air). In 
our calculations, an average glandular dose of 2 mGy on the breasts for one-view 
mammography is assumed. At the first screening, a two-view mammography was car-
ried out and a one-view mammography at a subsequent screening. 
Analyses 
In this study the number of breast-cancer deaths induced by radiation was directly re-
lated to the number of breast-cancer deaths prevented by screening in a dynamic popu-
lation. The number of breast-cancer deaths induced by a screening programme was 
calculated by multiplying the age-specific life-time risks (BEIR-modell and the radiation 
dose of screening mammography with the number of women receiving a mam-
mographic examination per 5-year age-category (MISCAN-model). In the BEIR-V report 
Geometric Standard Deviations (GSDs) due to sampling variation, model misspecifica-
tion and non-model factors like population differences and the dosimetry-system were 
reported, resulting in 95% credibility intervals (95%CI) around the predicted number of 
induced breast-cancer deaths. The precision of the number of deaths prevented is in 
accordance with the 95% Confidence Intervals of the Relative Risks from the Swedish 
trials (see also under 'BENEFITS OF SCREENING PROGRAMMES'). 
The screening scenario implemented at a national level in the Netherlands, i.e. 
screening women aged 50-69 with an interval of 2 years was defined as the baseline 
scenario. This was also the reference for calculating marginal results. The results of the 
scenarios were presented for a screening programme introduced in 1990 and carried 
out during a 27-year period. Effects resulting from this programme were also accumu-
lated beyond the 27-year period. 
The effects of different factors influencing the balance of the number of breast-
cancer deaths prevented and induced were analysed. First the effects of age group and 
intervals in screening programmes were predicted. Another variant was analysed in 
which stage specific values for sensitivity were all lowered by 12%, based on screening 
data from Germany (Beemsterboer et aI., 1994). The risk of radiation was proportional 
to the dose in the BEIR-model (an example is shown). The latency period in the BEIR-
model as well as the effectiveness of screening women under age 50 was varied in 
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Figure 4.1 
Expected lifetime risk of breast cancer death by age at screening per 1 million women 
exposed to 1 mGy (95% Credibility Intervals), BEIR-V (1990) and Howe and Mclaughlin 
(1996) 
other sensitivity analyses. Recently a study was published on radiation risk wilh a 7-
years longer follow-up of the Canadian Tuberculosis Fluoroscopy study (one of the 2 
cohorts as used by the BEIR-Committee) (Howe and McLaughlin, 1996). We also 
showed a scenario, based on the model proposed in that study 
Women with radiation induced cancers can only partly benefit from the same 
screening programme. The reason for this is that a fair amount of these induced cancers 
will not be detected by screening, either because they emerge at older ages, or they are 
diagnosed between screening examinations. These factors taking into account, a linear-
ly decreasing mortality reduction of 30% for cancers induced by exposure at age 40 to 
0% for cancers induced by exposure at age 70 (upper age-limit of screening) was as-
sumed. The results were shown in a sensitivity analysis. 
RESULTS 
The relationship between the risk of breast-cancer deaths induced by radiation and age 
is shown in figure 4.1. Based on the BEIR-model and the Dutch demography and mor-
tality from breast cancer, women aged 40-44 who are exposed to 1 mGy, have a life-
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time excess risk of dying from breast cancer of 5 per million. These lifetime risks 
decrease with increasing age at exposure. Using the recently published update by 
Howe and McLaughlin resulted in much lower age-specific radiation risks (Howe and 
Mclaughlin, 1996). 
In the Netherlands, the total expected number of breast-cancer deaths prevented 
through a 27-year screening programme for women aged 50-69 and at an interval of 2 
years is 19,000, that is approximately 700 breast-cancer deaths prevented each year in 
a steady state situation. The reduction in breast-cancer mortality in the total female 
population is expected to be 17% (de Koning et al., 1995). With the same programme, 
79 breast-cancer deaths were expected to be induced by radiation, yielding a ratio of 
breast-cancer deaths induced and prevented of 1 :242 (table 4.2). The 95% credibility 
intervals of the number of breast-cancer deaths induced, based on the GSDs of the 
BEIR-model were however wide. 
Table 4.2 
Number of breast cancer deaths induced and prevented in breast cancer screening programs 
for different age groups, intervals and improvement in prognosis 
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Scenario ~.S ~ z .S u ~ g a. ~ ~:.::-a. 
Screening ages and intervals 
BASElINE 50-69, 79 (10-627) 5.1 1:242 
SCENARIO interval 2 years 
40-69, 208 (34-1,318) 7.9 1 :97 1 :8 
interval 2 years 
40-69 322 (55-1,942) 8.6 1 :66 1 :8 
40-49, interval 1 year 
50-69, interval 2 years 
40-69 387 (63-2,468) 7.3 1 :73 1 :30 
interval 1 year 
Scenarios with the improvement in prognosis for under age 50 as hig!} as for 50-69 
40-69 322 (55-1,942) 8.6 1 :80 1 :27 
40-49, interval 1 year 
50-69, interval 2 years 
1 95%CI =95% Credibility Interval, based on the Geometric Standard Deviations by BEIR-V (1990). 
2 With the scenario of screening women aged 50-69 with a 2-year interval as a reference 
3 Marginal: the exIra number of breast cancer deaths prevented divided by the extra number of breast 
cancer deaths induced 
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Figure 4.2 
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D."=" point estimate 50-69 (242:1) 40-69 (112:1) 
0.68 0.7 0.72 0.74 0.76 
RR of dying from breast cancer 
Number of prevented breast cancer deaths to 1 induced with 95% Credibility Intervals of the 
BEIR-V report and the 95% Confidence Intervals of the mortality reduction in the Swedish 
trials for 2 scenarios (baseline scenario and the scenario of screening women aged 40-69 with 
an interval of 2 years) 
According to the study design of the trial for women under age 50 in the UK the effects 
of a scenario of screening women aged 40 to 49 with a 1-year interval and for the age 
group 50-69 with a 2-year interval were calculated. The ratio of the number of breast-
cancer deaths induced and breast-cancer deaths prevented was about 4 times worse 
than the baseline scenario (table 4.2). We also assumed the same improvement in prog-
nosis for women under 50 as for women aged 50-69. The number of breast cancers 
induced did not change but the number of women who benefited from screening 
increased, resulting in a more favourable ratio of breast cancer deaths induced to pre-
vented (table 4.2). If all women aged 40-69 were screened with a 2-year interval this 
ratio improved even more, while a 1-year interval would lead to a ratio of 1:73 (table 
2). The results of the marginal differences between the scenario of screening women 
aged 50-69 with a 2-year interval and the scenarios with an extension of these pro-
grammes to younger women with a 1- or 2-year interval are of special interest. In order 
to prevent 8 extra deaths from breast cancer, 1 breast-cancer death from radiation may 
be expected to occur in both scenarios (table 4.2). In the scenario with better prognosis 
for women aged 40-49 this marginal ratio was much more favourable for a 1-year and a 
2-year interval for women under 50 (table 4.2). 
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Table 4.3 
Number of breast cancer deaths induced and prevented in breast cancer screening programs 
for different sensitivity analyses 
Scenario Total no. deaths induced (95% el)' 
No. deaths 
induced 
1106 screens 
Ratio 
(induced: 
prevented) 
Scenarios with prevention of dying from radiation-induced breast cancer by screening 
50-69 65 (8-519) 4.2 
interva! 2 years 
40-69' 237 (40-1,451) 6.3 
40-49, interval 1 year 
50-69, interva! 2 years 
Scenario with a 12 % lower sensitivity 
50-69 79 (10-630) 5.1 
interval 2 years 
Scenario with a higher dose, 4mG}' per view 
50-69 158 (20-1,254) 10.1 
interva! 2 years 
Scenarios without a latency period (a) and latency period of 15 years(b) 
(a) 50-69 81 (10-647) 5.2 
interval 2 years 
40-69 ' 329 (56-1,985) 
40-49, interval 1 year 
50-69, interval 2 years 
(b) 50-69 66 (9-522) 
interval 2 years 
40-69 ' 283 (49-1,686) 
40-49, interva! 1 year 
50-69, interva! 2 years 
Scenarios with tIle model based on Howe and McLaughlin 3 
50-69 10 
interval 2 years 
40-69 ' 
40-49, interval 1 year 
50-69, interval 2 years 
67 
8.8 
4.2 
7.6 
0.7 
1.8 
1 :294 
1 :108 
1 :220 
1: 121 
1 :236 
1 :78 
1 :289 
1:91 
1:1912 
1 :317 
1 95%CI =95% Credibility Interval, based on the Geometric Standard Deviations by BEIR-Y (1990) 
2 Improvement in prognosis for under age 50 as high as for women aged 50-69 
J 95%0 cou!d not be assessed, because no overall standard error of the model was given in the article of 
Howe and McLaughlin (1996) 
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With the 95% confidence limits of the RR of the reduction in mortality for the age 
group 50-69 from the Swedish trials, we calculated the range of the number of breast-
cancer deaths prevented. The results of 2 scenarios (baseline scenario and age-group 
40-69, interval of 2-years) are presented in figure 4.2, together with the 95% credibility 
intervals of the number of induced cancer deaths. The same confidence boundaries of 
the RR of mortality reduction were used for both scenarios, because the improvement 
in prognosis for women under age 50 was assumed as high as for women 50-69 of age. 
The boundaries of the RR of mortality reduction did not greatly influence the ratio in-
duced to prevented, while the estimate of induced cancer deaths did. Due to large 
credibility 'intervals the worst ratio induced to prevented was 1 :31 while the mo~t fa-
vourable estimate was 1:1910 in the baseline scenario. The ratio prevented to induced 
is more favourable for the baseline scenario, but the absolute number of induced can-
cer deaths is however higher for the scenario for women aged 40-69 resulting in less 
wide credibility boundaries and thus a smaller area in figure 4.2. 
The ratios between the induced and prevented breast-cancer deaths taking into account 
prevention of dying from radiation induced breast cancer by screening are shown in 
table 4.3. These values did not deviate very much from the values where screen detec-
tion was not taken into account (tables 4.3 and 4.2). 
With lower sensitivity (12%) the number of induced breast-cancer deaths will not 
change because approximately the same number of women is screened. The nllmber of 
breast-cancer deaths prevented will however be lower, since less breast cancers are 
detected, resulting in less cancers prevented per one induced. 
The number of breast cancers induced in the BEIR-model is proportional to the 
dose of mammography resulting in twice as many induced cancers with a double dose 
(4mGy per view, table 4.3). The effect of variation in the latency period did not greatly 
influence the results (table 4.3). The scenarios with the estimate in radiation risk based 
on the study by Howe and Mclaughlin resulted in much lower (up to 5 times) numbers 
of cancers induced (table 4.3). 
DISCUSSION 
Screening women under 50 is still a controversial topic, also according to the result of 
the NIH Consensus Panel. They recently concluded that the data currently available do 
not warrant a universal recommendation for mammography for all women in their for-
ties (National Institutes of Health Consensus Development Panel, 1997). Women 
should be informed and decide for themselves about the balance of effects and risks. 
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The balance between the number of breast-cancer deaths induced by radiation and 
those prevented by early detection might be significantly more unfavourable for this 
age group. 
Compared to the baseline scenario of screening women aged 50-69 with an inter-
val of 2 years (ratio induced:prevented ~ 1 :242), it was shown that the ratio between the 
number of breast-cancer deaths induced and those prevented became less favourable 
when screening was extended to women aged 40-49 with a 2- or 1-year interval (1 :97 
and 1 :66, respectively). The marginal ratio for both these scenarios is even much 
worse, i.e. 1:8 (reference: baseline scenario). 
There are a number of reasons for this unfavourable marginal ratio. Firstly we 
assumed there would be less improvement in prognosis for women aged 40-49 than for 
women aged 50-69. This assumption was based on the initial Swedish trial results (de 
Koning et a/., 1995). If the improvement in prognosis for women under 50 was 
assumed to be as high as for women of 50-69 years of age, the balance became more 
favourable, but was still 2-3 times worse than for women aged 50-69 years (table 2). 
"Age at exposure" is an important determinant of the risk of radiation with higher 
lifetime risks of radiation for younger women (BEIR(V), 1990). Another reason is that 
the absolute effects of screening under 50 years are less because the mortality and 
underlying incidence is lower. In this age group more examinations have to be carried 
out to detect one breast cancer than in older women. Therefore more women are 
exposed to radiation to prevent one breast-cancer death. Finally a lower sensitivity of 
mammography among women aged 40-49 was assumed which also has a negative 
effect on the balance. 
The recently published model by Howe and Mclaughlin (Howe and Mclaughlin, 
1996) resulted in a ratio of cancer deaths induced to prevented that was 5-8 times less 
than the results attained using the BEIR-model. In this new model time since exposure 
was not taken into account. On the basis of biological plausibility with respect to time 
since exposure and the fact that 7 years longer follow-up of only 1 of the cohorts is un-
likely to change the risk estimates by a factor 5-8, the risk estimates in the present study 
seem the most reasonable approach until the new BEIR-report will emerge. Further-
more, both the BEIR-Committee and Howe and McLaughlin have decided not to in-
clude the Nova Scotia cohort, who had been exposed to much higher doses, resulting 
in relatively more excess deaths. Including these women for the risk estimates would 
have resulted in higher risk estimates, in spite of the relatively small study population. 
As with all studies on risk of low dose radiation there is no direct evidence of risk of 
doses within the mammographic range. To quantify these risks nonetheless, extrapola-
tions from high to low doses should be made. These extrapolations also include as-
63 
Chapter 4 
sumptions on fractionation versus one dose, linear versus quadratic and extrapolations 
across populations. 
The assumptions in the BEIR-model have not been disproved in recent literature. 
In a study on direct estimates on cancer mortality due to low doses of ionising radiation 
among nuclear industry workers (Anonymous, 1994), it was concluded that the risk 
estimates obtained by linear extrapolation from higli to low doses from the studies of 
atomic bomb survivors were unlikely to be substantially in error. Additionally they 
concluded that there was little evidence for heterogeneity of risk across study popula-
tions. This was confirmed by the analysis of the BEIR-committee in which no significant 
difference was found in the Relative Risk for mortality of breast cancer between atomic-
bomb survivors and patients treated for tuberculosis. Furthermore, the absolute excess 
risks were approximately equal (BEIR(V), 1990). Comparisons of the risk estimates of 
atomic bomb survivors with data from patient populations who received x-ray expo-
sures in a few fractions and mUltiple fractions suggest that dose-fractionation may not 
be an important modifier of risk (Land et a/., 1980; UNsCEAR, 1994). In the BEIR-V 
model, a linear relationship is assumed between risk and low doses of radiation which 
is in agreement with radiobiological target theories (UNsCEAR, 1993) and is in accor-
dance with other literature on this subject (Land, 1995; Mattsson et a/., 1995; Tokunaga 
et a/., 1994). 
Some uncertainty has occurred in estimating the glandular dose. In this study we 
did not use real estimates of the surface dose but used the values measured with a 
phantom. It could be questioned whether a phantom (computable to a composition of 
50% fat and 50% glandular tissue), is a good approximation of a breast. In a study by 
Cross the breast composition varied between 10% gland and 90% fat and 90% glandu-
lar tissue and 10% fat. The most frequent composition was 30% glandular and 70% 
fatty tissue. In their study of 212 women the calculated dose to the breast was between 
1.5 and 2.5 mGy, using the normalised dose values of the gland by Wu et al. (Cross, 
1994). Young et al. found a mean glandular dose of 1.24 mGy to the standard breast for 
258 mammography systems in the UK screening programme (Young and Ramsdale, 
1993). Recently they have suggested a higher target film denSity, which, with the same 
power (kiloVoltage) will result in higher doses to the breast (Young et a/., 1994). These 
reported values for doses are in the range of those we assumed in this study. 
Dose of mammography is an important determinant because the induction of 
breast-cancer deaths is proportional with dose (table 4.3). This study illustrates the 
importance of good documentation of the entrance exposure to the breast. The main 
reason for an increase in dose during the last decade is a trade off between dose and 
image quality. By improving image quality (contrast) more and smaller cancers can be 
detected (Thijssen, 1993) which is expected to result in a higher reduction in mortality 
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from breast cancer. Therefore the dose should not be lowered if the image quality is 
negatively influenced. Based on extensive research carried out in the Netherlands on 
the quality control network, we assumed an optimal image quality with a dose of 2 
mGy (Thijssen, 1993). Further research is needed to determine the doses given during 
screening mammography in relation to the thickness of the breast and the age of the 
women. This will enable better assessment of the risks to certain subgroups. law has 
already done this in some detail with respect to breast thickness and number of films 
per view (Law, 1995). 
Sub·optimal technical quality of mammography might also result in much larger 
quantities of radiation dose per examination or a lower sensitivity of mammography 
than assumed for the Netherlands. This affects the balance between the number of 
breast-cancer deaths prevented and induced substantially and is of special importance 
for countries where breast-cancer screening has not yet been introduced. Quality assur-
ance measurements have to be carried out before and during the introduction of new 
breast-cancer screening programmes to maximise the image quality and sensitivity with 
a minimum dose to the breasts. 
Feig has published on the same topic and has used the estimates of the BEIR-V 
Committee to calculate the extra number of breast-cancer deaths (Feig and Hendrick, 
1993). In our calculations we directly estimated the risk of radiation and the benefit 
from the screening programme in the total population by using the MISCAN-model. 
The estimate of the mortality reduction by Feig was based on a complete screening 
programme while the effects of radiation were based on only one screening examina-
tion at a certain age. It is arbitrary and too optimistic to assume a benefit in life 
expectancy for a woman aged 40-44 with screen detected cancer of at least 20% due to 
a single screening (Feig and Hendrick, 1993). 
Although we assume a mortality reduction of screen detected breast cancers of 
over 50% in our model (van Oortmarssen ct al., 1990), the 30% reduction of radiation-
induced cancers as used in this study should be judged as an upper limit. Firstly, due to 
the 10-year latency period and the shape of the risk function many fatal-cancers origi-
nate after the upper age limit of screening. This proportion increases with increasing 
age at exposure. After the age of 60, 100% of all radiation induced cancer deaths occur 
after the age of 70. Moreover not all induced cancers under the age of 70 will be de-
tected, either because they are missed by screening or because fast-growing tumours 
appear in the interval between screens. Another reason is that not all women will at-
tend the screening every time. 
Taking into account detection of radiation induced cancers by screening, the ratio 
of breast cancers induced to those prevented is still 1: 1 08 for women aged 40-69 
screened with a 1- and, from age 50 with a 2-year interval. This is not substantially dif-
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ferent from the situation in which the induced cancers were not detected by screening 
(ratio 1 :80). This relatively small difference in the ratio of breast cancers induced to 
those prevented illustrates that the radiation risk should not be neglected by simply as-
suming that the women with induced cancers will be prevented from dying by screen-
ing. 
The results of a study by Law et al. were not completely comparable, because the 
outcome measure they used was the number of cancers induced versus detected and 
they used other (higher) risk estimates, but the conclusions were however in agreement 
(Law, 1995). 
The most important determinants of radiation risk in breast cancer screening pro-
grammes are dose and age group of the screening. Despite the uncertainties in risk es-
timation, it is clear that effectiveness of screening is not the only criterion for the intro-
duction of a screening programme. Although the risk of radiation is very low, the raclia-
tion dose in any breast cancer screening programme should not be ignored. 
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MAMMOGRAPHY REQUESTS IN 
GENERAL PRACTICE DURING THE 
INTRODUCTION OF NATIONWIDE 
BREAST CANCER SCREENING, 
1988-1995 
Summary 
Introducing an organised breast cancer screening programme for cerlain age groups in 
a population might induce opportunistic screening in adjacent (non-invited) age groups 
and influence health behaviour in the target population. We analysed the effect of the 
start of the Dl/tch national screening programme on the number of mammographies 
requested by 43-45 general practices for the age groups 30-39, 40-49, 50-69 and 70 + 
years, using logistic regression analysis. In all age groups an immediate increase was 
observed in the number of mammography requests after the start of the screening, 
which was largest and stalistically significant in tile target-population of the screening 
programme (age 50-69 years). More tllan two years after the start of screening howe,ver 
the number of mammography requests in all age groups had decreased to the level of 
before the start and in the age group 50-69 years the number of mammograpllies was 
significantly lower than before the screening started. The unexpected increase in 
mammographies after the start of the breast cancer screening programme might be re-
lated to registry problems or to the process of building up the screening programme. 
Eventually there was a decrease in the number of mammographies in the target-popu-
lation, probably an effect of the introduction of the national screening programme. 
Opportunistic screening was not clearly demonstrated in adjacent age groups. 
Mammography requests and nationwide breast cancer screening, 1988-1995 
INTRODUCTION 
The Dutch national breast cancer screening programme started in 1989. Since then, 
women aged 50-69 years have been actively invited for biennial screening with mam-
mography. Theparticipation rate is 80% (de Koning et al., 1995; Fracheboud el a/., 
1998). Before screening was introduced, a cost-effectiveness analysis estimated a 16% 
reduction of breast cancer mortality in the total female population (de Koning el al., 
1991). Early effectiveness indicators of the screening programme are encouraging 
(Fracheboud el al., 1998). The detection rate at first screening was approximately 6A 
per 1000 screens, in accordance with expectations. The stage distribution of the screen-
detected cancers was much more favourable than for breast cancer clinically diagnosed 
before the start of the screening programme (de Koning el a/., 1995; Fracheboud et a/., 
1998). 
The expected changes in diagnostic procedures were also published (de Koning el 
al., 1990). One hypothesis was that the number of mammographies undertaken outside 
the screening programme in the target-population would decrease, because of the in-
troduction of screening. However, it was considered that the introduction ·of screening 
might induce more mammographies in adjacent (non-invited) age groups. Opportunis-
tic screening in the target population could negatively influence the effectiveness of 
screening and costs of health care. Induced opportunistic screening in adjacent age 
groups, where the balance between favourable and adverse effects of screening is con-
sidered to be worse, could be seen as a negative effect from the public health perspec-
tive. Quantifying these mechanisms is important for a complete evaluation of the na-
tional screening programme. 
In the Netherlands, the general practitioner functions as a gatekeeper to health 
care. All women who have symptoms of breast cancer or who are concerned about 
their breasts have to visit a general practitioner in order to be referred to a radiologist or 
surgeon for mammography. In an existing registration system of 43-45 general prac-
tices, a specific item was introduced that related to mammography practice during the 
build-up period of the screening programme (1988-1995). Using this registry we exam-
ined the effect of the start of the screening programme on the number of malil-
mographies requested in general practice. 
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MATERIAL AND METHODS 
Registration by general practices 
A group of 43'45 general practices (sentinel practices) annually register consultations 
about specific health problems, which are collected and processed by the NIVEL 
(Netherlands Institute of Primary Health Care). The population covered by this registra-
tion is approximately 1 % of the total population in the Netherlands. These practices are 
heterogeneous with regard to the degree of urbanisation and geographic area and are 
considered representative of the total population in the Netherlands (Bartelds, 1996). 
The popUlation covered by the general practice is classified in 5-year age groups and is 
reassessed every 2 years. 
The national screening programme was introduced gradually and complete na-
tional coverage was reached at the end of 1997. Between 1989 and 1997 screening 
took place in some parts of the Netherlands, but not in others. 
Since 1988, the number of mammographic examinations requested by general 
practitioners has been recorded. The present analysis involves all mammographies for 
which women were referred by their general practitioner and covers the period 1988 
until 1995. These mammographies cover the ones made for preventive and for clinical 
motives (on the basis of complaints or symptoms). These requests were linked to infor-
mation on the start of the national screening programme (by month and year) in the 
municipalities of the general practitioners participating in the registry. 
Statistical analysis 
All analyses were carried out using the SPSS-package. Logistic regression analysis was 
used to model the chance of mammography, depending on whether or not the screen-
ing programme had started at that time. Separate logistic regression models were fitted 
for the age groups studied (30-39,40-49, 50-69 and 70+ years). In the logistic model, 
calendar time (in months) was included as a continuous variable. General practice was 
also included to adjust for different levels of mammography requests. 
To describe the effect of the start of the screening programme in the model, the 
total period covered in each general practice was divided into three intervals. The first 
interval ended at the start of the screening programme in each practice, the second in-
terval covered the 2 years after the start of the programme and the last interval was 
from 2 years after the start until the end of the observation period. Each interval was 
modelled, using a separate linear trend with calendar time (termed TREND). An instant 
leap to a new value was allowed at the start of the screening programme, that is at the 
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transition from the first to the second interval (termed START). The transition from the 
second to the third interval however, was continuous (termed REBOUND). The dilfer-
ence between the. level before the start of the national screening and more than 2 years 
afterwards was modelled by DIFF. See figure 5.1 for the general pattern of mammogra-
phy. 
The logistic regression model of the start of the screening was somewhat complex. 
We also fitted models with a 1- and 3-year interval after the start of the screening, but 
this did not result in a better fit. We tested the underlying trend before and after the 
start of the screening, but this was not statistically significant different. 
RESULTS 
The number of general practices participating in this study ranged from 43 to 45 per 
year (average duration of participation from 1988 to 1995: 6,4 years). Three practices 
were in municipalities where experimental screening projects had already been carried 
out before the start of the national screening programme in 1989. In 1995, in 5 prac-
tices, the national screening programme had not yet begun. The coverage of the na-
tional screening programme accorded well with the percentage of general practices 
where the screening had already started, emphasising the representativeness of the 
sample of the population covered by the general practitioners (data not shown). 
During the whole period mammography was requested each year for an average 
of 2.7% of the women in the age group 40-49 years and, for 1.8% in the age groups 
30-39 years and 50·69 years. For the oldest age group (70+ years) this was 0.5%. The 
number of mammographies by age and year showed a fluctuating pattern, but overall 
(and age standardised) a gradual increase occurred from 1988 to 1992 with a gradual 
decrease from 1993 onwards. The age group 30-39 years and 40-49 years showed 
fewer fluctuations than older ages. For the number of mammographies by start of the 
national screening programme overall (and age standardised) a higher level was ob-
served 0-2 years after the start than before and more than 2 years after the start (table 
5.1). 
In table 5.2, the average number of mammographies requested by general practitioners 
is presented, stratified by start of the screening. Since screening had already started 
before 1988 in some municipalities of the general practitioners and in some the 
screening did not start in period studied, table 5.2 compares the results from these two 
groups. In all age groups, the rate of mammography requests was significantly higher if 
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Table 5.1 
Number of participating general practices and number of mammographies by age and start of screening per year. 
'88 '89 '90 '91 '92 '93 '94 . '95 '88-'95 
participating general practices 45 45 44 43 43 45 45 45 
% of general practices where screening started' 4% 16% 9% 21 % 24% 22% 11% 
number of mammography per 10,000 women) 
age 30-39 162 164 147 166 186 192 220 199 180 
age 40-49 200 233 231 295 277 275 323 300 269 
age 50-69 103 120 158 197 151 323 218 192 184 
age 70+ 24 25 39 55 41 87 65 59 50 
before start (age stand.) 129 139 150 170 177 156 190 169 157 
0-2 years after start (age standardised) 200 212 276 172 376 259 194 267 
> 2 years after start (age standardised) 105 164 110 203 138 148 198 207 175 
total (age standardised) 127 141 151 186 170 235 216 195 179 
absolute numbers 471 514 542 646 572 708 718 663 4834 
tin 3 practices the screening had already started as result of experimental screening project in '74-'75 
0.04 
0.03 
0.02 
0.01 
0.00 
Figure 5.1 
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the screening programme had started, compared with practices where screening had 
not yet started. This could still, however, be only a reflection of differences by general 
practices or area without reference to the introduction of the screening programme. 
In the logistic regression model general practice, calendar time and 3 parameters for the 
start of the screening programme (see Material and Methods) were included. The logis-
tic regression model contained the same variables for all age groups in order to achieve 
a consistent presentation. The general pattern that emerged from the analyses is shown 
in figure 5.1. 
Table 5.2 
Number of mammographies per 10.000 women by age and start of the screening, period 1988-
1995 
screening: 
not (yet) started 
started 
age group 
30-39 40-49 50-69 
rate (95%CI) rate (95%CI) rate (95%CI) 
166(156-176) 237(224-250) 151 (142-160) 
208 (192-223) 329 (309-350) 238 (224-253) 
70+ 
rate (95%CI) 
36 (30-42) 
70 (60-80) 
75 
Table 5.3 
Relation between start of the screening, age and mammography requests with adjustment for calendar time and general 
practice (separate age-models, see also figure 5.1) 
age group 
30-39 40-49 50-69 70+ 
OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) 
underlying TREND (per year) 0.99 (0.96-1.02) 1 .03 (1.00-1.06) 1.12 (1.09-1.16) 1.14 (1.05-1.24) 
START 1.12 (0.90-1.38) 1.29 (1.08-1.54) 2.79 (2.40-3.24) 1.74 (1.13-2.67) 
REBOUND (O~2 years; trend per year) 1.05 (0.92-1.20) 0.88 (0.79-0.98) 0.50 (0.46-0.55) 0.84 (0.66-1.07) 
DIFF (level before START - level after REBOUND) 1.26 (1.01-1.56) 0.93 (0.77-1.13) 0.56 (0.46-0.69) 0.94 (0.57-1.56) 
Mammography requests and nationwide breast cancer screening, 1988-1995 
For the youngest age group (30-39 years), almost none of the parameters corre-
sponding to intervals of the start of screening were statistically significant. For all age 
groups, an increase after the start of the screening was observed, but it was most 
prominent for the age groups 50-69 years. The overall time trend in mammography 
. requests was also largest for the age group 50-69 years and for the 70+ group (12% 
and 14 % increase per year, table 5.3). 
During the third interval (more than 2 years after start of screening), the level of 
mammography was lower in all age groups, except the youngest. This reduction in 
mammography examinations was largest and statistically significant for the target popu-
lation (age 50-69 years) of the national screening programme (odds ratio (OR) 0.56, 
95% confidence interval (CI) 0.46-0.69), but not significant in the adjacent age groups 
(table 5.3). It should be noted that this is over and above the increasing background 
trend (see figure 5.1). 
DISCUSSION 
The introduction of the national screening programme has significantly influenced the 
number of mammography requests by general practitioners, except in the age group 
30-39 years. The number of requests first increased after the start and then decreased. 
As expected the number of mammography requests was significantly lower more than 
2 years after the start of the programme in the target ag<> group of the national screening 
programme (50-69 years) than before. In the adjacent age groups, the number of mam-
mography was also lower more than 2 years after the start of the screening programme, 
but the difference was small and not statistically significant. 
Increased opportunistic screening under the age of 50 years after the introduction 
of the screening programme could not be demonstrated in this data. The temporary 
increase after the start of the national screening programme was less prominent in this 
age group than for women aged 50-69 years. We would have expected a permanent 
increase in the number of mammographies that might last more than 2 years after 
screening had started in the case of opportunistic screening: In some European coun-
tries (Sweden, Iceland) screening is carried out also for women under the age of 50 
years. Screening women under 50 years is still a controversial topic, according to the 
results of the NIH Consensus Panel. This panel recently concluded that the data cur-
rently available do not warrant a universal recommendation for mammography for all 
women in their forties (Anonymous, 1997). 
Until 1993, women aged 70 years and older were allowed to participate in the 
screening programme. From 1994 onwards, these women were excluded from the pro-
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gramme. This could have resulted in more mammographies via the general practitioner. 
Furthermore, these measures have directed attention to screening older women that 
could itself have resulted in more requests for mammography. 
Although it has to be noted that· some of the mammographies as requested by the 
general practitioner were for preventive motives and some for diagnostic motives, we 
conclude that opportunistic screening in adjacent age groups did not increase after the 
introduction of the national screening programme for women aged 50-69 years. 
During the period of introducing screening for women aged 50-69 years, a 
continual increase in mammographies was however observed in those aged 40 years 
and over. This could be caused by more breast awareness generated by the programme 
and other factors as was suggested in part to be the cause of the decreased mortality 
from breast cancer in the UK, predating the effect of screening (Stockton et a/., 1997). 
In the period before the introduction of the screening programme the total number of 
mammographies (radiology departments included) had however already shown an 
increase in the Netherlands, implying that other factors also act on this trend. 
Furthermore this increasing background trend was very smali in the age group 40-49 
years, who would be expected most sensitive to breast awareness resulting from the 
screening programme. 
The temporary rise (followed by a decline) in the number of mammography 
request 0-2 years after the local introduction of the national screening programme is 
somewhat surprising for the age group 50-69 years. When asked about this result, the 
participating general practitioners said they were confident that only mammographies 
outside the national screening p~~gramme had been registered, even in this age group. 
These were, however, self-reported data (data not shown). 
The increase could be an artefact caused by extra alertness of the general practi-
tioners to register mammographies after the start of screening. This would imply that 
the real number of mammography requests before the start and possibly also more than 
2 years after screening was introduced was underestimated. Another explanation of 
these results might be that women who had not yet received an invitation, were en-
couraged by publicity surrounding the introduction of screening in their municipality to 
have a mammography via their general practitioner. Furthermore, women who already 
have breast problems or symptoms might not wait for the screening invitation but con-
sult their GP immediately. It is also possible that the general practitioners refer, for a 
clinical mammography, women who did not attend screening. A smali loss in atten-
dance at the population-level could have a relatively high impact on mammography 
numbers in general practice. Literature regarding these issues is scarce. Garstin and col-
leagues observed a 42% increase in mammographies after the start of the national 
screening programme in the UK, which was mainly caused by referral by menopausal 
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clinics and general practitioners (Garstin et a/., 1993). In that study, concern was raised 
that double screening might take place or a false sense of security would occur. 
The decrease in mammography requests by the general practitioner in the target 
population of the Dutch national screening programme can be interpreted as an effect 
of the introduction of screening. Part of this reduction may be due to false reassurance 
after a negative screen result. Still, a considerable number of breast cancer cases is 
diagnosed in the interval between 2 screening examinations (Day et al., 1995; Tabar et 
al., 1992). False reassurance might result in fewer cancers detected in the interval and, 
thus, an undesirable delay of diagnosis and treatment. Additional (qualitative) research 
is needed to unravel further the occurrence of false reassurance and to further interpret 
the sudden rise (and decline) as observed in this study. 
The population covered by the general practices of the NIVEL is representative for 
the total Dutch population with respect to degree of urbanisation and geographic 
spread (Bartelds, 1996). The general practitioners may not be representative of all 
general practitioners. Participating in the registration is on a voluntary basis and it could 
be argued that this implies some selection. These general practitioners could, for 
example, be more restrictive in referring for mammography. Such selection would 
influence the overall level of mammography referrals, but is unlikely to lead to other 
conclusions. Some general practices contributed more to the time trend before the start 
of the screening programme whilst others contributed more to the trend after the start. 
By including general practice as a confounding variable, we adjusted for this. 
Only 1.8% of all women have a mammography via their general practitioner each 
year, whilst 80% of all women aged 50-69 years attend the biennial screening in the 
Netherlands. The relative changes, as represented by the OR's, observed in this study 
were quite large, but have to be interpreted within this perspective. 
In this study, the start of a national screening programme had a large temporary 
effect on the level of mammography requests by general practitioners. We have no 
information on whether this is caused by a change in requests by the women 
themselves, a change in policy of the general practitioner, or both. A decrease of 
mammography requests in the target population of the screening (age 50-69 years) was 
observed after some time. It may reflect the increased uptake of breast cancers and true 
negative results by the national screening programme and certainly supports the 
hypothesis that a screening programme reduces the number of clinical 
mammographies. Our study shows that at the same time it seems not to result in a 
permanent increase in opportunistic screening in wornen from adjacent age groups. 
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CHANGING ROLE OF THREE 
SCREENING MODALITIES IN THE 
EUROPEAN RANDOMISED STUDY OF 
SCREENING FOR PROSTATE CANCER 
(ROTTERDAM) 
Summary 
Objectives: In Europe a randomised screening trial was started to show the effect of 
early detection of prostate cancer on mortality (European Study on Screening of Pros-
tate Cancer). In one centre (Rotterdam), the screening protocol initially consisted of 3 
screening tests: Prostate Specific Antigen (PSA), digital rectal examination (ORE) and 
transrectal ultrasonography (TRUS). A PSA value of;> 4 nglml andlor an abnormality on 
the ORE andlor the TRUS were lIsed to indicate that a biopsy was required. In this 
study we examined the possibilities for a more efficient screening protocol. 
Methods: A logistic regression model was used (0 predict the number of cancers for 
PSA < 4 nglml if af{ men were biopsied (Predictive Index). Effects' of a change in PSA 
cut-off on the outcomes of the screening were explored. Weights were applied (0 pro-
cedures and cancers to explore the possibility of expressing the differences between 
scenarios in one overaf{ figure. 
Results: Biopsies in men with a PSA of < 1 nglml and a positive ORE or TRUS were 
very inefficient. Applying a ORE and a YRUS only in the PSA-range 1.5-3.9 and 2-3.9 
nglml to indicate that a biopsy was required, would result in a decrease of biopsies by 
29%-36% and a decrease of 5%-8% of cancers. However ORE and TRUS were difficult 
to reproduce. A protocol with only PSA ;> 3 nglml as a direct biopsy indication resulted 
in a decrease of detected cancers by 7.6% and of biopsies by 12% and a much more 
simple screening procedure. With the use of the Predictive Index more efficient proto-
cols could be achieved, but this should be viewed as a preliminary finding with the 
disadvantage of necessitating many additional screening visits. 
Conclusion: Given the fact that ORE and TRUS appeared diffiClift to reproduce, a 
change in protocol towards PSA ;> 3 nglml seems acceptable. If screening proofs to be 
effective, a final judgement about an optimal combination of screening tests can be 
made. 
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INTRODUCTION 
Prostate cancer is the second leading cause of cancer deaths in men in many industrial-
ised countries. Tests have been developed to detect prostate cancer at an early stage. In 
retrospective studies, Prostate Specific Antigen (PSA) has been shown to advance the 
diagnosis of prostate cancer (Parkes et a/., 1995; Stenman et a/., 1994). These studies 
cannot however address the effectiveness of screening in the community. 
The goal of the European Randomised Study of Screening for Prostate Cancer 
(ERSPC) is to test if a significant (and relevant) mortality reduction from prostate cancer 
can be achieved by screening (Auvinen et a/., 1996). This is expected to be effected 
through detection of cancer at earlier stages followed by effective treatment. In the Rot-
terdam and Antwerp section of the ERSPC a combination of 3 screening tests were ini-
tially chosen, partly because these (combined) tests had not yet been evaluated in a 
population-based setting. A screening interval of 4 years was based on the ratio of 
prevalence in the first pilot screening to the incidence in the general population 
(McWhorter et a/., 1992; Schroder et a/., 1996) and the knowledge that the disease has 
a slow growth rate, on average. Pilot projects in Rotterdam had shown a high detection 
rate of 3.5%, but the percentage of biopsies was also high, with a high percentage of 
false positive biopsy indications (Schroder et a/., 1996). In order to be acceptable the 
positive effects of screening in terms of mortality reduction should obviously outweigh 
the negative effects (e.g. negative biopsies, costs and side effects of treatment). One 
difficulty in assessing this is the large time lag between the initial negative effects and 
any possible future positive effects. It is too early at present to show whether definite 
mortality reduction can be demonstrated, nevertheless it is important to investigate 
whether the combination of screening tests or cut-off levels of PSA can be changed and 
optimized. In this study, we analysed the balance between disadvantages (screening 
tests and biopsies not resulting in the detection of cancer) and the benefits (cancers de-
tected) from a public health point of view using results from the first 8,600 men 
screened. 
MATERIAL AND METHODS 
The ERSPC in Rotterdam started after pilot projects had been undertaken in Antwerp 
and Rotterdam in June 1994 (Schroder et a/., 1995). In the Rotterdam area, all men in 
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the age group 55-74 were identified by means of the population registry and received a 
letter asking them to participate. Men who responded by returning the intake question-
naire and who provided informed consent were randomised. 
Initially all men in the screening arm received 3 screening tests consisting of a PSA 
determination in the serum (Hybritech-assay), a digital rectal examination (ORE) and a 
transrectal ultrasonography (TRUS) by a resident or staff urologist or trained paramedic. 
Prostate volume was determined by a TRUS using 5-mm step-section planimetry. The 
ORE and TRUS were carried out blind with respect to the PSA-Ievel of the participants. 
If one or more of the 3 tests was positive or suspicious (PSA;o> 4 nglml, hypoechoic le-
sions for the TRUS or induration for the ORE) the participant was referred for transrectal 
biopsy. Biopsies were carried out with a TRUS-guided needle biopsy gun (Man an pro-
mag® 2.2) and 18 gauge Bard® biopsy needle, after taking prophylactic antibiotics at 
least 1 hour before. Sextant biopsies were taken augmented by one biopsy of the hypo-
echoic lesion, if applicable. In cases of positive histology, men were seen by their gen-
eral practitioner and referred for treatment to one of the hospitals in the region. The 
results presented in this study were obtained from the start of the study (June 1994) [1Il-
til january 1997. There was some delay between the final diagnosis and biopsies. As 
this would have influenced the calculations we therefore used a cut-off date when al-
most all biopsy results were known (N ~ 11 biopsies were pending (1.0%), which was 
neglected). 
From june 1994 until january 1996 the participants received all the screening 
tests, i.e. ORE, TRUS and PSA determination (INITIAL PROTOCOL). It became clear that 
below a PSA of 1 nglml the Positive Predictive Value (PPV) was very unfavourable, re-
sulting in the omission of ORE and TRUS below a PSA of 1 nglml from February 1996 
onwards. This change was supported by the Medical Ethical Committee and the Data 
Monitoring Committee of the trial (MODIFIED PROTOCOL). In this study we examined 
grounds for a further change in the screening protocol. Three options to improve the 
screening process were investigated. The first option was a cut-off value of PSA as a 
single and direct indication for biopsy. The second option was a ORE and TRUS below 
a certain PSA cut-off (resulting in additional screening visits for these men). Test results 
above this cut-off were viewed as a direct indication for biopsy. Third, we evaluated the 
use of the Predictive Index (PI, see below) in combination with a PSA cut-off as a bi-
opsy indication, implying additional screening visits for men with PSA below the cut-off 
to determine the PI. 
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Statistical analyses and Predictive Index 
For the statistical analysis, the SPSS-PC package for windows was used. logistic regres-
sion analysis was performed to model the Predictive Index (PI) based on the screening-
test results (ORE, TRUS, log PSA) and log prostate volume (Kranse et a/., in press). The 
PI was defined as the chance of detecting a cancer at biopsy in its dependency on log 
PSA, log prostate volume and the outcome of a TRUS and ORE. Above PSA <: 4 nglml 
the prediction of the number of cancers based on the logistic regression analysis, 
corresponded well with the number of cancers detected by the screening. Therefore we 
applied the logistic regression model to all men screened. Summarising the resulting 
probabilities mounted to the number of potentially detected cancers, if biopsies were 
performed for all men with a PSA < 4 nglml (Kranse et al., in press). 
Applying weights to procedures/events 
Since the non-detection of a cancer is presumed to have more negative impact (lower 
chance of cancer mortality reduction) than performing an additional biopsy (impact on 
Quality of life; negligible chance of mortality induced), we applied weights to the 
screening procedures, the biopsies and the screen detected cancers. These weights 
were used to explore the possibility of expressing the differences between scenarios in 
one overall figure. For the first visit for a PSA test we applied a weight of -1. An addi-
tional visit for the screen tests was weighted as -5. Biopsy was assumed to have a 
weight of -25, while detecting a cancer was weighted as + 250. In this way, a higher 
weight indicates more positive effects for the screened population. Because a screen 
detected cancer could also be a cancer that would never have been diagnosed without 
screening, the weight was chosen quite conservatively with regard to screening. Some 
sensitivity analyses were performed to evaluate the influence of a change in weights on 
the preference between scenarios. 
RESULTS 
June 1994-January 1996, initial protocol 
In table 6.1 the screen results, the number of biopsies and number of cancers detected 
are presented for different PSA-Ievels in the first 4190 men screened. Below a PSA of 4 
nglml, most biopsies were indicated by a positive TRUS either alone or in combination 
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Table 6.1 
Number of screening examinations, ORE and TRUS results, number of biopsies and cancers detected and positive predictive value (PPV) for 
different PSA-values, June 1994-January 1996 (INITIAL PROTOCOL) 
PSA (ng/mll 
0-0.9 1-1.9 2-2.9 3-3.9 4-5.9 &-7.9 8;9.9 ,,10 total 
A number screened 1451 1339 541 298 293 119 60 89 4190 
% 35% 32% 13% 7% 7% 3% 1% 2% 100% 
B % of biopsies among screened 12% 15% 17% 15% 96% 89% 97% 92% 25% 
indicated by: DRE+,TRUS+ 18% 22% 18% 18% 6% 10% 14% 23% 15% 
DRE-,TRUS+ 40% 45% 44% 53% 8% 9% 7% 6% 26% 
DRE+, TRUS- 42% 33% 38% 29% 7% 10% 3% 13% 22% 
PSA only 78% 71% 76.% 57% 37% 
C number of cancers 4 10 13 8 50 28 23 47 183 
D PPV of biopsy (all) 2% 5% 14% 18% 18% 26% 40% 57% 18% 
indicated by: DRE+,TRUS+ 6% 7% 13% 25% 44% 100% 88% 100% 35% 
DRE-,TRUS + 0% 3% 18% 8% 30% 22% 75% 100% 11 % 
DRE+ ,TRUS- 3% 6% 12% 31% 35% 46% 100% 55% 15% 
PSA only 13% 13% 25% 36% 17% 
E % of cancers detected among screened 0.3% 0.7% 2.4% 2.7% 17.1% 23.5% 38.3% 52.8% 4.4% 
Table 6.2 
Changes in number of screening visits, biopsies and cancers detected for different changes to less intensive protocols compared to the 
INITIAL PROTOCOL 
# screening visits 
% false positive cancer: Screen j ng Protocol Biopsy # ORE & TRUS # biopsies # cancers biopsy indication additional biopsies first visit 
visit (incremental) 
PSA, ORE and TRUS PSA <:!: 4 or 4190 4190 1039 183 20% 1,45 
(INITIAL PROTOCOL) DREfTRU5+ 
CHANGES IN # screening visits # ORE & TRUS % false positive cancer: PROTOCOL Biopsy # biopsies # cancers biopsy 
indication first visit additional less (screening) less (% tess (%) biopsies (incremental) 
Screening Protocol (1) visit (2) (%) (3) (4) 
PSA, and for::: 1-3.9 PSA:::4or 4190 2178 -2022 (-48%) .180 (-17%) -4 (·2%) 16 % 1,24 
ng/ml, ORE and TRUS DREfTRUS+ 
PSA, and for;:; 1.5-3.9 PSA;:; 4 or 4190 1396 -2794 (-67%) -299 (-29%) -9 (-5%) 14% 1,16 
ng/ml, DRE and TRUS DREfTRUS+ 
PSA, and for '2:: 2-3.9 PSA '2:: 4 or 4190 839 -3351 (-80%) ·377 (-36%) -14 (·8%) 12% 1,7 
ng/ml' ORE and TRUS OREfTRUS+ 
PSA, and for:== 3-3.9 PSA~4or 4190 298 -3892 (-93%) -467 (-45%) -27 (-15%) 10% 1,6 
ng/ml, DRE and TRUS OREfTRUS+ 
PSA PSA~4 4190 -4190 (-1 aDO/oJ -512(-49%) -35 (- 19%) 9% 
(1) PSA-test 
(2) ORE and TRUS for men with PSA between cut-off value and 4 nglml 
(3) # of bioQsies - # of cancers 
# of participants 
(4) reference is less intensive protocol 
Table 6.3 
Number of screening examinations, ORE and TRUS results, number of biopsies and cancers detected and positive predictive value (PPV) for 
different PSA-values, January 1996-January 1997 (MODIFIED PROTOCOL) 
PSA (ng/ml) 
0-0.9 1-1.9 2·2.9 3-3.9 4-5.9 6-7.9 8-9.9 <:10 total 
A number screened 1594 1324 552 344 307 141 60 109 4431 
36% 30% 13% 8% 7% 3% 1% 2% 100% 
B % of biopsy among screened 21% 20% ~3% 91% 90% 93% 95% 24% 
i nd i cated by: DRE+,TRUS+ 18% 14% 22% 14% 18% 13% 35% 18% 
DRE-,TRUS+ 37% 34% 32% 16% 16% 11% 15% 25% 
DRE+, TRUS- 46% 52% 47% 18% 17% 25% 9% 31% 
PSA only 52% 50% S2~Jo 42% 26% 
C number of cancers 28 10 33 64 35 13 59 242 
D PPV of biopsy (all) 10% 9% 29% 23% 28% 23% 58% 23% 
indicated by: DRE+,TRUS+ 17'% 0% 60% 65% 52% 71% 89% 50% 
DRE-,TRUS+ 9% 10% 19% 13% 20% 33% 73% 16% 
DRE+, TRUS- 9% 11% 21% 27% 19% 29% 44% 16% 
PSA only 13% 24% .7% 27% 17% 
E detection rate among screened 2.1% 1.8% 9.6% 20.8% 24.8% 21.7% 54.1% 5.5% 
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with a positive DRE, while for PSA <: 4 nglml, most biopsies were indicated by PSA 
only. The overall Positive Predictive Value (PPV) increased with increasing PSA-Ievels, 
but for PSA categories < 4 nglml the PPVs were very low. The highest PPV (80%) was 
observed in men with three positive screening tests. The number of cancers divided by 
the number of men screened increases with increasing PSA-Ievels. An increase at the 
transition of PSA of 3-3.9 nglml to 4 nglml and above is reflects the policy that biopsies 
were available for everyone from PSA 4 nglml and upwards. 
Implications of changes in protocol 
The INITIAL PROTOCOL seemed clearly quite inefficient with regard to the use of a DRE 
and a TRUS for some categories of PSA. In table 6.2 we estimated the consequences of 
less intensive screening protocols, comparing the number of biopsies and screening 
tests, the resulting number of cancers detected and the false positive rates (FP%). Both a 
DRE and a TRUS have approximately the same test characteristics (table 6.1) and 
therefore omitting them would result in approximately the same decrease in the 
number of biopsies at the expense of about the same number of cancers. For both the 
participants and the logistics of the trial it would have been preferable to have both 
tests omitted below certain PSA-Ievels. A change in protocol with no DRE and TRUS for 
certain levels of PSA implies that a portion of the participants having to attend twice for 
the screening would have to have an additional DRE and TRUS. 
With increasing cut-off levels of PSA, less additional visits would be needed, re-
sulting in less biopsies and less cancers detected (table 6.2). All changes in the protocol 
would lead to a lower percentage of false positive biopsies than the INITIAL PROTOCOl, 
at the expense of missing screen-detected cancers (2-19%). The trade-off between both 
is reflected in the incremental cancer/biopsy rate, calculated as the less number of can-
cers detected, divided by the less number of biopsies, when the PSA cut-off is increased 
by one step (last column). This ratio improved with increasing cut-off levels of PSA, 
showing that the number of men biopsied decreased relatively less than the number of 
cancers detected. 
February 1996-January 1997; modified protocol 
From February 1996, no DRE and TRUS were performed in men with a PSA < 1 nglml 
on the basis of the results from table 6.2. In table 6.3, the results of the next 4431 
screens are presented for the MODIFIED PROTOCOL. An absolute increase in the number 
of biopsies compared to the INITIAL PROTOCOl was found for PSA-Ievels below 4 nglml. 
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Consequences of different protocols including the Predictive Index (PI) for number of screening examinations, biopsies, cancers detected (expected) 
and test-characteristics (FUTURE PROTOCOL (111 
# screening visits cancers predicted! cancers 
detected de-
tected 
Screening Protocol Biopsy first additional # biopsies PSA PSA change in # of change in # of PPV <>to FP total 
indication visit (2) visit (3) <4 ~4 biopsies (%) cancers (%) biop- weight(S) 
nglml nglml sies(4) 
PSA, and for 1-3.9 nglml: PSA2::40r 8621 4398 1923 102 319 22% 17% 26564 
DRE and TRUS DREfTRUS+ 
(MODIFIED PROTOCOL) 
PSA PSA;:: 2 8621 2686 141 319 +763 (+40%) +39 (+9.3%) 17% 26% 39229 
PSA PSA ~ 3 8621 1683 70 319 -240 (-12%) ·32 (·7.6%) 23% 15% 46554 
PSA PSA;<: 4 8621 1094 0 319 ·829 (.43%) -, 02 (-24.2"/0) 29"f., 9% 43779 
PSA PSA~ 6 8621 533 0 205 ·1390 (-72%) -216 (-51.3%) 39% 4% 29304 
PSA. and for 2-2.9 nglml, PSA;;::30r 8621 1093 1885 93 319 -38 (-2%) -9 (-2.1 %) 22% 17% 41789 
DRE and TRUS DREfTRUS+ 
P5A. and for 2-3.9 nglml, P$A ~ 4 or 8621 1735 1455 64 319 -468 (-24%) -38 (-9.0%) 26% 12% 42079 
DRE and TRUS DREfTRUS+ 
PSA, and for;:: 1 nglml: PI;:: 0.08 8621 S576 1704 118 30S -219 (-11%) +2 (+0.5%) 25% 15%. 26654 
DRE and TRUS 
PSA, and for;:: 1 nglml: PI;:: 0.15 8621 5576 927 64 270 -996 (-52%) -87 (-20.7%) 36% 7% 23829 
DRE and TRUS 
PSA, and for;:: 1 nglml: PI> 0.10 8621 5576 1409 99 298 -514 (-27%1 -23 (-5.7%) 28% 12% 27S29 
DRE and TRUS 
PSA, and for;:: 1.5 nglml: PI;:: 0.10 8621 3989 1366 92 298 -557 (-29%) -30 (-7.4%) - 29% 11% 34789 
DRE and TRUS 
P5A, and for;:: 2 nglml: PI> 0.10 8621 2913 1290 80 298 -633 (-33%) -42 (-10.2%) 29% 11% 39069 
ORE and TRUS 
PSA, and for 2: 3 ngfml: 
DRE and TRU5 
P5A, and for ~ 4 nglml, 
DRE and TRU5 
PI ~ 0.10 8621 
PI ~ 0.10 8621 
1820 1109 48 
1178 877 o 
298 -814 (-42%) -75 (-17.8%) 31% 9"/0 41054 
298 -1046 (-54%) -123 (-29.2%) 34% 7% 38064 
(1) the percentage of biopsy advice not resulting in a biopsies, because of drug use (anti coagulants), refusal or loss to follow-up (6%)were projected the same in FUTURE PROTOCOLS 
(2) PSA-test 
(3) DRE and TRU5 
(4) number of biopsies - number of cancers 
number of participants 
(5) WEIGHTS: first visit -1, 2nd visit -5, biopsy -25, cancer + 250, the higher the total weight the higher the positive effect for the population screened 
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For PSA ;, 4 nglml the observed differences between the protocols were smaller, 
reflecting the less fluctuating test-characteristics of PSA as a biopsy indication. 
Although we expected a decrease of biopsies by approximately 17% (table 6.2l, 
the proportion of biopsies of the MODIFIED PROTOCOL was as high as before (25% and 
24%, respectively). The PSA distributions at the screening were approximately the same 
in both protocols, but the number of suspicious ORE and TRUS was significantly higher 
in the MODIFIED PROTOCOL. The percentage of suspicious ORE among the screened men 
(PSA;, 1 nglmi) had increased from 10% to 18% while the percentage of positive TRUS 
had increased from 12% to 16%. The number of cancers detected also increased in 
these biopsies, resuiting in higher PPVs and an increase in overall detection rate from 
4.4% to 5.5%. In ailS-year age groups an increase in detection-rate was observed, but 
the largest increase was in men aged 70-74 (from 5.3% to 9.7%, data not shown). 
Future protocol 
In table 6.4, ways were investigated to further increase the PPV and decrease the false-
positive rate with the smallest loss in cancers detected. All FUTURE PROTOCOLS were 
compared to THE MODIFIED PROTOCOL. In the first part of table IV, scenarios with PSA as 
a direct biopsy indication are shown. The second part consists of protocols in which 
additional visits are needed depending of the initial PSA-Ievel and biopsy is indicated 
by both a positive ORE/TRUS or PSA cut-off. In the last part, screening consisted of 2 
visits for a portion of men dependent on their PSA level to establish their PI, which also 
determined the indication of biopsy. 
The total weight (last column) was most favourable for the scenario with a PSA;, 3 
nglml as a biopsy indication. The scenarios where ORE and TRUS were carried out for 
a certain cut-off of PSA were rather favourable with respect to their total weight and the 
number of cancers missed. The disadvantage of these scenarios was that a portion of 
men (13-20%) have to attend the screening twice. The scenarios in which a PSA cut-off 
was combined with a PI of;, 0.10 as a biopsy indication were rather favourable with 
respect to both the lower numbers of biopsies required and fewer numbers of cancers 
detected. For cut-offs of 2 nglml and higher, the total weight was also rather high, but 
relatively many additional visits would be needed to determine the PI. 
Sensitivity analysis for the weighing of screening testsr biopsies and 
screen detected cancers 
Lowering the weight for detecting a cancer from 250 to 200 would favour the scenario 
with PSA;, 4 nglml as a direct biopsy indication in table 6.4. From a weight of 400 and 
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higher, the scenario with PSA ;" 2 ng/ml as a direct biopsy indication would have the 
most positive weight. A negative weight of biopsy of -35 or more would favour the 
screening policy of PSA ;" 4 ng/1l11 as a direct biopsy indication and vice versa. Chang-
ing tl,e weight of the additional visit to -2 resulted in the highest total weight for the 
scenario using a PSA cut-off of 2 ng/ml in combination with the PI of;" 0.10 as a biopsy 
indication. Other scenarios would then have almost the same total weight. From these 
sensitivity analyses it was clear that the scenario using PSA ;" 3 ng/ml as a direct biopsy 
indication was rather stable with regard to total weight, compared to other scenarios. 
DISCUSSION 
The results of this study show a very unfavourable balance between the number of bi-
opsies performed and the number of prostate cancers detected under a PSA cut-off of 2 
ng/ml, according to very low PPVs between 2% and 5%. A few cases of severe compli-
cations occur due to the biopsy (sepsis 0,18%) and a large number of moderate to mild 
complications (e.g. fever, pain, haematuria and haematospermia, 64.6% in total) 
(Rietbergen et al., 1997). Because of the high percentage of biopsies in this screening-
study, reducing this number is important. The value of the detected cancers in terms of 
mortality reduction is yet unknown, while side effects of treatment occur early after 
screen detection. The quality of life study which is being conducted alongside this 
screening-trial will help to derive better weights for the balance between the positive 
and negative side effects (Essink-Bot et a/., 1998). 
The MODIFIED PROTOCOl. (i.e. no DRE and TRUS for PSA below 1 ng/ml) was ex-
pected to result in a small decrease in detection rate (2%) and biopsies (16%). Different 
results were observed, which are most likely caused by a change in personnel. Th is 
change was introduced simultaneously with a training scheme with supervision. 
Screening using a DRE and TRUS are clearly examiner-dependent and not reproducible 
as a standardised procedure. Smith observed that the reproducibility of a DRE among 
urologists was only fair (Smith and Catalona, 1995). Therefore, extrapolations of the 
results of this study should be performed with caution. 
The base-line characteristics such as age-distribution, rating of own health, the 
WHO prostate symptom score, familial prostate cancer and previous screen history did 
not show large differences between both protocols. The participation rate in the study 
was also almost equal for the INITIAL and MODIFIED PROTOCOl. (45% and 48%). The 
compliance (attending screening after randomisation) did not differ either. These factors 
could not give a sufficient contribution to explain the unexpected differences. 
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From the data presented in this study, choosing an option that recommends a change in 
the protocol is rather difficult, because none of the scenarios was favourable with re-
spect to all parameters studied. Weights were applied to explore the possibility of ex-
pressing the differences between scenarios. Choosing these weights was quite arbitrary 
and subjective. Conservative weights have been used here, compared to values that. 
have been applied in breast-cancer screening, based on empirical studies (de Koning et 
a/., 1991). 
Some scenarios reached high positive weights with the weights as used in this 
study. The protocol with PSA:2' 3 ngiml as a direct biops)' indication has major practical 
advantages, because the screening is limited to PSA testing. This test is the least inva-
sive and a decrease in the number of cancers detected of approximately 8% (of a total 
detection rate of about 5%) seems acceptable. 
The protocols where a PSA cut-off was combined with a DRE and TRUS for certain 
values of PSA also had quite positive weights. These protocols may not be preferred 
however, because of the poor reproducibility of DRE andlor TRUS. With the use of the 
Predictive Index (PI) representing the probability of detecting a cancer based on the 
screening results and the volume of the prostate in combination with a PSA cut-off, bi-
opsies could be performed more efficiently, i.e. with a higher PPV and without missing 
many cancers. It is however judged as a preliminary finding also because not all pa-
rameters seemed reproducible and standardised. The PI should be tested prospectively 
before implementation. Eventually, the PI is expected to be able to increase the speci-
ficity of the screening test with only a small loss of sensitivity (Kranse et a/., in press). 
Catalona et al. concluded that free serum PSA measurements may reduce the 
number of biopsies in lower PSA cut-off (Catalona et a/., 1997). We did not study the 
effects of free PSA on the sensitivity and specificity of the screening. In decision-making 
about screening as a health care service free serum PSA should also be evaluated as an 
optional screening test. 
Lodding et al. showed that 25% of all screen-detected cancers had PSA values be-
tween 3 and 4 ngiml (Lodding et a/., 1998). With the PI we would estimate 22% of all 
cancers being within this PSA range, another indication that the PI might be usable in 
the future. Lodding et al also concluded that a majority of these cancers were clearly 
significant and suitable for curative treatment, therefore providing another argument to 
implement a screening protocol with a PSA cut-off of 3 ngiml (Lodding et al., 1998). 
As with any protocol utilising random biopsies the results may be affected by ran-
dom sampling. Because it is plausible that this would affect all studied protocols in the 
same way it has not altered our conclusions. 
Changing a protocol where cancers are not detected when previously they were, 
could in theory result in missing those cancers with the largest potential to contribute to 
96 
Value of screening rests for prostarc cancer 
the reduction in mortality from the disease. in a study by Hoedemaeker et al. the group 
of tumours detected by a ORE andlor TRUS below a PSA of 4 ng/ml had the lowest 
pathological stages with a considerable fraction (43%) filling criteria for 'minimal tu-
mour' and 86% with a tumour volume smaller than 0.5 ml (Hoedemaeker ct a/., 1997). 
A minimal tumour was defined as a tumour smaller than 0.5 011, lacking a Gleason pat-
tern 4 or 5 and being confined to the prostate (stage pT2). Men with low PSA levels are 
therefore most likely to harbour clinically insignificant tumours (Hoedemaeker et a/., 
1997). The numbers studied were however small (N ~ 14). These data indicate that a 
change in protocol where a ORE and TRUS are omitted in lower PSA-ranges may not 
result in significant loss in potential mortality reduction, if re-screening is performed at 
an adequate time interval. 
By using the very intensive protocol in the first instance, more is known about the 
ORE and TRUS in very low PSA-ranges. it was shown that these procedures are not (yet) 
reproducible and have made a small contribution to the number of cancers detected for 
PSA < 2 ng/ml. it seems very difficult to change a trial protocol if the effects of these 
changes in terms of prevention of prostate cancer deaths are not yet known. On the 
basis of the data presented in this study, combined with the knowledge of the tumours 
in low PSA-ranges (Hoedemaeker et a/., 1997) all men in the ERSPC Rotterdam with a 
PSA <: 3 ng/ml have received a biopsy from May 1997 onwards. This change implies 
that biopsies were no longer driven by a ORE andlor TRUS. in the future, we will hope-
fully be capable of defining PSA ranges, combined with other screening tests or e.g. a 
Predictive index to discriminate between the slowly growing non-life threatening can-
cers and the aggressive cancers. Changes in mortality resulting from randomised trials 
will give the only definitive answer regarding the effectiveness of prostate cancer 
screening. 
References 
Auvinen, A., Rietbergen, J.B., Denis, LJ., Schroder, F.H. and Prorok, P.C, Prospective evaluation 
plan for randomised trials of prostate cancer screening. The International Prostate Cancer 
Screening Trial Evaluation Group. J Med Screen, 3, 97-104 (1996). 
Catalona, W.J., Smith, 0.5. and Ornstein, O.K., Prostate cancer detection in men with serum PSA 
concentrations of 2.6 to 4.0 nglmL and benign prostate examination. Enhancement of 
specificity with free PSA measurements {see cOlllmentsJ. Jama, 277, 1452-5 (1997). 
de Koning, H.J., van Ineveld, B.M., van Oortmarssen, G.J., de Haes/J.C, collette, H.J., Hendriks, 
J.H. and van der Maas, P.}., Breast cancer screening and cost-effectiveness; polk}' 
97 
Chapter 6 
alternatives, quality of life considerations and the possible impact of uncertain factors. Int J 
Cancer, 49, 531-7 (1991). 
Essink-Bot, M.L., de Koning, H.J., Nijs, H.G., Kirkels, W.J./ van clef Maas, P.J. and Schroder, F.H., 
Short-term effects of population-based screening for prostate cancer on health-related quality 
of life. J Natl Cancer Inst, 90, 925-31 (1998). 
Hoedernaeker, R.F., Rietbergen, J.B.W., Kranse, R., van clef Kwast, T.H. and Schroder, F.H., 
Comparison of pathologic characteristics of Tlc and non-Tlc cancers detected in a 
population-based screening study, the European Randomized Study of Screening for Prostate 
Cancer. World I Ural, 15,339-345 (1997). 
Kranse, R./ Beemsterboer, P.M.M" Rietbergen, J.B.W., Habbema, J.D.F., Hugosson, J. and 
Schroder, F.H., Predictors for biopsy outcome in the European Randomized Study of 
Screening for Prostate Cancer (Rotterdam region). the Prostate (in press). 
Lodding, P., Aus, G., Bergdahl,S., Frosing, R., Lilja, H., Pihl, CG. and Hugosson, J., 
Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 
ngJml. Prostate specific antigen [see comments]. J Urol, 159, 899-903 (1998). 
McvVhorter, W.P., Hernandez, A.D., Meikle, AVV., Terreros, D.A., Smith, J.A., Jr., Skolnick, 
M.H., Cannon-Albright, L,A and Eyre, H.J" A screening study of prostate cancer in high risk 
families. JUral, 148, 826-8 (1992). 
Parkes, c., v\lald, N.L Murphy, P., George, L., Watt, H,C, Kirby, R., Knekt, P., Helzlsouer, K.J. 
and Tuomilehto, J., Prospective observational study to assess value of prostate specific 
antigen as screening test for prostate cancer [see comments}. Bmi, 311, 1340-3 (1995). 
Rietbergen, J.B., Kruger, AE., Kranse, R. and Schroder, F.H" Complications of transrectal 
ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication 
rates and risk factors within a population-based screening program. Uroiog}" 49, 875-80 
(1997). 
Schroder, F.H., Damhuis, R,AM., Kirkels, W.J., de Koning, H.J., Kranse, R., Nijs, H.G.T. and 
Blijenberg, B.G., European randomised study of screening for prostate cancer, the Rotterdam 
pilot studies. Int. j. Cancer, 1996, 145-151 (1996). 
Schroder, F.H., Denis, L.J., Kirkels, W., de Koning, H.J. and Standaert, B., European randomized 
stud}' of screening for prostate cancer. Progress report of Antwerp and Rotterdam pilot 
studies. Cancer, 76, 129-34 (1995). 
Smith, 0.5. and Catalona, W.J" Interexaminer variability of digital rectal examination in detecting 
prostate cancer. Urology, 45, 70-4 (1995). 
Stenman, U.H., Hakama, M., Knekt, p" Aromaa, A., Teppo, L. and Leinonen, J., Serum 
concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin 
before diagnosis of prostate cancer. Lancel, 344, 1594-8 (1994). 
98 
----- 7 ------
PSA-TESTING AND USE OF ORE 
BEFORE AND DURING A 
RANDOMISED TRIAL FOR SCREENING 
OF PROSTATE CANCER 
(ERSPC, ROTTERDAM) 
Summary 
Determination of prostate specific antigen (PSA) is a simple test that might influence 
the outcome of the European Randomised study on Screening for Prostate Cancer 
(ERSPC), if frequently utilised. In this study PSA and digital rectal examination (ORE) 
before and during the screening trial in Rotterdam and in the general population is 
quantified. 
The data from the intake questionnaire regarding PSA-testing and ORE were ana-
lysed to evaluate the use of these tests before participation in the screening study. Data 
on PSA from the Laboratory of General Practice were linked to information from par-
ticipants in the ERSPC. Different sources were used to quantify PSA-tests and OREs in 
the general population in a situation where no screening exists. 
On average, 45% of the men had had a ORE and 73% reported that they had 
been PSA tested before participating in the trial. Both these percentages increased with 
age. No statistically significant effects of former PSA-testing or OREs oll the cancer de-
tection rate could be demonstrated. The rate of PSA determinations was approximately 
twice as high in the control arm than in the screen arm during the trial (76 and 33 per 
7000 person-years, respectively). After randomisation, the number of PSA determina-
tions first decreased in the screening arm, but after some time· an increase was ob-
served. The number of PSA determinations increased in the control arm after randomi-
sation. The number of PSA determinations in the general population of the same age 
was estimated at 45/7 000 person-years. 
The use of PSA-tests in the control arm was moderate, but if different men un-
dergo this test every year the contamination rate in the control arm might be rather 
high during a screening interval of 4 years. In the final analysis on mortality, PSA-test-
ing should be taken into account. The motives and outcomes of PSA-testing are useful 
for further interpretation. 
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INTRODUCTION 
A PSA determination in serum is a very simple test that has been shown to be useful in 
following the clinical course of men treated for prostate cancer (Catalona, 1996). Its 
value for population screening has not yet been demonstrated, but widespread use of 
the test has been reported Oacobsen el a/., 1995). In the United States an exponential 
increase in Prostate Specific Antigen (PSA) testing has been seen over the period 1988-
1991, which was assumed to be the most plausible explanation for the increase in pros-
tate cancer incidence (Potosky el a/., 1995). Effects of PSA screening on prostate cancer 
mortality however have not (yet) been shown (Wingo et a/., 1998). Different authors 
disagree about the effectiveness of screening on the basis of data about trends in inci-
dence, stage distribution and mortality (Smart, 1997; Weyler, 1998). The value of pros-
tate cancer screening can only be reliably demonstrated in randomised trials. In Europe 
and the United States large randomised trials have begun to study the effect of early 
detection on the mortality of this disease (Auvinen el a/., 1996; Gahagan et a/., 1994; 
Schroder el a/., 1995). 
In the Netherlands, there is also evidence that the increased incidence of prostate 
cancer is in part a result of increased PSA use (Post et a/., 1998). PSA-testing in the con-
trol and to a lesser extent in the screen arm (apart from PSA-testing in the trial) might 
bias mortality reduction estimates in the screening trial. Because of the simplicity of the 
test and the observed rapid dissemination in other countries it is very important to 
monitor PSA use in Rotterdam (one of the centres of the ERSPC). In this study, the fre-
quency of PSA-testing before and during the screening trial is quantified, together with 
the use of Digital Rectal Examination (ORE) as well as the number of biopsies resulting 
from PSA-determinations outside screening. 
MATERIAL AND METHODS 
PSA-use before inclusion in the trial 
The ERSPC in Rotterdam started in June 1994, after pilot projects had been carried out 
in Antwerp and Rotterdam (Schroder et a/., 1995). In the Rotterdam area, all men in the 
age-group 55-74 were identified by means of the population registry and were asked by 
letter to participate. Men who responded by returning the intake-questionnaire and a 
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signed informed consent form, were randornised. The men in the screen arm were in-
vited to be screened by PSA-testing, ORE and TRUS until May 1997. From then, the 
screening consisted of PSA-testing only. Some intake-questions asked about prior pros-
tate examination(s) using ORE or PSA-testing. For this study, all data on men random-
ised until March 3,d 1998 were used for the analysis. 
PSA use after inclusion in the trial 
All data from PSA-testing were obtained from the Laboratory of General Practice (GP-
lab) for the period january 1996 to March 1998. This laboratory covers the total city of 
Rotterdam and some suburbs, comprising approximately 1 million inhabitants in total. 
The PSA determinations carried out by this laboratory were not performed within the 
context of the ERSPC, because the latter were collected and sampled in the Central 
Laboratory of the Academic Medical Hospital Oijkzigt. The data of the G P-Iab were 
linked to individual data of men randornised in the screening study. The linkage was 
carried out by generating an identifier consisting of the first initial, the first and last 
character of the surname and the day, month and year of birth. This identifier was built 
into both data files and thereafter both files were linked. To calculate rates per 1000 
person-years, all person-years at risk from randomisation until 3 March 1998 were cal-
culated. Persons who were randomised before 1 january 1996 were at risk during the 
total period from 1 january until 3 March 1998, except in instances where their screen-
ing interval of 4 years ended before that date. 
PSA use, referrals and biopsies outside the trial (actual practice) 
The actual practice of PSA-testing, referrals and prostate biopsies by both general practi-
tioners and urologists was extracted from 3 different sources. For each, the source 
population was known allowing the calculation of rates per 1000 person-years. 
One source was a Health Insurance Company (HIC), covering the Rotterdam area. 
These data were from january 1995 until April 1997, a period during which screening 
had not taken place in that area. For each individual, the number of declarations of a 
PSA-test, a biopsy and a fee per person, representing the treatment by a urologist, were 
available in chronological order. It was also known whether the PSA was requested by 
a urologist or a general practitioner. 
Two other sources of information were the GP-Lab and the sentinel practices of 
the NIVEL (Netherlands Institute of Primary Health Care) (Bartelds, 1998). In 1997, 
ORE, PSA requests and referral to a urologist were introduced into the registration sys-
102 
PSA-lesling and use of ORE before and during a screening trial 
tem of 45 sentinel practices. All participating general practitioners were asked to record 
OREs, PSA-tests and referrals to urologists with regard to prostate disease by age. 
RESULTS 
Table 7.1 presents the number of men participating in the Rotterdam part of the ERSPC 
trial, who reported having had a PSA-test or ORE before participation. 45% reported 
Table 7.1 
PSA-testing and ORE before randomisation in fhe ERSPC (N = 28,550)' 
ORE I'SA 
(%) N of men (%) N of men 
Ever 44 12,474 13 3,618 
Never 49 14,005 77 22,038 
Unknown 7 2,071 10 2,894 
Ever 
age 55-59 34 3,059 9 797 
60-64 44 3,047 12 849 
65-69 52 3,347 15 1,007 
70-74 58 2,802 19 904 
unknown {non-attenders)2 22 219 6 61 
Ever, year of participation in trial 
1993-1994 39 1,142 10 278 
1995 47 3,019 14 875 
1996 44 3,412 12 958 
1997 45 4,097 14 1,276 
1998 45 585 13 170 
unknown (non-attenders)2 22 219 6 61 
Ever, time since inclusion 100 12,474 100 3,618 
0-1 year before 24 2,975 58 2,103 
1-2 years before 21 2,635 . 15 533 
2-5 years before 26 3,242 16 594 
> 5 years before 29 3,622 11 388 
Ever, done by 100 12,372 
General Practitioner 39 4,802 n.a. 3 
Urologist 46 5,750 n.a. 
Olher 15 1,820 n.a. 
, includes both screen and control arm; no differences observed in both arms 
2 because of missing date or participation due to not attending the screening, age and year of participation 
could not be calculated in the screen ann 
3 not asked 
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ever having undergone an examination of the prostate and 13% a PSA-test. The non-
attenders (randomised to the screen-arm, but not showing up for screening) reported 
significantly less PSA-tests (6%); the percentage of OREs was also lower, but approxi-
mately 50% of the answers were missing. 
Year of participation in the trial did not show a relationship with the percentage of 
reporting having OREs or PSA-tests, while most previous PSA-tests were performed 0-1 
year before participation. These results were also analysed for the age-group 55-69 
separately, which did not change the conclusions. 
The impact of former PSA-testing and prostate examinations on the detection rate of 
cancers in the trial is shown in table 7.2. The detection rates of those men having PSA-
testing or ORE was higher than of men not tested before participation, but the differ-
ence was not statistically significant. The detection rates increased if the PSA-test or 
Table 7.2 
Detection rates (number of cancers per 100 men screened) by fonner DRE and PSA~testing 
Cancers (NI 
Total 663 
No DRE before 323 
ORE before, missing 1 26 
DRE before 314 
Time since participation in trial 
0-1 year before 66 
1-3 years before 64 
3~5 years before 85 
> 5 years before 99 
Done by 2 
General Practitioner 122 
Urologist 135 
Other 54 
No PSA before 508 
PSA before, missing 1 59 
PSA before 96 
Time since participation in trial 
0·1 year before 50 
1-3 years before 16 
3-5 years before 23 
> 5 years before 7 
1 missing, meaning that the question was not filled in 
1 from N = 3, information is missing 
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(/1001 
4.8 
4.6 
3.6 
5.2 
4.7 
5.1 
5.2 
5.8 
5.3 
5.0 
6.0 
4.8 
4.2 
5.4 
5.1 
5.6 
7.2 
3.8 
P-value. (chi-21 
test for trend P ~ 0.17 
P~0.21 
P~0.44 
P~0.06 
P~0.31 
P~0.26 
test for trend P ~ O. 74 
100.0 
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80.0 
'" '" 70.0 
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1996 
PSA-rcsting and use of ORE before and during a screening tria! 
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year 
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o GP lab 
PSA-testing in screen and control ann of the trial and in GP-Iab by year, age 55-69. 
ORE had been performed longer ago, except for PSA, if it was performed more than 5 
years before participation. These trends were not statistically significant either. 
If the ORE had been carried out by a physician other than a urologist or general 
practitioner, the detection rate was higher and of borderline significance (p~O.06). The 
most frequently reported other specialities (in order of occurrence) were internal medi-
cine, surgery and occupational medicine. A combination of having both a PSA-test and 
a ORE did not show other effects on the detection rates. 
Table 7.3 
PSA lise in screen and control arm of the trial by age at randomisation (data from G P lab), from 
1/1/'96 until 3/3/'98 
PSA Screen arm Control arm Rate Ratio Control/Screen 
Total PSA (N) 800 1629 
PSA rate (/1000 py) 37.9 78.6 2.1 
age 55-59 28.4 56.4 2.0 
60-64 32.3 91.2 2.8 
65-69 41.5 86.5 2.1 
70+ 58.2 88.6 1.5 
age 55-69 33.4 76.3 2.3 
105 
Chapter 7 
120.0 
100.0 
'" 80.0 ~>-
c g 
v 60.0· Q. 
0 
0 
;" 
iD Q. 40.0 
20.0 . _____ screen-arm 
---{}- control-arm 
0.0 ---
-30 -20 -10 o 10 20 30 40 
time since randomisation (months) 
Figure 7.2 
PSA use in screen and control arm before and after randomisation with 95% confidence 
intervals (per 1000 person-years) 
In figure 7.1 and table 7.3 PSA-testing in both the screen and the control arm of the 
screening trial are presented. On average, the PSA rate in the control arm was more 
than twice as high as in the screen arm (Rate Ratio 2,1) while it was 60% higher in 
comparison with the GP-Iab (figure 7.1). An increase of PSA-testing was observed in 
both the screen and control arm and the GP-Iab in the period 1996-1998. The largest 
difference between screen and control arm, represented by a Rate Ratio of 2.8 was 
present in the age group 60-64 (table 7.3). The same age-pattern was seen in the 
separate years (data not shown). 
Figure 7.2 shows that after participating in the screening trial, different patterns in 
PSA-testing occurred in the screening and control-arm. In the screening-arm the number 
first decreased, while it started to" increase from 6 months after randomisation onwards. 
In the control arm however, an increase of PSA-testing through the general practitioner 
took place that continued during the total follow-up time. 
In table 7.4 an overview is given of PSA-tests, DREs and biopsies in a non-screening 
situation. The rate of PSA examinations as requested by general practitioners obtained 
from 3 different sources shows quite large differences (table 4, first part). The number of 
examinations per 1000 men is twice as high in the GP-Iab than in the Sentinel Practi-
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Table 7.4 
PSA, DRE and referrals by age and specialty, according to 3 different sources 
National Sentinel 
practices (GPs) 
1997 
Health insurance 
company 
1995-1997 
laboratories of General 
Practice 
1996-1998 
_ ~~y_e!?g~J~ _n:~!1! .?l~ ~g~~) _________ ~?L~Q? ____________ l_~q,_I_~~~ ___________ ?_1_~,~_8_~: ______________ _ 
GENERAL PRACTITIONER 
PSA requested /done (N) 
PSA ra'e (/1000 PY) 
age<40 
4(},S4 
55-69 
~70 
DRE periormed (N) 
DRE ra'e V1000 py) 
age<40 
40-54 
55·69 
2':70 
Referral (N) 
Referral rate (/1000 PY) 
age<40 
4(}'54 
55-69 
2':70 
----------------
UROLOGIST 
PSA(N) 
PSA ra'e (/1000 PY) 
age<40 
40-54 
5S-69 
2':70 
Biopsies (N) 
Biopsy rate (/1000 PY) 
age<40 
40-54 
55-69 
2':70 
------------
OTHER SPECIALIST 
PSA(N) 
PSA ra'e (/1000 PY) 
age<40 
1 '96 
1 '97 
40-54 
55·69 
2':70 
, 7(}.74: 30,3/1000 
, 70-74: 49,8/1000 
, 70-74 8,5/1000 
510 
732 
59 
8.1 
0.3 
6.7 
22.2 
14.4 3 
11.6 
1.6 
13.3 
26.2 
18,9 4 
0.9 
o 
0.2 
2.1 
2.560 
445 
11.3 
0.4 
9.2 
37.0 
60.0 
2.0 
0.1 
1.2 
6.2 
3.0 S 11.7 
3,833 
255 
759 
16.9 
1.1 
9.4 
45.2 
111.1 
1.1 
o 
0.2 
3.5 
8.0 
3.5 
0.0 
1.6 
9.8 
24.2 
18.075 
16.0 
0.7 
13.4 
48.1 
85.3 
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ces. In all 3 sources, a steep increase in the number of PSA-tests was reported from the 
age 55 onwards. This increase persisted in both the GP-Lab and the HIC, but a decrease 
was found for the age group 70 and over in the Sentinel practices. The. number of OREs 
in the sentinel practices was on average 44% higher than the number of PSA-tests and 
this percentage decreased with age. A ORE resulted in more cases of PSA-testing from 
the age 55 and older, than in younger ages. On average, the referral rate to a urologist 
was only approximately 10% of the number of PSA-tests and OREs. 
From the HIC data it was clear that on average approximately 20% of men who 
had a PSA-test were referred to a urologist and that about half of the referrals resulted in 
a biopsy. This latter rate also increased with increasing age. The number of PSA exami-
nations requested by a urologist was higher than requested by a general practitioner 
and showed a steeper increase with age. The number of PSA-tests requested by other 
specialists was lower than by the general practitioner and urologist but still amounted 
to 11 % of all PSA-tests requested. 
Based on the weighted average of the 3 sources, we assumed a baseline PSA use 
of 15 per 1000 person-years in the total population and 45 per 1000 in the age-group 
55-69 through the general practitioner in a situation without a screening programme. 
DISCUSSION 
The rate of PSA-testing was 76/1000 person-years in the control arm of the trial in the 
age group 55-69 and participation in the trial raised this level compared to the rate in 
the general population in the same age-group (45/1000). A rate of PSA-testing of 7.6% 
per year (assuming that different individuals undergo a PSA-test every year) would re-
sult in a contamination percentage of 30% in the control arm, during the first screening 
interval of 4 years. In the screen arm, however PSA-testing outside screening still also 
takes place, increasing with time since randomisation. 
It can be assumed that the number of cancers detected by these PSA examinations 
will be much lower than in the trial. This is also in agreement with the standard of gen-
eral practitioners operating in the Netherlands. General practitioners are advised to re-
fer a patient on the basis of a PSA-test higher than 10 nglml, doubt about the benign 
character of the prostate after ORE, relevant comorbidity, haematuria without infection 
or acute urine retention (Klomp el a/., 1997). This standard will result in much fewer 
referrals and biopsies than in the trial. To clarify this, more insight is needed in the mo-
tives for PSA-testing. Furthermore the outcomes of PSA-testing (number of biopsies and 
cancers detected) should be evaluated. The final analysis of the trial should use data 
about PSA-testing within the screen arm and control arm to allow controlling for the 
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effect of contamination. Evaluation of the trial should also include analyses of trends in 
PSA use in the future. 
Having had a PSA·test before participation in the trial without having prostate 
cancer diagnosed may result in healthy screenee bias. This is also supported by the fact 
that non·attenders (men who were randomised but never participated) had reported 
much lower rates of PSA·testing (4% versus 13%). This would result in a bias towards 
zero, meaning that the effect on prostate cancer mortality will be larger than can be 
assessed in the trial. The higher the proportion of men with a prior PSA·test the larger 
this bias will be. Fortunately the percentage of men receiving a PSA·test before 
participation is quite low (13%) and not clearly increasing in more recent years, 
although a widespread increase of PSA·testing is assumed between 1990 and 1995 
(Post et a/., 1998). Healthy scree nee bias is however partly contradicted, because men 
who had previously PSA tested or who had had a ORE showed higher cancer detection 
rates. Although -these results were not statistically significant, this might represent a 
high·risk group. 
The data obtained form the GP·Lab allowed us to link two data sources. By using 
the key·variable only 0,9% false matches occurred (which were deleted). By this way of 
linking we have of course no knowledge about the number of persons not linked be· 
cause of missing initials or typing errors in initials. Our approach resulted in an under· 
estimate of the real number of PSA·tests performed outside the trial, but it will not 
greatly influence the results of this study. 
In some countries, a widespread use of PSA·testing has been reported especially 
related to the increase in incidence Uacobsen et a/., 1995; Post et a/., 1998; Potosky et 
a/., 1995). The rates in the USA as reported by Jacobsen et al were much higher than 
those reported in this study. Their PSA rates in 1992 were between 150/1000 and 
400/1000 for the age groups 55·69 Uacobsen et al., 1995). The effects on incidence are 
thus also expected to be less in the Netherlands. Post et al reported on the increase in 
incidence in the Netherlands, which showed the same patterns as in the US. The 
increase was approximately 40% between 1991 and 1995, while this increase was 
more than 100% between 1987 and 1992 in the US. The increase in incidence was 
merely attributed to more diagnoses of localised disease in both studies, although Post 
also demonstrated a decrease in the rate of locally advanced and metastasised disease. 
Our data from the GP·lab are in agreement with the observation of Post et al that 
an increase in PSA·testing is occurring. In a study of PSA requests from general practi· 
tioners it was concluded that PSA·testing is not focused on higher risk groups and 
shows tendencies towards a screening approach. In that study, although screening was 
not recommended, rising levels of PSA·testing were observed, resulting in an increase 
of PSA results of lower than 4 ng/ml (McGing, 1998). Ward et al concluded in a study 
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among general practitioners that more than half of the PSA-tests ordered were screening 
tests (Ward et aI., 1998). 
PSA-testing of a asymptomatic men should not be disseminated through the 
general population without proven benefit of screening. It has still to be established 
whether PSA-testing does more harm than good (de Koning and Schroder, 1998). 
Furthermore widespread dissemination might introduce very serious problems in 
interpreting the results of ongoing randomised trials. In that way the effectiveness of 
prostate cancer screening with PSA will only be based on surrogate endpoints, an 
undesirable situation. 
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ADVANCED PROSTATE CANCER; 
CARE AN D COST IMPLICATIONS 
Summary 
Background: If prostate cancer screening proves to be effective, some cases will be pre-
vented from reaching tHe advanced stage. In order to evaluate screening programs 
thoroughly, it is important to quantify course, care and accompanying costs of ad-
vanced disease. 
Methods: We studied 70 files of patients in 2 hospitals, who had received a diagnosis 
of distant metastases of prostate cancer and had died in the years 1994-1998. The total 
healthcare received by these patients, including symptoms and complaints was re-
corded 
Results: Most frequently reported symptoms were pain (42%), urogenital s}'mptoms 
(25 %) and malaise (20%). 89 % of all patients were hormonally treateci (either by or-
chidectomy and lor chemical castration) and 47% received one or more series of radia-
tion therapy. 69% of all patients were treated with pain medication. The average dura-
tion of advanced disease in all patients was 24 months. Average costs of advanced dis-
ease were estimated at $11,182 over the lotal period. $1,547 (14%) was al/ocated to 
assessment and outpatient care and $9,635 (86%) to treatment and costs of hospital 
stay. Almost half of the total costs were determined by hospital stay. 
Conclusions: These data give a better understanding of the course, care and costs of 
advanced prostate cancer. These estimates together with the effects of advanced pros-
tate cancer on quality of life will be used for the evaluation of prostate cancer screen-
ing. 
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Advanced prostate cancer; care and cost implications 
INTRODUCTION 
Screening for prostate cancer has been the subject of intense debate for many years. 
Still many questions have to be resolved before the value of screening can be estab-
lished satisfactorily. International trials have been set up to assess the effect of prostate 
cancer screening and the early diagnosis and treatment, on prostate cancer-related mor-
tality and morbidity (Auvinen el a/., 1996; Gohagan et a/., 1994). The final results of 
these trials are not expected until the year 2005-2010. 
To support decision making, the effects of screening and early treatment of pros-
tate cancer on long-term mortality and morbidity outcomes and costs should be as-
sessed. In the European Randomized Study on Prostate Cancer (ERSPC) (Schroder et a/., 
1995), a prostate cancer disease model was developed in which the course of prostate 
cancer through different disease states with different durations was simulated. This was 
similar to the model developed for breast cancer and cervical cancer (de Koning et al., 
1991; Habbema el al., 1985; van Oortmarssen el al., 1990). 
If screening is effective, the advanced stages of prostate cancer will (in part) be 
prevented or postponed. Some patients will therefore die of other causes, without pass-
ing through the stage of advanced prostate cancer. A full evaluation of screening will 
thus not only cover the early stages of the disease and the short-term effect of early de-
tection and treatment, but also the effects on the advanced stages. 
In the literature, information on course of advanced prostate cancer is scarce and 
the populations studied were not curatively treated (Aus et a/., 1995; Otnes el a/., 
1995). In the Netherlands and many other countries, localised prostate cancer is treated 
more aggressively. Furthermore, in these studies the patients had died between 1988-
1991, while in the meantime new treatment options for advanced disease became 
available (Anonymous, 1995). If screening is effective in avoiding advanced prostate 
cancer it will also reduce the care and costs of advanced disease. In this study, the 
course, care and costs of advanced disease of prostate cancer were studied. 
MATERIAL AND METHODS 
Selection of Patient-Files 
Patient-files were collected in the Academic Hos!)ital Rotterdam and the residential 
hospital Sint Franciscus Gasthuis (SFG) Rotterdam. In each hospital, we used a different 
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procedure to identify eligible patients. In the Academic Hospital, we used the local pa-
tient flow information system. This system assigns a code to every outpatient on the 
basis of the extent of disease (localised, metastasised to the regional lymph nodes and 
distant metastases). Included were patients who had distant metastases from prostate 
cancer who had died between 1994 and 1997. 
In the SFG hospital we checked the medical records of two groups of patients. The 
first group consisted of 213 patients with prostate cancer who had regularly visited the 
hospital in 1994. The second group were patients using LHRH-analogues, the conven-
tional treatment option in the SFG for prostate cancer patients with lymph nodes or dis-
tant metastases. From these two groups, we only included patients with distant metasta-
ses from prostate cancer who had died between 1995 and 1998. 
In the Academic Hospital, 50 patients were identified. We excluded patients 
whose medical records could not be traced (n ~ 6), those who had visited the hospital 
only for a second opinion (n ~ 6), or those who were lost to follow-up due to treatment 
in another hospital or a removal (n ~ 6). In the Academic Hospital, 32 patients were 
included and in the SFG hospital 38 patients. 
Patients were distinguished between those who had distant metastases as a first 
diagnosis of prostate cancer (M,-patients) and those who had either localised prostate 
cancer or positive lymph nodes as a first diagnosis, developing distant metastases in the 
course of time. This latter group is referred to as MoMI-patients. 
Data Collection 
Data were retrieved from the patient's medical records, from the diagnosis of distant 
metastases onwards. Data were recorded using a structured registration form. The fol-
lowing data were collected for eligible patients: resource use (e.g. outpatient visits, 
hospital admissions, use of analgesics, palliative surgery or radiation) and clinical data 
(stage at first diagnosis, location and course of distant metastases, symptoms etc.). All 
symptoms requiring treatment were recorded, including complaints and symptoms that 
were simultaneously present. The incidence of symptoms was defined as the number of 
periods in which the complaint or symptom occurred. 
A diagnosis of distant metastases was extracted directly from the medical records. 
The date of diagnosis of advanced disease was based on the date of the positive bone 
scan with additional radiological images (as judged by the urologist and radiologist) or 
pathology andlor CT scan in cases where the metastases were located elsewhere. Hos-
pital admissions and assessment clearly related to other concomitant diseases were not 
used in the analysis. Place and date of death was recorded but only the information 
from the medical records was used. 
116 
Advanced prostate cancer; care and cost implications 
Assessing the Cause of Death 
The cause of each death was assessed independently by two medical doctors on the 
basis of the extracted information. In cases of disagreement a consensus was reached. 
Three criteria were used to establish the cause of death. First, presence of invalidating 
metastases directly preceding death (not more than 9 months), that had to be relieved 
by pain medication or were treated by abstinence. Second an increasing Prostate Spe-
cific Antigen (PSA) before death, based on at least 3 measurements. The third criterion 
consisted of the presence of direct/indirect impairment due to metastases, such as 
anaemia or treatment with corticosteroids. In case at least 2 criteria were fulfilled, death 
was categorised as 'definitely prostate cancer'. In cases of one positive criterion, death 
was rated as 'probably prostate cancer'. If none applied death was considered as 'other 
cause'. 
Cost Calculations 
Costs were calculated as actual resource use multiplied by the respective cost per re-
source unit taking into account the duration of treatment if applicable. In this study, 
only the hospital based resource use was considered. If available, costs per unit of re-
source use were based on actual economic costs, i.e. including fixed and indirect costs 
(Finkler, 1982). Estimates were obtained from internal reports (de Koning et a/., 1990; 
Krenning et a/., 1998), literature, guidelines, or calculated from data retrieved from the 
hospital's budgetary and financial control system. Financial charges were used if true 
economic costs were not available. 
Costs were converted in U.S. $ by using gross-domestic product purchasing power 
parity of 1996 (1 $ ~ Dfl 2.07). If health care purchasing power parities would have 
been used, the costs (in $) would become much higher, because of the relatively high 
costs of health care in U.S. compared to the Netherlands. 
Analysis 
Differences between MI- and MoMI-patients were tested using Student's t-test or Chi2. 
Kaplan Meier analysis combined with the Log-rank test was used to analyze the sur-
vival-function after the diagnosis of distant metastases. In cases where censoring was 
applied, patients whose death was assessed as 'other cause' were censored. 
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RESULTS 
The baseline characteristics of the men included in this study are presented in table 8.1. 
The differences between both groups of patients were not statistically significant and 
the absolute differences were mostly small. For patients who first were diagnosed as 
having localised disease (MoMl-patients), the time to metastases was 34 months on av-
erage (median 26). The average duration of advanced disease, defined as the period 
from the diagnosis of metastases until death, was for all patients was 24 months (me-
dian 19). The survival of advanced disease of both M,- and MoMl-patients is shown in 
figure 8.1. 
Table 8.1 
General characteristics of advanced prostate cancer for MoM! and Ml patients, from two 
hospitals in the Netherlands. 
lv\oMl-patients Ml-patients Total 
(N~35) (N~35) (N~70) 
Age at first diagnosis of prostate 
cancer (years) 
mean 71.4 70.6 71.0 
median 72.0 73.9 72.5 
min-max 51.9-86.5 39.7-83.9 39.7-86.5 
T stage at first diagnosis (%) 
T1-2 20 9 14 
T3-4 63 80 71 
unknown 17 11 14 
Grade at first diagnosis ('Yo) 
G1-2 57 40 48 
G3-4 34 43 39 
unknown 9 17 13 
First treatment (not for M 1) (%) 
-radiation therapy 37 l1.a,1 l1.a,1 
-hormonal 29 l1.a,1 /l,a. 1 
-WW 17 n.a,' l1.a,1 
-other/unknown (N = 1) 17 l1.a,1 l1.a. 1* 
Time to metastasis (months) 
mean 33.9 o.a,1 l1.a. 1 
median 25.6 l1.a,1 l1,a,1 
min-max 2.9-140 l1,a. 1 l1.a,1 
Age at diagnosis of advanced 
disease (years) 
mean 74.2 70.6 72.4 
median 74.1 73.9 74.0 
min-max 53.8-87.9 39.7-83.9 39.7-87.9 
location of distant metastasis ('Yo) 
-bone 74 89 81 
-other 26 11 19 
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Of all metastases 81 % were located in the bone, which was more often the case in 
MqJatients than MoM,-patients. Patients with distant metastases at other locations than 
bone had a statistically significant shorter survival (16 versus 26 months; M,-and MoM,-
patients grouped, P~O.05). Advanced disease was generally diagnosed on the basis of 
urogenital complaints and symptoms as a result of metastases (e.g. loss of weight, mal-
aise, pain, fracture). The cause of death was judged probably to be due to prostate can-
cer in 75% of patients. The average duration of lost to follow-up was 21 days, repre-
senting the time between last contact with the urologist and the date of death. 31 % 
died in the hospital. 
Table 8.1 - continued 
MoMt-patients Mt-patients Total 
(N~35) (N~35) (N~70) 
Event leading to diagnosis of 
Ml (%) 
-urogenital symptoms 20 29 24 
~complaints/sYlllptoms as a 
result of Ml other than 
urogenital 40 51 46 
-screening/follow-up visit 23 3 13 
-other/unknown 17 17 17 
Duration of M + until death 
(01 on th s)( ce nsorcd)l 
mean 21.1 (26.9) 27.8 (33.3) 24.2 (30.6 
median 14.9 (19.2) 25.6 (26.6) 18.9 (26.3) 
min-max 0.1-65 (0.6-65) 0.6-127 (0.6-127) 0.1-127 (0.6-127) 
Age at death (years) 
mean 76.0 72.8 74.4 
median 75.1 76_3 75.7 
min-max 53.8-90.9 41.9-85.1 41.9-90.9 
Cause of death (%) 
-definitely prostate cancer 66 63 64 
(PC) 9 14 11 
-probably PC 26 23 24 
-other cause 
Time between last contact and 17 24 21 
death (days) (N ~ 69)' 
Place of decease (%) 
-hospital 31 31 31 
-at home 20 9 14 
-other/unknown 49 60 54 
t not applic<lble 
1 men who died from other causes were censored 
J information missing from' patient 
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Figure 8.1 
Survival of MoMt and MI patients after diagnosis of distant metastases 
Table 8.2 
Incidence of symptoms in advanced prostate cancer in 70 patients (average duration 24 
months> 
symptoms 
pain 
-bone 
lower spine, 51, sacrum, pelvis 
other locations 
-other 
urogenital problems 
-haematuria 
-urine retention 
-other 
malaise 
-anaemia Iblood loss 
-other 
neurological 
-decrease of sensibility/power 
-other 
otlier/unknown 
Total 
120 
N(%) 
135 
(16%) 
(27%) 
(58%) 
81 
(17%) 
(17%) 
(65%) 
63 
(41 %) 
(59%) 
27 
(78%) 
(12%) 
9/5 
320 
('!o) of total 
(42%) 
(25%) 
(20%) 
(8%) 
(4%) 
(100%) 
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Table 8.2 presents the symptoms related to advanced prostate cancer. The most fre-
quently registered symptoms were pain (42%) and urogenital symptoms (25%). Pain 
was most frequently treated with radiation therapy and pain medication. For urological 
symptoms, catheters were most often applied, while anaemia associated with malaise 
was mostly treated by blood transfusions. Neurological symptoms were generally re-
lieved by radiation or laminectomy and pain medication. 
Table 8.3 
Assessment procedures and costs in all advanced disease patients (N = 70) 
-E ~ !§ 3 o ~ 0 0 ~ ~ 
'" 
~ ~ 
~ 0 S o 3 ID C ID ~ 
"-
'" 
c u 
'- ,~ c u 
" 
+-' 0 ';::;' ID ~ ,9 ';::;' 
'~ ~t;;<3 "-Cl t ~ 
'" c ~ '" c ~ c o g ~ '" 
o '" '" ~fuO "-on ID .-<~ - '" e ,~ ?f!.i=O:O U:O "-" 
Outpatient visits 16' 97% 22 22% 
ORE 3.3 80% 0' 
TRUS 0.4 33% 45 1% 
Prostate biopsy 0.4 36% 48 1% 
Pathology 0.2 17% 48 1% 
PSA 8.2 100% 17 9% 
Other lab 6.6 93% 10' 4% 
CT-scan 1.0 50% 181 12% 
MRI 0.4 23% 580 13% 
Bone scans 1.9 91% 167 21% 
X-ray 
- thorax 1.3 57% 22 2% 
- bone 2.0 71% 22 3% 
IVP (intra venous pyelogram) 0.2 9% 65' 10/0 
Ultrasonography 
- abdomen 0.8 57% 41 2% 
- kidney 0.4 20% 41 1% 
- prostate 0.3 13% 41 1% 
Other 1.8 63% 495 6% 
1 including 1 visit of another specialist during hospital stay 
2 based on cost calculations, unless stated otherwise 
J cost of DRE are included in cost of outpatient visit 
4 based on tariffs (COTG 1997) 
S weighted average 
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The assessment procedures during the course of advanced disease and as a result of 
symptoms/complaints are presented in Table B.3. DRE and PSA were most frequently 
used to monitor the course of advanced disease. Every patient had on average 2 bone-
scans, one to establish the presence of bone metastases and an additional one to local-
ise progression for treatment with palliative radiation therapy. 
Other imaging techniques were also used to localise the (bone) metastases. To 
diagnose local obstruction or local extension of the cancer, intra venous pyelography 
(lVP) and ultrasonography were applied. On average 15 outpatient visits were recorded 
over a period of 24 months and 1 consultation with another specialist during hospital 
stay. 
Table 8.4 
Treatment and cost of treatment for all advanced disease patients (N = 70) 
.c 
.'= ...c ~ 
~ u " ~ 
" 
.D>-
'" ~ ~ -@ p Total number c " 
" c c"2 ~ (%) '';:::::; 0 c 
'" ~ " ~.6.'~ o..:=dE 
'" ~ 0. O~~ ~ 0 ".c ~ 
rf2."iil~ ~ 4- ~ 0_ 
Hormonal (total) 110 (24%) 89% 3.4 (15%) 
- orchiedectolllY (27%) 
- LHRH' (40%) 
- other (non-LHRH or (33%) 
combinations) 2 
Radiation therapy (total) 84 (19%) 47% 4.2 (18%) 
- external radiation 3 (89%) 
- metastron (11 %) 
Palliative TURP 11 (2%) 14% 1.2 (5%) 
Chemotherapy 5 (1%) 6% 0.2 (1 %) 
Pain medication (total)4 92 (20%) 69% 3.2(14%) 
- non-opioids (57%) 
- opioids (43%) 
Other treatment (total) 161 (34%) 80% 10.3 (45%) 
- CAO/PCNs (32%) 
- blood transfusions (27%) 
- other (41%) 
TOTAL 463 (100%) 22.6 (100%) 
1 costs or hospital days (all out) $ 242 
1 duration based on date of diagnosis until date of hormone refractory disease 
] average number of sessions (external radiation) 7.4 
-t assumed duration 1 month 
5 CAD = catheter a demeure I PCN = percutaneous nephrostomy 
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Forty-three percent of the costs of assessment consisted of the costs of outpatient 
visits (22%) and the costs of bonescans (21 %). PSA was performed 8 times on average 
per patient (every 3 months) and amounted to 9% of the costs of assessment. 
Table 8.4 shows the total number of treatments for advanced disease (6.6 on average 
per patient). Hormonal treatment, radiation therapy and pain medication were most fre-
quently applied. The category 'other treatment' consisted of, in addition to the use of 
catheters and blood transfusions, heterogeneous types of treatment. Hospitalisation for 
fractures, treatment by abstinence (before death), further (neurological) analysis and 
laminectomy, represented almost two-third of the hospital days in 14 patients. Of all 
hospital days, 45% were related to category 'other treatment', followed by hospital 
days related to radiation (18%).14% of all costs of hospital days were attributed to the 
pain treatment with medicine. 
The total costs (table 8.5) of advanced disease were $11,182 and consisted for the 
mostly of hospital days, followed by cost of treatment (49% and 37% respectively). The 
cost of outpatient visits and the cost of assessment accounted for only a small part of 
the total cost. 
Table 8.5 
Average total costs of advanced disease of prostate cancer per patient 
Cost ($) % 
outpatient visits 348 3% 
assessment 1199 11% 
treatment 4173 37% 
- hormonal (chemica/) 2339 56% 
- radiation rherapy 1306 31% 
- surgery (orchidectomy, (urp) 225 5% 
- other 301 7% 
hospital days 5462 49% 
TOTAL 11182 100% 
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DISCUSSION 
The average total costs per patient in the advanced disease stage of prostate cancer is 
$11,182 of which $1,547 (14 %) relates to assessment (including outpatient visits) and 
$9,635 (86%) to treatment (including hospital days). If screening proves to be effective 
and in part prevents advanced disease, then our cost estimates can be used to calculate 
savings proportionately to the number of men prevented from dying of prostate cancer. 
This reduction in costs of advanced disease will partly balance costs of screening, diag-
nosis and early treatment. 
We had to enrol a representative group of patients with distant metastases of 
prostate cancer. Because an academic hospital might select more serious patients we 
analysed the baseline characteristics for the hospitals separately (data not shown). The 
patient characteristics did not show statistically significant differences between both 
hospitals (although the numbers are small). Furthermore, in the academic hospital 
patients with a first diagnosis of advanced disease (MI-patients) were not 
overrepresented. Exclusion of patients that were referred for a second opinion has also 
enhanced comparability by preventing overrepresentation of the more serious cases 
and problems of loss to follow-up. The survival of patients in both hospitals was also 
not statistically different. We therefore conclude that no serious selection effects were 
observed in this study. 
The stopping of medication (e.g. hormonal, pain) was incompletely registered in 
the medical files, so we had to make assumptions about duration of these episodes. Be-
cause the average period of hormonal resistant disease was known (6 months), the du-
ration of hormonal treatment could be estimated. The costs of other medication con-
tributed relatively little, so the uncertainty of these estimates will have little effect on 
the reliability of the total cost estimates. 
Information bias could have occurred as a result of incomplete registration of all 
care received by the patients, resulting in an underestimate of the care and thus the 
costs of advanced disease. It is unknown to what extent this was the case, but the files 
were documented in detail in both hospitals. With the approach used in this study it 
was not possible to accurately register nursing home care and home care. In other stud-
ies concerning advanced disease of breast and cervical cancer, the costs of nursing 
home care covered 7-8% of the total costs (de Koning et a/., 1992; van Ballegooijen et 
a/., 1992). 
The burden of disease of prostate cancer was also investigated in the Nordic 
countries (Aus et ai., 1995; Borre et ai., 1997; Gtnes et a/., 1995). However in those 
countries, prostate cancer was not curatively treated and no division was made 
between MoMI- and MI-patients. We compared some outcomes of our patients 
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presenting with distant metastases at first diagnosis with these studies. The median 
crude survival in the studies by Aus and Gtnes were 19 and 23 months, which was 
slightly less than our survival of MJ-patients (26 months). Gtnes et al. found that the 
period from progression until death was 11 months, while the period was 6 months in 
our study. Compared to Aus et al. and Gtnes et aI., we found less palliative TURP (25% 
and 30% versus 14%) and more palliative radiotherapy (31% and 16% (all patients) 
versus 47%). This difference in the number of TURPs might also explain why both 
studies found a higher mean hospital stay (35 days and 1 month, respectively). Causes 
that might contribute to these differences are improved palliative care during recent 
years and differences between countries. Borre et al studied the human and economic 
burden of prostate cancer, but this was carried out irrespective of treatment strategy and 
thus stage of disease, which makes it impossible to compare the results (Borre el a/., 
1997). 
The survival of MoMJ-patients was somewhat worse than of MJ-patients during the 
first 30 months of follow-up. This might be explained by the higher percentage of dis-
tant metastases in other locations than the bone in these patients. Metastases in other 
locations were associated with a lower survival. 
Taplin also studied the health care costs of prostate cancer (Taplin el al., 1995). 
Although a different approach was used, the net cancer costs for distant prostate cancer 
were higher than in our study (about $17,776), but not totally different. This difference 
could in part be caused by the relatively expensive health care in the U.S. compared to 
the Netherlands. 
Advanced disease has been also evaluated for screening programs of breast cancer 
and cervical cancer. For breast cancer screening, the largest saving of both costs and 
quality of life was made through the prevention of advanced disease. Approximately 
40% of the extra costs induced by a screening program for women aged 50-70 with an 
interval of 2 years are compensated for by the prevention of advanced disease (de 
Koning el a/., 1992). For cervical cancer, the saving in regard to advanced disease was 
approximately 10% (van Ballegooijen el a/., 1992). Studying the care and cost of breast 
cancer revealed that almost all women with advanced breast cancer die of their 
disease. For prostate cancer we found that the percentage was 75%. 
The absolute costs of advanced disease of prostate cancer were lower than the 
costs of both advanced breast cancer and cervical cancer, while the duration of ad-
vanced disease of prostate cancer was longer than of both breast and cervical cancer 
(average duration 21 and 11 months, respectively). The costs were fl 34,200 and 
28,200, respectively. The average number of hospital days (45) for breast cancer was 
higher than for cervical cancer (27 days) which was similar to prostate cancer (23 days). 
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The difference in costs between advanced breast cancer and prostate cancer was 
mainly caused by the difference in numbers of hospital days. 
Future developments in assessment and treatment of prostate cancer might change 
the conclusions of this study. The widespread use and increasing knowledge about 
PSA, might result in a decrease of the number of bonescans and MRI for the assessment 
of distant metastases in the future. New therapy trials, such as immediate versus 
delayed treatment and continuous versus intermittent therapy are ongoing to improve 
the treatment of advanced disease. Especially new therapeutic options for patients with 
hormone refractory advanced disease have potency. The improvement in drug 
treatment will merely consist of developing (combinations 00 drugs with less side 
effects, which in themselves could help to improve the quality of life in this last phase 
of the disease. These new developments are likely to involve extra costs, resulting in 
higher costs of the treatment of advanced disease. 
This study described the symptoms, complications and accompanying treatment 
and costs from advanced prostate cancer. Combined with additional information about 
quality of life, these data give a better understanding of advanced disease and the pos-
sible health gains and savings due to early detection and effective treatment. 
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General discussion 
INTRODUCTION 
Screening is evaluated in different ways throughout the course of its development. The 
evaluation starts with the preparation of a randomised screening trial and continues 
after the implementation of a screening programme, ending only when a screening 
programme is finally abolished (table 9.1). During the course of preparing a trial and 
the process of deciding to introduce screening, many evaluation issues will emerge for 
consideration. Next to favourable effects, screening often also has important unfavour-
able effects. The latter in particular justify extensive and continuous evaluation. 
A nation-wide screening programme has already been introduced in the Nether-
lands for breast cancer, which requires a different evaluation perspective than that for 
prostate cancer, for which a randomised screening trial was started in 1994. In this the-
sis, aspects of the evaluation of screening programmes and of trials were brought to-
gether. This discussion offers an overview of the results and discusses the future chal-
lenges for the evaluation of screening of both cancers. The discussion of these chal-
Table 9.1 
Evaluation issues in different phases of programme development 
EVALUATION OF SCREENING 
151 phase: Trial 
Study design (internal validity) 
Screening effects (mortality reduction) 
Test-characteristics screen test 
Quantify factors influencing the main outcome 
2nd phase: Implementation of a programme 
Demography 
Epidemiology (incidence, stage distribution, mortality, survival) 
External validity 
Test-characteristics screening programme 
(Changes in) treatment and assessment 
Cost and savings 
Qual ity of life 
Screening effects (improvement in prognosis) 
3,d phase: Continuation of a programme 
Early outcomes (detection rates, stage distribution etc.) and late outcomes (mortality) 
Changes as a result of screening 
New scientific evidence: epidemiology, behavioural factors, therapy etc. 
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lenges highlights the different perspectives from which screening programmes may be 
evaluated, i.e. as a health care service or within the context of a trial. 
SUMMARY OF THE RESULTS 
First research question: cost effectiveness in other countries and 
settings 
The first research purpose of this thesis was to identify and quantify factors that influ-
ence the cost-effectiveness of breast cancer screening programmes in different countries 
and thus health care settings (Part I). These results may also be of use for the evaluation 
of the cost-effectiveness of other cancer screening programmes. 
This research question was addressed by two studies on breast cancer screening, 
in Germany and Spain. Both studies showed that the incidence and mortality of breast 
cancer were important determinants of cost-effectiveness. The incidence (I) and mortal-
ity (M) (European Standardised Rate) in Spain were 29% (I) and 38% (M) lower than in 
the Netherlands, while in Germany the rates were 16% (I) and 24% (M) lower. This 
negatively influenced the CE-ratio for both countries. The age distribution of the inci-
dence and mortality is also important as was illustrated in Spain. Cost-effectiveness of 
screening in the age-group 40-50 was more favourable, due to a relatively high inci-
dence in this age group compared to other European countries. 
The effect of lower sensitivity and specificity was studied in Germany, resulting in 
higher CE-ratios. This was further elaborated in a later study by Wannerdam et ai, 
showing that the costs of extra quality assurance can be counterbalanced by the savings 
obtained through improved sensitivity and specificity (Warmerdam et ai., 1997). 
Attendance appeared to influence costs and effects more or less equally, resulting 
in almost no effect on the CE-ratio. At attendance rates ranging between 50% and 80%, 
the overhead costs of organisation and evaluation have little influence on the costs per 
life-year gained. With lower attendance rates, however, these overhead costs will 
markedly increase CE-ratios. 
In the German study, the effect of health care setting was clearly demonstrated. 
Were the organisation of the screening programme to be decentralised, many mam-
mographs would not be used at maximum capacity. While this may negatively effect 
cost-effectiveness, it is more importantly also very likely to have a negative effect on the 
quality of mammography. A decentralised approach would lead to less experience in 
reading mammograms by medical professionals. Mammographs would tend to be less 
often replaced by newer equipment, which is likely to negatively influence sensitivity 
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and specificity. A decentralised organisation thus has many disadvantages, with possi-
bly as only benefit a more personal approach, as for some women mammography is 
done by their own physician. 
Both in Germany and Spain, opportunistic screening, i.e. mammography per-
formed for preventive purposes in the absence of an organised screening programme, 
occurs on a considerable scale (personal communication Robra, 1993 and Borras, 
1995). Using the Micro simulation SCreening ANalysis (MISCAN) model, the situations 
with screening and without screening were compared. An organised screening 
programme is expected to replace to some extent part of the opportunistic screening 
performed. A major problem is, however, that the effectiveness of screening outside 
screening programmes (opportunistic screening) is hard to quantify and therefore 
difficult to deal with in a cost-effectiveness analysis. We did not take opportunistic 
screening into account, but the savings in cost by the introduction of a screening 
programme, especially achievable where opportunistic screening is widespread could 
be considerable. 
Conclusion 
Costs and effects are determined by many factors that can differ between countries. The 
relative contribution of each factor separately is difficult to quantify, because many fac-
tors are mutually correlated. All factors should therefore be considered together. De-
spite these limitations, we have shown that standardised cost-effectiveness analyses for 
different countries are possible, and that these may result in very different cost-effec-
tiveness ratios between countries. 
Second research question: secondary effects of screening programmes 
The second research question concerns the quantification of secondary effects 01 
screening after the introduction of a nation-wide breast cancer screening programme 
(Part II). This research question was studied by quantifying the effects of radiation risk 
on breast cancer mortality and by quantifying screening outside the target population 
(opportunistic screening). 
Radiation risk 
The effects of radiation risk are quite difficult to assess because the dose used in breast 
cancer screening is only about 2 mGy per mammogram, whereas available risk esti-
mates are based on doses that are 100-300 times higher. Extrapolation of the risk esti-
mates to very low doses is thus needed to estimate the number of breast cancer deaths 
and the balance between deaths induced and prevented for different screening policies. 
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This balance was favourable in the Dutch screening programme (age-group 50-69, in-
terval of 2 years), but this balance becomes less favourable in younger women for at 
least two reasons. The first is an increased radiation risk at younger ages, when the 
breast tissue is more sensitive to radiation. Secondly, the breast cancer incidence and 
mortality of women in their forties is lower, thus screening may prevent fewer breast 
cancer deaths. Although screening in women under 50 was assumed to be ineffective 
for a long time, recently published trial results suggest a smaller than for the age group 
50-69, but statistically significant mortality reduction (Hendrick et ai., 1997; Larsson ct 
al., 1997). Assuming the same effectiveness of screening in women aged 40-49 as in 
women aged 50-69, the ratio of cases induced/prevented deaths remained favourable. 
Because of the many uncertainties in the risk estimates, the confidence limits of these 
estimates were wide. Recently, lower risk estimates than those \ve used were pub-
lished, resulting in 3-6 times lower estimates for induced breast cancer. If screening was 
extended to include women in their forties, radiation risk should be considered, but its 
importance is mainly determined by the extent of effectiveness of screening in this age 
group. 
Mammograms outside screening 
The effect of the introduction of nation-wide screening on the number of mammograms 
requested by general practitioners for women outside the target ages (50-69) was stud-
ied. A steady increase in requests for mammograms was revealed for women older than 
40 during the period 1988-1995. Taking into account this overall increase, in the target 
population a decrease in mammograms performed outside the scope of screening pro-
grammes was observed. This decrease had been expected at the time the cost-effective-
ness analysis for breast cancer screening was done (de Koning et al., 1991), It was as-
sumed that the number of clinical mammograms and the breast cancer diagnostics 
would decrease proportionally with the number of cancers detected by screening in-
stead of clinically. 
Conclusion 
During the implementation of a screening programme, the monitoring of effects and 
costs remains essential, as developments in health care and the epidemiology of the 
disease can influence the effects and costs of the programme. The factors studied in this 
thesis did not put the nation-wide screening programme in a different perspective, be-
cause both outcomes of the evaluation of radiation risk estimates and of 'opportunistic 
screening' were favourable. The section on the evaluation challenges (section 9.3) pro-
vides more examples of the need for a continuous evaluation of the programme. 
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Third research question: determinants ()f prostate cancer screening 
effectiveness 
The third research question concerns the quantification of factors influencing the per-
formance of the present prostate cancer screening trial and thus a possible future 
screening programme (Part III). This research question was addressed in 3 studies. 
The first study was intended to optimise the screening protocol used in the Euro-
pean Randomised study on Screening of Prostate Cancer (ERSPC, Rotterdam). This was 
prompted by the objection from both researchers and the Health Council of the Nether-
lands to the high proportion of false positive biopsy indications (Health Council of the 
Netherlands, 1996). We looked at several combinations of screening tests (prostate 
specific antigen (PSA), digital rectal examination (ORE) and transrectal ultrasonography 
(TRUS) and estimated the resulting number of false negatives in each combination in an 
attempt, to reduce the number of false positive biopsy indications. By weighing screen-
ing and assessment procedures and the cancers detected, we concluded that screening 
with PSA alone would be the best option. Although about 8% of the cancers would 
consequently be missed, the advantages would be a reduction of the false positive bi-
opsy indications and a very simple screening procedure. Since May 1997, screening 
has consisted of PSA only, followed by a biopsy if the PSA is :,. 3ng/ml. 
In the second study, PSA-testing before and during the ERSPC and the base-line use of 
assessment procedures such as ORE and biopsy for prostate disease was quantified for 
Rotterdam. PSA-testing is very simple and its use should be monitored, especially in the 
control arm of the trial, as it could influence the outcome of the trial. In the screen arm 
of the trial, 3.3% underwent a PSA annually outside the screening trial, while this was 
7.6% in the control arm. An average of 45% of the men had had a ORE at some point, 
and 13% reported having a PSA test before participating in the trial. Undergoing PSA-
testing and ORE before participation in the trial did not result in statistically significant 
differences in detection rates. 
The 4-year screening interval yields a contamination level that must also be taken 
into account in the final evaluation. The results moreover underscore the importance of 
a continuous follow-up of further monitoring of PSA use in all trial participants. 
In the third study, we studied the course of advanced prostate cancer and its health care 
costs. The most frequently reported symptoms were pain (42%), urogenital symptoms 
(25%) and malaise (20%). 80% of all patients were hormonally treated (either by orchi-
dectomy or chemical castr(ltion or a combination) and 47% received one or more 
courses of radiation therapy. 69% of all patients were on pain medication. 
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The average costs of advanced disease were estimated at $11,182 over the total 
period of advanced disease of 24 months. 14% was allocated to assessment and outpa-
tient care, 37% to treatment costs and 49% to costs of hospital stay. If screening proves 
to be effective in preventing advanced disease in some participants, this will result in a 
sizeable reduction of treatment costs for advanced disease. These estimates, together 
with the effects of advanced prostate cancer on quality of life, will be used for the 
evaluation of prostate cancer screening. 
Conclusion 
The evaluation of an ongoing screening trial requires continuous attention to directly 
related questions that can not be answered in the main screening trial. This is extremely 
important as the answers to these questions may determine the final judgement about 
the possible mortality reduction and the desirability of introducing screening. 
EVALUATION CHALLENGES FOR BREAST CANCER 
Breast cancer screening, a national health care service that has reached the 3,d phase 
(table 1), is facing two main evaluation challenges. The first challenge is to maintain an 
optimal breast cancer screening programme in the light of new scientific evidence on 
e.g. treatment, techniques, screening effectiveness and policy developments. 
The second challenge regards the evaluation of the mortality reduction as a result 
of breast cancer screening. This issue is all the more interesting as standard methods 
used in evaluation trials can not be easily applied. A 'control arm' is not available for 
breast cancer screening as a health care service. A few aspects of these challenges are 
presented in this paragraph. 
Maintenance of an optimal screening programme 
Screening of women aged 40-49 and over the age of 70 
Breast cancer screening for women aged 40-49 is still a controversial topic. Many ques-
tions concerning the screening of women in their forties could not be resolved, because 
the studies were not especially designed to produce age-specific results. Nevertheless, a 
recent meta-analysis of 8 randomised trials showed a statistically significant mortality 
reduction of 18 % for women aged 40-49 at entry (Hendrick er al., 1997). When all the 
data on women aged 40-49 at entry of 5 Swedish randomised trials were combined, a 
statistically significantly 29% mortality reduction was found among WOmen invited for 
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screening (Hendrick et a/., 1997). Part of this mortality reduction could, however, be 
due to screen detection of cancers in these women above the age of 50, as was sug-
gested by de Koning et al. (de Koning et a/., 1995). The magnitude of this effect was 
studied in four Swedish randomised trials, which concluded that almost the entire effect 
in the group aged 40-44 years at randomisation was due to screening before the age of 
50 (Larsson et a/., 1997). Now that screening women in their forties may be as effective 
as for women in the age-group 50-69, the questions arises if screening should become 
available as a health care service for this group. The cost-effectiveness of screening 
women in their forties is less favourable, mainly because breast cancer incidence and 
mortality are much lower in this age-group in most countries. One study concluded that 
the cost-effectiveness of screening women in the age-group of 40-49 years was almost 5 
times as high as in older women (age 50-69) (Salzmann et a/., 1997). 
A new trial has already been set UI} to quantify the effectiveness of screening 
women aged 40-49 years (Moss, submitted). The first mortality analyses are expected 
around 2010-2012. After the effectiveness (if present) has been proved, additionally 
cost-effectiveness analyses will support policy decisions about the introduction of 
screening women in their forties. 
In 1998, the upper age limit of the Dutch screening programme was moved from 69 to 
74, resulting in 3 more invitations per woman. Political pressure has been brought to 
bear on the upper age limit, with age discrimination as an argument. The effectiveness 
of screening women older than 75, however, has never been addressed in randomised 
trials (Nystrom ct a/., 1993). Case-control studies have indicated that screening until the 
age of 75 could reduce the mortality of breast cancer (van Dijck et a/., 1997; van Dijck 
et a/., 1996). The number of life-years gained per women prevented from dying of 
breast cancer decreases with increasing age. Due to the (assumed) longer preclinical 
period, more years with lead-time are generated by screening until an older age. At 
older ages, screening will thus result more often in diagnosis and treatment of breast 
cancer in women that would have died from another cause, before they themselves 
would have noticed a breast abnormality. The combination of these factors results in a 
less favourable balance between positive and negative effects of screening at older 
ages. Screening until the age of 75 may be as cost-effective as for the age group 50-69, 
but a further increase would show a markedly less favourable balance (Boer et a/., 
1995). While a trial might be the best method to quantify the effect of screening 
women aged 75 years and older, very large numbers would be required in order to fi-
nally establish an optimal upper age limit. 
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Interval cancers 
Evaluating the detection rates together with the interval cancer rates in the 2-year pe-
riod after the screening, and the stage distribution of screen-detected and interval can-
cers (incidence rate of advanced cases) is necessary to judge the performance of the 
programme. The first results of the Dutch nation-wide screening programme have re-
cently been published (Fracheboud e1 aI., 1998). Although the interval cancer rate was 
as high as estimated in advance (with the use of the MISCAN-model), these results also 
revealed a somewhat worse performance in comparison with screening in two regions 
of the UK. Despite a relatively high breast cancer incidence the Dutch screening pro-
gr"mme showed a lower detection rate of invasive cancers, followed by somewhat 
higher interval cancer rates. Furthermore, the stage distribution of the screen-detected 
cases was less favourable than in some regions of the UK (Day et aI., 1995; Woodman 
c1 aI., 1995). The interval cancer rates were also almost twice as high as those reported 
from one Swedish trial (T"bar e1 aI., 1987). These results were one of the reasons for 
starting reseilrch on the possible improvement of sensitivity in the national screening 
programme (see under Optimisation). 
New screening and assessment techniques 
One of the most important new developments in mammographic screening is perhaps 
the use of Computed Assisted Diagnosis (CAD). With the use of CAD the computer sets 
a prompt on a digitised mammogram, preventing the radiologist from overlooking an 
abnormality. Several studies have shown that this method could improve the sensitivity 
of mammography reading (te Brake e1 al., 1998; Thurfjell e1 al., 1998). However, the 
CAD in itself had a very low specificity, which may need improvement before becom-
ing useful in mammographic screening (Thurfjell e1 al., 1998). Furthermore, issues such 
as developing optimal detection schemes for the computer, assessment of the costs in-
volved, possibility of training etc. need to be addressed, before this technique c"n be 
"pplied in screening 
As a result of screening, the number of non-p"lpable breilst abnorm"lities has in-
cre"sed. The "ssessment of these lesions is time consuming and costly due to a compli-
cated procedure (stereot"ctic surgic,,1 biopsy) demanding total an"esthesi" and hospital 
st"y of 1 or 2 days. A new study w"s started in the Netherlands to rate the value of 
stereotactic core needle biopsy (Anonymous, 1997). This new technique hils the adv"n-
t"ge th"t no hospit,,1 admission is needed, there is less mutilation and scar tissue and 
the interpretation of future mammograms (in the case no cancer is present) is less ham-
pered. Moreover, this technique may prove less expensive, because the costs of a hos-
pital stay are saved. If this new technique proves to have the same sensitivity it could 
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replace the existing procedure, reducing the burden for women diagnosed with a non-
palpable breast lesion. 
High risk groups 
Hereditary risk of breast cancer has attracted more attention with the discovery of the 
BRCA 1 and BRCA2 genes. Presence of the BRCA 1 or BRCA2 mutations are supposed 
to give about 70% risk of developing breast cancer before the age of 70 on the basis of 
population based studies (Claus et a/., 1991; Whittemore et a/., 1997). Presence of this 
gene results in a psychological load and has already resulted in decisions for preventive 
amputation of both breasts (DudokdeWit et a/., 1997). In the Netherlands, genetic 
counselling is available for women who request this service. Women attending the 
counselling vary in breast cancer risk and the guidelines are not yet clear. An alterna-
tive to preventive amputation might be (frequent) screening from young ages onwards. 
In particular, development of a proper guideline for young women bearing a hereditary 
burden is a challenge. 
Women with dense breast tissue seem to be at higher risk of developing breast 
cancer (van Gils, 1998). If these findings are confirmed in other studies, this might re-
sult in a separate screening programme (with other intervals or more views) for some 
women. 
Chemoprevention 
The first results of prevention of breast cancer with tamoxifen have recently become 
available (Fisher et a/., 1998). Although the incidence of breast cancer was significantly 
reduced by 49% in women aged 35 and over, many questions still have to be resolved. 
The increased incidence of cervical cancer, stroke, pulmonary embolism and deep vein 
thrombosis must be weighted against the reduction in the incidence of breast cancer. 
Furthermore, the incidence of breast cancer might only be postponed, which, among 
other long-term effects, will emerge with longer follow-up. Because the effects were 
also strong at younger ages (44 % reduction in incidence for women aged 49 or 
younger), the developments in this field must be continuously monitored, especially if 
an expansion of screening towards younger ages is considered. These developments 
have to be followed carefully and may have a profound consequence for the present 
screening programme in the Netherlands. 
Optimisation 
Now that the first data about interval cancers and repeat screening examinations have 
become available, the performance of the nation-wide screening programme in the 
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Netherlands can be better assessed (Fracheboud et al., 1998). The data suggest that the 
screening performance might be improved. 
The Netherlands Evaluation Team of Breast cancer screening (NETB) and the Na-
tional Expert and Training Centre for Breast Cancer Screening (LRCB) will start a study 
on a possible improvement of sensitivity in the national screening programme. Re-
search questions concern the practice of independent double reading, two-view screen-
ing in subsequent screens for all women, minimal signs predictive for cancer and the 
effect of higher referral rates. Many studies have already demonstrated the improved 
detection by 5-15% with independent double reading (Anderson et al., 1994; Anttinen 
et a/., 1993; Brown et a/., 1996; Ciatto et a/., 1995; Thurfjell, 1995). This increased 
detection was counterbalanced by an increased referral in most studies, resulting in a 
lower specificity. The extra detection has even been balanced against the incurred 
costs, concluding that a consensus double reading was more cost-effective than single 
reading policy (Brown et al., 1996). Extrapolation of these results should however be 
done with caution, because the referral rates are much lower in the Dutch screening 
programme than in other programmes (Chamberlain et a/., 1993; Hakama et al., 1995; 
Thurfjell, 1995). 
The effect of two-view screening has been studied in the UK, because that pro-
gramme initially had one-view screening. Wald et al showed a 24% increase in detec-
tion rates with two-view screening as compared with one-view (Wald et al., 1995). The 
extra costs were balanced by the extra cancers detected, resulting in similar cost-effec-
tiveness. Another study also showed an improved detection of small invasive cancers 
« 15 mm) from 45% for first screens and 25% for subsequent screens by two-view 
mammography compared to one-view (Blanks et al., 1997). In the Dutch situation, two-
view mammography is carried out during first screens and the results of a previous 
screening round are used for the interpretation of the following mammogram. This dif-
ferent approach makes extrapolation of these results difficult and justifies additional 
research. 
Minimal signs on screening mammograms have been often studied, especially in 
relation to review of previous mammograms (Ciatto et aI., 1995; Daly et al., 1998; van 
Dijck et al., 1993). The interpretation of these signs prospectively in relation to breast 
cancer detection is, however, unknown. Improved knowledge of the predictive value of 
certain types of minimal signs might improve the sensitivity of breast cancer screening 
by mammography in the future. 
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Assessing cancer mortality reduction 
One of the most challenging topics in the future evaluation will be to assess the mortal-
ity reduction of national breast cancer screening. A first model-based analysis, compar-
ing expected mortality due to the introduction of screening with the one observed, was 
done for the Netherlands and the UK for the period 1989-1996. This study showed that 
the effects of screening in the Netherlands are expected to be demonstrable from 1998 
onwards (van den Akker-van Marie et a/., in press). 
The effectiveness of the Finnish national screening programme could be evaluated 
because of the gradual invitation of different cohorts of women (Hakama et a/., 1997). 
They concluded that a breast screening programme can achieve a similar effect on mor-
tality as achieved by the trials for breast cancer screening. This methodology may be 
used in The Netherlands, where the screening programme was gradually introduced by 
region. The number of screened women might, however, be not sufficient. The assess-
ment of mortality reduction due to screening is a major methodological challenge. 
Trend analysis taking into account other developments alongside the implementation 
will be a method of analysis. Yet, inevitably, a comparison will have to be made be-
tween women having attended the screening and those having not attended. This may 
be done in a case-control study, which however always entails some problems with the 
interpretation of the results (Cronin et a/., 1998; Demissie et a/., 1998). 
EVALUATION CHAllENGES FOR PROSTATE 
CANCER 
The major challenge for prostate cancer screening evaluation involves establishing the 
effectiveness of screening in reducing deaths from prostate cancer, in the context of e.g. 
changes in therapy, increase in screening outside the screening trial, and perhaps the 
development of more specific screening tests. In the mean time, also because of the 
adverse side effects of screening, it is ethically unacceptable to offer a-symptomatic 
men screening for prostate cancer outside experimental randomised settings (de Koning 
and Schroder, 1998). After the value of prostate cancer screening has been established, 
the evaluation will be directed towards a decision about screening in the general popu-
lation. In the next paragraphs these challenges are further discussed. 
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Establishing of the effectiveness of prostate cancer screening 
Analysis of cancer mortality reduction 
The largest challenge in the evaluation of prostate cancer screening is a reliable esti-
mate of its effectiveness in reducing prostate cancer mortality, based on well-designed 
studies. The ERSPC and PLCO will give a large contribution by enrolling 200.000-
250.000 men in randomised trials (Auvinen et ai., 1996; Gahagan et a/., 1994). Screen-
ing will in general result in a more favourable stage distribution of detected disease, 
which often entails a different distribution of treatment modalities applied. A difference 
in distribution in treatment modalities within a stage of prostate cancer between the 
screening and control arm of the study might hamper the interpretation of the results of 
the trial. There is to date no convincing evidence, based on a randomised trial, to show 
whether radiation therapy or prostatectomy should be preferred as the curative treat-
ment modality for localised prostate cancer. If one of these should, in theory, be supe-
rior to the other and this treatment is more often applied to the screening ann than the 
control arm, a distortion of the results might occur. 
Opportunistic 'screening', i.e. screening outside the trial in both screening and 
control arm, was reported in this thesis. The level of opportunistic screening in the con-
trol arm was about 8% per year and this phenomenon warrants further evaluation in 
the future. Registering both treatment and opportunistic screening for all persons in the 
study and control group, will enable adjustment for these factors to be made in the final 
mortality analysis. 
Screening tools 
The optimal (combination of) screening tools for the early detection of prostate cancer 
has not definitively been established. PSA test is very promising, but the test character-
istics of this test are far from ideal (Rietbergen et al., 1997). The sensitivity is likely to 
be quite high, but the specificity is moderate. This results in low positive predictive 
value of the biopsies done on the basis of some PSA cut-off values. Several methods 
have been suggested to reduce the number of false positive biopsy indications, like PSA 
density (PSA corrected for total prostate volume or transition zone volume) and free to 
total PSA ratio (Babaian et a/., 1992; Catalona et a/., 1995; Kalish et a/., 1994). Until 
now this has not resulted in a clear preference for one of these methods, because im-
provement in specificity resulted in a considerable loss in sensitivity (Bangma et al., 
1997; Rietbergen et ai., 1998). Within the different centres participating in ERSPC vari-
ous cut-off levels of PSA and screening intervals are used, that will help to determine 
the optimal screening protocol. New developments, to improve the test-characteristics 
of PSA have to be taken into account to optimise the screening protocol. 
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Natural history 
The natural history of prostate cancer is largely unknown. The screening trial will yield 
much knowledge, especially from the comparison of the screening and control arm. 
Differences in number of cancer diagnoses, stage distribution, grade and timing of the 
diagnosis will help to unravel the natural history. The incidence of interval cancers and 
timing since screening of these cancers will also contribute. The use of micro-simula-
tion will help to estimate the mean preclinical-duration of prostate cancer (van Oart-
marssen et al., 1990). 
Deciding about the introduction of prostate cancer screening 
External validity 
An important theme in future evaluation should be the external validity of the results 
obtained in the ERSPC, Rotterdam. The screening trial has been set up as an efficacy 
trial, because randomisation took place after informed consent. This will result in an 
estimate of the effect of screening of only 45% (attendance rate) of the target popula-
tion. If people participating in the trial are selected according to e.g. disease prevalence 
or general health status, the result might not be valid for the general population, for 
which the screening is eventually intended (Nijs et al., 1997). This issue has to be fur-
ther addressed. 
Cost-effectiveness analysis 
In order to perform a thorough cost-effectiveness analysis, many issues remain to be 
quantified in the next few years. Some men will be diagnosed and treated for prostate 
cancer and die (of other disease) before the time they would have been diagnosed 
without screening. Those men have a diagnosis of prostate cancer without benefiting 
from screening. Due to the probable longer preclinical period and the higher age at 
which prostate cancer occurs than for breast cancer, this adverse effect will be more 
prominent than in breast cancer. Furthermore, with the present screening modality 
(PSA ;0, 3 nglml as a biopsy indication) a considerable percentage of men will still have 
a false positive biopsy indication. Therefore assessment of the quality of life effects of 
screening attendance, false positive test results and of prostate cancer during different 
stages of disease and stratified for different treatment modalities is indispensable. In 
Rotterdam quality of life studies are conducted alongside the screening trial (Essink-Bot 
et a/., 1998; Madalinska et al., in preparation). The outcomes of these studies will help 
to weigh many aspects of prostate cancer. 
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In order to estimate the effects of population screening the present practices of 
diagnosis and treatment of prostate cancer should be documented. The costs of assess-
ment, treatment, organisation and evaluation of screening must also be assessed. With 
the MISCAN model, stage-specific improvement of prognosis due to screening and 
therapy will have to be estimated. By combining all this information, the effects of dif-
ferent screening intervals and age groups can be analysed and will support the decision 
about introducing screening. 
CONCLUDING REMARKS 
Screening always has to strike a balance between favourable and adverse effects. This 
balance should always guide the implementation and monitoring a nation-wide screen-
ing programme. Changes in elements included in the cost-effectiveness analysis or new 
developments may lead to changes in the screening programme and in theory eventu-
ally the abolition of the screening programme. The results achieved in trials may differ 
from the results in a total population. An obvious reason for such a divergence may be 
differences in the quality of follow-up assessment and therapy. A profound evaluation 
has to include all these aspects, also because national cancer screening programmes 
are rather costly. The Dutch breast cancer screening programme costs, for example, 59 
million guilders per year which is 0.1 % of the total health care costs in the Nether-
lands. 
The main question to be answered by the evaluation of a screening trial is the 
quantification of the cancer mortality reduction. However, many other factors must also 
be quantified to obtain a balanced judgement on the benefit/harm ratio. 
It should be kept in mind that the benefit/harm ratio of screening for cancer is sub-
ject to continuous change, as a result of improvement in test properties and diagnostic 
and therapeutic improvement. This necessitates continuous alertness to adapt the pro-
gramme in order to obtain optimal results. Obviously, the ideal will remain to find ef-
fective forms of primary prevention or therapy that will make screening superfluous. 
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Screening for cancer may be evaluated from different perspectives, which relate to the 
phases of evaluation. During a randomised trial the evaluation of screening is aimed to 
demonstrate the effectiveness, but also to facilitate the interpretation of the trial out-
comes. After effectiveness has been proofed, the possible introduction as a health-care 
service should be evaluated. During implementation continuous monitoring is also 
needed to compare the results with the expectations and the developments in clinical 
practice. Screening has, besides favourable effects often also important unfavourable 
effects. Especially the latter justify an extensive and continuous evaluation in these dif-
ferent phases. In this thesis parts, of the evaluation of both breast and prostate cancer 
are described. 
Breast cancer screening is already introduced in the Netherlands and many other 
European countries. The effectiveness of prostate cancer screening has not yet been 
shown and therefore a large European randomised trial was started in 1994. This re-
sulted in a different evaluation perspective for breast cancer than for prostate cancer. In 
this thesis the evaluation of screening of both breast cancer and prostate cancer is com-
bined. 
Although the effectiveness of breast cancer screening has been demonstrated in 
randomised trials and the cost-effectiveness was determined for the Netherlands, the 
balance between the positive and negative effects of screening might be different in 
other countries. Factors that might influence the cost-effectiveness of screening are for 
example, the incidence and mortality of breast cancer, the clinical stage distribution 
and the organisatklll of health care. In this thesis the effects and costs of the introduc-
tion of a breast cancer screening programme in Germany and Spain were studied 
In chapter 2 the effects and costs of a national breast cancer screening programme 
in Germany were evaluated. Special attention was paid to the decentralisecl German 
health-care system and to the influence of attendance, interval and age group. The 
analysis shows that a programme providing for the screening of women aged 50-69 at 
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2-year intervals might be expected to result in a decrease in mortality from breast can-
cer estimated at 11 % for the total German population, representing 2,100 deaths from 
breast cancer prevented each year. The predicted cost per life-year gained was 2 to 3 
times less favourable than in the UK and the Netherlands. The sensitivity of mammog-
raphy was estimated to be approximately 12 % lower than in the Netherlands and the 
attendance rate was calculated at 47% on average (70-80% in the Netherlands). A 
greater effort to ensure the quality of the screening programme and to improve the invi-
tation system to improve the attendance to the Dutch level might finally lead to a mor-
tality reduction of 18%. 
In Spain (Catalonia) the emphasis lay on the effects and costs of different policies 
for breast cancer screening, to give a basis for setting priorities and deciding on the in-
troduction of a screening programme (chapter 3). The reduction in breast cancer mor-
tality in the total female population due to a screening programme for the age group 
50·64 years would be 16, 12 and 9%, with screening intervals of 1, 2 and 3 years re-
spectively. The most cost-effective screening scenario is the one in which women aged 
50-69 years are screened with an interval of 3 years with a mortality reduction of ap-
proximately 12% in the total female population. Screening until the age of 69 years (2-
year interval) was almost as cost-effective as screening the age group 50-64 years with a 
2-year interval, with a reduction in breast cancer mortality of 15%. Extension to under 
the age of 50 years resulted in diverging results depending on the assumptions for im-
provement in prognosis for younger women (40-49 years). If an extension of a 2 yearly 
screening programme for women aged 50-64 years is considered, extension to older 
women would be more advisable, based on proven benefits and costs, than extension 
to younger age groups. 
Although the screening with an interval of 2 years has been introduced in the 
Netherlands as a national screening programme for all women aged 50-69 and since 
1998 until the age of 75, the evaluation still continues. In that phase, secondary effects 
of the screening were also investigated. In this thesis the effect of radiation risk was 
evaluated and the use of mammography through the general practitioner, related to the 
start of the screening programme. 
In chapter 4 the effects of radiation due to mammography were studied, to esti-
mate the number of breast-cancer deaths induced by low dose radiation in breast-can-
cer screening programmes compared to numbers prevented. A computer simulation-
model on the natural history of breast cancer was combined with a model on induced 
breast-cancer mortality from low levels of radiation. Different scenarios (ages and inter-
vals) were used to show the effects on the balance between breast cancer deaths in-
duced and prevented. For a screening programme, age group 50-69, 2-year interval, 2 
mGy per view, the balance between the number of deaths induced versus those pre-
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vented was favourable; 1 :242. When screening is expanded to the age-group 40-49 the 
results may be less favourable, but if screening was equally effective in young women 
as in women aged 50-69, the balance would become more favourable again. The new 
risk estimates by Howe and Mclaughlin resulted in 5 to 8 times more favourable bal-
ance. Besides age group, dose of mammography is the other determinant of radiation 
risk. It was concluded that for screening under the age of 50, the balance between the 
number of breast-cancer deaths prevented by screening versus the number induced by 
radiation seem less favourable. Credibility-intervals were however wide, because of 
many uncertainties of radiation risk at very low doses. 
Another possibly secondary effect of the introduction of screening is the increase 
of screening in adjacent (non-invited) age groups and a change in health behaviour in 
the target population. In chapter 5, we analysed the effect of the start of the Dutch na-
tional screening programme on the number of mammograms requested by 43-45 gen-
eral practices for the age-groups 30-39, 40-49, 50-69 and 70+. In all age-groups an 
immediate increase was observed in the number of mammography requests after the 
start of the screening of age-group 50-69 in that area, which was largest and statistically 
significant in the target-population of the screening programme. More than two years 
after the start of screening however the number of mammography requests in all age-
groups had decreased to the level of before the start and in the age-group 50-69 the 
number of mammograms was significantly lower than before the screening started. The 
unexpected increase in mammograms after the start of the breast-cancer screening pro-
gramme might be related to registry problems or to the process of building up the 
screening programme. Eventually there was a decrease in the number of mammograms 
in the target-population, probably as an effect of the introduction of the national screen-
ing programme. Screening outside the organised screening programme in adjacent age 
groups was not clearly demonstrated. 
In this thesis some studies were conducted alongside the European Randomised Study 
of screening for Prostate Cancer (ERSPC) in Rotterdam. The screening protocol was in-
vestigated to optimise the combination of screening tests. Furthermore the use of PSA-
testing and DRE before and during the trial was studied. Finally the care and costs of 
advanced disease were studied in this thesis. 
For prostate cancer the combination of different screening tests to come to a more 
efficient screening protocol was studied in chapter 6. The screening protocol initially 
consisted of 3 screening tests: prostate specific antigen (PSA), digital rectal examination 
(DRE) and transrectal ultrasonography (TRUS). A PSA value of 24 nglml andlor an ab-
normality on DRE andlor TRUS were an indication for biopsy. Effects of a change in 
PSA cut-off on the outcomes of the screening were explored. A logistic regression 
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model was used to predict the number of cancers if all men would have been biopsied. 
Biopsies in men with a PSA of < 1 nglml and a positive ORE or TRUS were very ineffi-
cient. Increasing the PSA cut-off to 1.5 or 2 nglml to indicate a biopsy would result in 
5%-8% cancers less and many (29%-36%) biopsies less. A protocol with PSA" 3 nglml 
as a direct biopsy indication resulted in 7.6% cancers detected less and 12% biopsies 
less. Given these results and the fact that ORE and TRUS appeared difficu It to repro-
duce, a change in protocol towards PSA" 3 nglml seems acceptable. With this protocol 
ORE and TRUS could be omitted. If screening proofs to be effective in savi ng prostate 
cancer deaths, a final judgement about an optimal combination of screening tests 
should be made. 
Determination of (PSA) is a simple test, possibly resultir~g in frequent usage. This 
might influence the outcome of the European Randomised study on Screening for Pros-
tate Cancer (ERSPC). In chapter 7, PSA and digital rectal examination (ORE) before and 
during the screening trial in Rotterdam and in the general population were quantified. 
Data from the intake questionnaire regarding PSA testing and ORE were analysed to 
evaluate the use of these tests before participation in the screening study. Data on PSA 
from the Laboratory of General Practice were linked to information from participants in 
the screening study. Different sources were used to quantify PSA and ORE in the gen-
eral population, in a situation without screening. On average, 45% of the men had had 
a ORE and 13 % reported that they had been PSA tested before participating in the trial. 
Both these percentages increased with age. No statistically Significant effects of former 
PSA-testing or OREs on the cancer detection rate could be demonstrated. The rate of 
PSA determinations was approximately twice as high in those not offered screening 
(control-arm) than in those offered screening (screening-arm), which was 76 and 33 per 
1000 person-years, respectively. After inclusion in the trial the number of PSA determi-
nations first decreased in the screening arm, but after 6 months an increase was ob-
served. The number of PSA determinations increased in the control arm after inclusion 
in the trial. The number of PSA determinations in the general population was estimated 
on 45/1000 person-years. The use of PSA tests in the control arm was moderate, but if 
different men undergo this test every year the contamination rate in the control arm 
might be rather high during a screening interval of 4 years. In the final analysis on mor-
tality, PSA-testing should be taken into account. The motives and outcomes of PSA test-
ing would be useful for further interpretation. 
If prostate cancer screening proves to be effective in preventing prostate cancer 
deaths, some cases will be prevented from reaching the advanced stage of prostate 
cancer. In order to evaluate screening programs thoroughly, it is important to quantify 
course, care and accompanying costs of advanced disease. In chapter 8, 70 files of pa-
tients in 2 hospitals, who had received a diagnosis of distant metastases of prostate can-
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cer and had died in the years 1994-1998, were studied. The total healthcare received 
by these patients, including symptoms and complaints, was recorded. Most frequently 
reported symptoms were pain (42%), urogenital symptoms (25%) and malaise (20%). 
89% of all patients were hormonally treated and 47% received one or more series of 
radiation therapy. 69% of all patients were treated with pain medication. The average 
duration of advanced disease was 24 months. Average costs of advanced disease were 
estimated at $ 11,182 over the total period of which 14 % was allocated to assessment 
and outpatient care and 86% to treatment and costs of hospital stay. These data give a 
better understanding of the course and costs of advanced prostate cancer. These esti-
mates can be used for the future evaluation of prostate cancer screening. 
In chapter 9 some future evaluation challenges of breast cancer and prostate can-
cer screening are summarised. For breast cancer these challenges consist of new devel-
opments in diagnostics, primary prevention and the evaluation of the screening pro-
gramme. These include digital mammography, fine needle biopsy and tamoxifen to 
prevent breast cancer. Evaluation challenges of the current breast cancer screening pro-
gramme are the screening of younger (40-49) and older women (70 +), the establish-
ment of the mortality reduction as a result of screening and the question whether the 
performance of the present national screening programme is the maximum achievable. 
The main question to be answered by the evaluation of a prostate screening trial is the 
quantification of the cancer mortality reduction. However, many other factors like qual-
ity of life, have to be quantified in order to give a balanced judgement about the bene-
fit/harm ratio. Future evaluation challenges are the determination of the effectiveness of 
prostate cancer screening and making up the balance of favourable and unfavourable 
effects to support a decision to introduce screening. 
Screening always has to strike a balance between favourable and adverse effects. 
This balance should be taken into account during the evaluation of a screening trial, 
during the possible introduction and during the execution of a screening programme. 
The benefit/harm ratio of screening for cancer is subject to continuous change, as a re-
sult of, for example, improvement in test properties and diagnostic and therapeutic de-
velopments. This necessitates continuous alertness to adapt the programme in order to 
obtain optimal results. Obviously, the ideal remains to find effective forms of primary 
prevention or therapy that will make screening superfluous. 
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SAMENVATTING 
Evaluatie van kankerscreening kan met verschillende doelstellingen worden uitgevoerd. 
Deze doelstellingen hangen sam en met de fase waarin de evaluatie zich bevindt. Het 
belangrijkste doel van evaluatie van een gerandomiseerde screeningstudie is de 
effectiviteit van de screening aan te tonen. De evaluatie in die fase is echter ook van 
belang om de interpretatie van de uitkomsten te vergemakkelijken. Ais effectiviteit is 
aangetoond kan een mogelijke invoering van de screening als een gelOndheidslOrg-
voorziening worden geevalueerd. Een continue evaluatie tijdens de uitvoering van een 
programma is nodig om de resultaten af te zetten tegen de verwachtingen en veran-
deringen in de klinische praktijk. Screening kent naast gunstige effecten ook nadelige 
effecten. Vooral de nadelige effecten maken evaluatie in deze verschillende fases van 
belang. In dit proefschrift worden delen van de evaluatie van zowel borstkanker als 
prostaatkanker beschreven. 
Borstkankerscreening is in Nederland en in sommige andere Europese landen 
reeds ge.,.ntroduceerd. In juni 1994 is een gerandomiseerd onderzoek gestart om de 
effectiviteit van screening 01' prostaatkanker aan te tonen. Dit resulteerde in een ander 
uitgangspunt voor de evaluatie van borstkankerscreening dan voor prostaatkanker. 
Hoewel de effectiviteit van borstkankerscreening was aangetoond in geran-
domiseerde studies en de kosten-effectiviteit was vastgesteld voor Nederland, kan de 
balans tussen positieve en negatieve effecten van de screening in andere landen anders 
uitpakken. Factoren die van invloed kunnen zijn 01' de kosten-effectiviteit van 
screening zijn bijvoorbeeld het niveau van incidentie en sterfte aan borstkanker, de 
klinische stadiumverdeling en de organisatie van de gelOndheidslOrg. In dit proef-
schrift zijn de effecten en kosten onderzocht van invoering van een screening-
programma in Duitsland en Spanje. 
In hoofdstuk 2 is dit voor Duitsland geevalueerd. Speciale aandacht werd besteed 
aan opkomst, screeningsinterval, leeftijdsgroep en aan de organisatie van de gezond-
heidszorg in relatie tot screening, die in Duitsland decentraal is. De analyse liet zien 
dat een screeningprogramma voor vrouwen van 50-69 met een interval van 2 jaar lOU 
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resulteren in een sterftereductie van 11 %, hetgeen overeenkomt met 2100 sterfgevallen 
per jaar. De kosten per gewonnen levensjaar waren echter 2 tot 3 keer hoger dan in 
Nederland en Engeland. De sensitiviteit van de mammografie was 12% lager dan in 
Nederland en de verwachte opkomst bedroeg slechts 47% (70~80% in Nederland). Een 
grotere inspanning om de kwaliteit van de screening te garanderen en de opkomst te 
verhogen tot de Nederlandse waarden, lOU kunnen leiden tot een sterftereductie van 
18% in Duitsland. 
De nadruk van de analyse van de effecten en kosten van screening in Spanje 
(Cataloni;;) lag 01' verschillende leeftijdsgroepen en screeningsintervallen (hoofdstuk 3). 
De uitkomsten dienden als basis voor een beslissing over de invoering van screening. 
Voar de leeftijdsgroep 50~64 zou een screeningsprogr~mma met een 1, 2 of 3 jaars 
interval resulteren in een sterftereductie van respectievelijk 16%, 12% en 9%. Het 
meest kosten~effectief was het programma waarbij de leeftijdsgroep 50~69 met een 3 
jaars interval gescreend werd. Screening tot 69 jaar met een 2 jaars interval was bijna 
even kosten~effectief als voor de leeftijdsgroep 50~64 en resulteerde in een sterfte~ 
reductie van 15%. Een uitbreiding naar onder de leeftijd 50 resulteerde in verschillende 
bevindingen afhankelijk van de aanname over effectiviteit van screening in dele 
leeftijdsgroep. Ais een uitbreiding van screening in de leeftijd van 50~64 wordt over~ 
wogen is het wenselijker naar oudere leeftijdsgroepen uit te breiden dan naar jongere. 
Hoewel screening met een 2 jaars interval in Nederland is geYntroduceerd voor 
vrouwen van 50~69 en sinds 1998 tot de leeftijd 75, wordt de evaluatie gecontinueerd. 
In die fase is, onder andere, de evaluatie van seclindaire effecten van screening van 
belang. In dit proefschrift is het risico van door straling geYnduceerde sterfte onder~ 
locht. Ook is het effect van het bevolkingsonderzoek in de leeftijdsgroep 50~69 01' het 
gebruik van mammografie via de huisarts buiten deze leeftijdsgroep bestudeerd. 
In hoofdstuk 4 is het effect van rontgenstraling van mammografie bestudeerd om 
het aantal verwachte voorkomen borstkanker sterfgevallen af te zetten tegen het aantal 
geYnduceerde gevallen ten gevolge van straling. Uit dit onderloek bleek clat cle balans 
gunstig uitviel voor de doelgroep van de screening (leeftijd 50~69, 2 jaar interval, 2 
mGy per opname). Het aantal verwachte voorkomen sterfgevallen bedroeg 242 
tegenover een geYnduceerd sterfgeval. Uitbreiding naar de leeftijclsgroep 40~49 
resulteercle in een minder gunstige balans, maar als aangenomen werd dat screening 
van jongere vrouwen even effectief is als van vrouwen van 50~69 jaar, werd de balans 
weer gunstiger. Ook toepassing van de recent verschenen schattingen van stralings~ 
risico van Howe en Mclaughlin resulteerde in een 5 tot 8 keer gunstiger balans. Naast 
leeftijdsgroep is stralingsdosis een andere belangrijke determinant van stralingsrisico. 
Geconcludeerd werd dat voor jongere vrouwen de balans minder gunstig is dan voor 
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vrouwen van 50-69 jaar. De betrouwbaarheidsintervallen zijn echter groot, omdat er 
veel onzekerheden zijn over stralingsrisico bij deze lage doses. 
Andere secundaire effecten van screening zijn de toename van mammografie 
buiten de doelgroep en een verandering in gedrag van de doelgroep. In hoofdstuk 5 is 
het effect van de invoering van het Nederlandse bevolkingsonderzoek 01' de 
hoeveelheid mammografie via de huisarts onderzocht in de leeftijdsgroepen 30-39, 40-
49, 50-69 en 70+. In aile leeftijdsgroepen werd een toename in mammografie via de 
huisarts waargenomen na het begin van het bevolkingsonderzoek in de leeftijdsgroep 
50-69. Twee jaar na de start, was het niveau van mammografie buiten de doelgroep 
echter weer gelijk aan het niveau van voor de start en in de doelgroep van de screening 
zelfs significant lager. De onverwachte toename zou kunnen worden verklaard door 
een probleem met de registratie of door de opbouw van de screening. De afname van 
mammografie via de huisarts in de doelgroep van de screening is waarschijnlijk een 
gevolg van het landelijke programma. Screening via de huisarts buiten de doelgroep 
werd niet duidelijk aangetoond. 
In dit proefschrift is ook een aantal studies uitgevoerd in relatie tot het Rotterdamse 
deel van de Europese gerandomiseerde studie naar screening op prostaatkanker. Het 
screeningprotocol werd onderzocht om de combinatie van screeningtesten te opti-
maliseren. Ook werd het gebruik van een test 01' Prostaat Specifiek Antigen (PSA) en 
rectaal toucher voor en tijdens deelnarne aan de screeningstudie onderzocht. Het 
laatste onderzoek in dit proefschrift beschrijft het beloop, de zorg en de kosten van 
gemetastaseerd prostaatkanker. 
De cornbinatie van de 3 screeningtesten (pSA-test, rectaal toucher en trans rectale 
ultrasonografie (TRUS» werd bestudeerd in hoofdstuk 6. Een waarde voor PSA van 
meer dan 4 nglml of een afwijking bij rectaal toucher of TRUS waren een indicatie voor 
biopsie bij het begin van de studie. Ten eerste werd het effect van een verandering in 
de afkapwaarde van PSA bepaald. Bovendien werd een logistisch regressie model 
gebruikt orn het aantal verwachte kankers te berekenen in het geval aile mannen 
zouden zijn gebiopteerd. Biopten onder een PSA van 1 nglml waren erg inefficient. Een 
toename in PSA afkapwaarde naar 1,5 nglml of 2 nglml zou resulteren in 5 tot 8% 
minder ontdekte turnoren, rnaar ook tot een afname van 29 tot 36% biopsieen. Een 
protocol waarbij iedereen (dus onafhankelijk van de bevindingen bij rectaal toucher 
en TRUS) werd gebiopteerd met een PSA waarde van meer dan 3 nglrnl zou resulteren 
in 7,6% minder kankers en 12% minder biopten. Gegeven deze resultaten en het feit 
dat rectaal toucher en TRUS moeilijk te reproduceren waren, leek een protocol met een 
biopsie voor iedereen met een PSA groter dan 3 nglml acceptabel. Bij dit protocol 
konden ook het rectaal toucher en de TRUS achterwege blijven. Ais screening effectief 
157 
Samenvatting 
blijkt te zijn om sterfte aan prostaatkanker te verminderen, moet weer een beoordeling 
van de meest gunstige combinati.e van screeningtesten plaatsvinden. 
Een PSA bepaling is een zeer eenvoudige test, waardoor deze mogelijk op grote 
schaal zal worden toegepast. Dit kan de uitkomst van de Europese studie naar het effect 
van screening op vrostaatkankersterfte beYnvloeden. In hoofdstuk 7 is het gebruik van 
testen, zoals rectaal toucher en PSA voor en tijdens de gerandomiseerde screening-
studie en in de algemene populatie in kaart gebracht. Op basis van de gegevens van de 
vragenlijst, die bij deelname was ingevuld, is het gebruik van deze testen voor 
deelname aan de screeningstudie gekwantificeerd. Data van de deelnemers in de studie 
werden gekoppeld aan data van het huisartsen laboratorium, waarmee het gebruik van 
PSA tijdens de screeningstudie, van zowel de screening- als de controlegroep, kon 
worden vastgesteld. Voor het vaststellen van PSA en rectaal toucher in de algemene 
populatie werden verschillende bronnen gebruikt, waaronder gegevens van een 
zorgverzekeraar. Gemiddeld had 45% van de mannen een rectaal toucher ondergaan 
voor deelname aan de screeningstudie en 13% een PSA test. Deze percentages namen 
toe met de leeftijd. Er kon echter geen effect van deze testen op de kankerdetectie 
tijdens de studie worden waargenomen. Het aantal PSA testen tijdens de studie was 
ongeveer twee keer zo hoog in de controlegroep als in de screeninggroep (76/1000 en 
33/1000 per jaar). In de screeninggroep werd na deelname eerst een afname in het 
aantal PSA testen waargenomen, maar na ongeveer 6 maanelen weer een toename. Het 
aantal PSA testen in de algemene bevolking werd geschat op 45/1000 per jaar. 
Geconcludeerd werd dat het gebruik van PSA testen tijdens de stuclie matig was, maar 
als ieder jaar andere mannen deze test ondergaan, zou het percentage contaminatie 
hoog kunnen zijn gedurende het interval van 4 jaar. In de definitieve steffte-analyse 
moet contaminatie in beschouwing worden genomen. Inzicht in de motieven en 
uitkomsten van de PSA testen zou nuttig zijn voor aanvullende interpretatie. 
Indien prostaatkankerscreening effectief blijkt in het voorkomen van sterfte ten 
gevolge van deze ziekte, zal een dee I van de patienten het gemetastaseerde stadium 
van prostaatkanker niet meer doonnaken. Bij de evaluatie van screeningprogramma's 
moet elit in beschouwing worden genomen en is het van belang het beloop, de zorg en 
de daarmee gepaard gaande kosten in kaart te brengen. In hoofdstuk 8 zijn 70 statussen 
bestudeerd van patienten met gemetastaseerd prostaatkanker, die waren gestorven in 
de jaren 1994-1998. De totale zorg inclusief symptomen en klachten werden 
geregistreerd. De meest frequent gerapporteerde symptomen waren pijn (42%), 
urogenitale klachten (25%) en malaise (20%). Van de patienten werd 89% hormonaal 
behandeld en 47% onderging een of meerdere series van bestraling. 69% van de 
patienten werd behandeld met pijnmedicatie. De gemiddelde duur van gemetastaseerd 
prostaatkanker was 24 maanden. De gemiddelde kosten van het gemetastaseerde 
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stadium van de ziekte bedroeg $ 11,182, waarvan 14% werd besteed aan diagnostiek 
en poliklinische zorg en 86% aan behandeling en ziekenhuisopnames. Deze studie 
heeft bijgedragen aan een duidelijker beeld van het beloop en de kosten van 
gemetastaseerd prostaatkanker. Deze schattingen kunnen in de toekomst worden 
gebruikt bij de verdere evaluatie van prostaatkankerscreening. 
In hoofdstuk 9 wordt een aantal toekomstige uitdagingen ten aanzien van de 
evaluatie van borst- en prostaatkankerscreening samengevat. Voor borstkanker bestaan 
deze uitdagingen uit nieuwe ontwikkelingen in diagnostiek, primaire preventie en uit 
de evaluatie van de screening. Voorbeelden zijn digitale mammografie, dunne naald 
biopsie en het gebruik van tamoxifen om borstkanker te voorkomen. Uitdagingen voor 
de screeningevaluatie van het huidige borstkanker screeningprogramma zijn screening 
van jongere (40-49) en oudere vrouwen (70 +), het vaststellen van de sterftereductie ten 
gevolge van een ingevoerd screeningprogranl'na en de vraag of het huidige bevolkings-
onderzoek verbeterd kan worden. 
De belangrijkste vraag waar de evaluatie van de prostaatscreeningstudie antwoord 
op moet geven is de prostaatkanker sterftereductie. Andere effecten, zoals bijvoorbeeld 
de kwaliteit van leven, moeten ook worden gekwantificeerd om een evenwichtig 
oordeel te kunnen geven over de balans tussen gunstige en ongunstige effecten. De 
uitdagingen van de evaluatie bestaan met name uit het vaststellen van de effectiviteit 
van prostaatkankerscreening en de ondersteuning van de beslissing over de invoering 
van een programma. 
Screening is altijd een balans tussen gunstige en ongunstige effecten. Deze balans 
moet in beschouwing worden genomen geclurende de evaluatie van een screening-
stuclie naar de effectiviteit, gedurende de mogelijke invoering en gedurende de 
uitvoering van screeningprogramma's. Het is duidelijk dat de nutlrisico-verhouding van 
kankerscreening kan veranderen ten gevolge van bijvoorbeelcl verbeteringen in 
testeigenschappen, diagnose of therapeutische mogelijkheden. Dit maakt continue 
oplettendheid nodig om het programma aan te passen, opdat de meest optimale 
resultaten worden bereikt. Het ideaal is zonder twijfel om effectieve vormen van 
prirnaire preventie of behandeling te vinden, waardoor screening overbodig wordt. 
159 

LIST OF PUBLICATIONS 
This thesis 
Chapters 2 to 8 are based on the fol/olVing papers and manuscripts: 
Beemsterboer, r.M,M" de Koning, H.J., Warmerdam, P,G., Boer, R., Swart, E., Dierks, M-l., 
Robra B-P" Prediction of the effects and costs of breast-cancer screening in Germany, Int J 
Cancer, 58, 623~628 (1994).' 
Beemsterboer, Y.M.M" Warmerdam, P.G., Boer, R., Borras, J. M' I Moreno, V., Vilac!iu, P., de 
Koning, H.)., Screening for breast cancer in Catalonia, which policy is to be preferred? fUr J 
Public Neallh, 8, 214~246 (1998)' 
Beemsterboer, P.M.M., Warmerdam, P.G., Boer, R., de Koning, H.J., Radialion risk of 
mammography related to benefit in screening programmes: a favourable balance? J Med Screen, 
5, 81~87 (1998).' 
Beemsterboer, r.M.M., de Koning, H.J" looman, C.W.N., Borsboom, C.j.j.M., Bartelds, I.A,M' I 
van def Maas, P.)., Mammography requests in general practice during the introduction of 
nationwide breast-cancer screening, 1988-1995, fur J Cancer, 35, 450-454 (1999).3 
Beemsterboer, P.M.M" Kranse , R., de Koning, H.)., Habbema, ).D.F., Schroder, F.H., Changing 
role of 3 screening modalities in the European Study of Screening for Prostate Cancer 
(Rotterdam), Int J Cancer (in press).1 
Beemsterboer, P.M.M., de Koning, H.J., Kranse, R., Trienekens, P.H., van cler Maas, P.J., 
Schroder, F.H., PSA-testing and use of DRE before and during a randomised trial of screening for 
prostate cancer (ERSPC, Rotterdam), (submitted). 
Beemsterboer, P.M.M., de Koning, H.J., Birnie, E., van der Maas, P.)., Schroder, F.H., Advanced 
prostate cancer: course, care and cost implications, the Prostate (in press). 1 
Reproduced with permission from: 
, J. Wiley & Sons, Inc. 
2 Oxford University Press 
3 Elsevier Science 
, BMJ Publishing GrollI' 
161 
List of publications 
Other scientific publications 
Boer, R., de Koning, H.J" Beemsterboer, P,M., Warmerdam, P,G. and Schroder, F.H., A 
comparison of disease specific survival of patients who died of and who had newly diagnosed 
prostate cancer. J Urol, 157, 1768-71; discussion 1771-2 (1997). 
Borras, J.M., Espinas, J.A., Beemsterboer, P.M.M., Granados, A. and de Koning, H.J., Anticipating 
the consequences for the primary therapy of breast cancer after introducing screening, A Illore 
global picture for health care policy making. Int J Technol Assess Healrl, Care, 14, 268-76 
(1998). 
de Koning, H.J., Boer, R., \"Iarmerdam, P.G., Beemsterboer, P.M.M. and van der Maas, P.J., 
Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-
screening trials [see comments]. J Naif Cancer Insl, 87, 1217-23 (1995). 
Fracheboud, J., de Koning, H.J., Beemsterboer, P.M.M, Boer, R., Hendriks, J.H., Verbeek, A.L., 
van [neveld, B.M., de Bruyn, A.E. and van der Maas, P.J., Nation-wide breast cancer screening in 
The Netherlands: results of initial and subsequent screening 1990-1995. Nationaf Evaluation 
Team for Breast Cancer Screening. 1m J Cancer, 75, 694-8 (1998). 
Fracheboud, J., de Koning, H.J., Beemsterboer, P.M.M., Boer, R., Verbeek, A.L.M., Hendriks, 
J.H.C.L., van Ineveld, B.M. Broeders, M.J.M., de Bruijn A.E., and van der Maas, P.J., IntelVal 
cancers in the nationwide breast cancer screening programme in the Netherlands. submit/ed 
(1999). 
Kranse, R., Beemsterboer, P.M.M., Rietbergen, J.B.\I\I., Habbema, J.D.F., Hugosson, J. and 
Schroder, F.H., Predictors for biopsy outcome in the European Randomized Study of Screening 
for Prostate Cancer (Rotterdam region). the Prosrale (accepted for publication). 
Schroder, F.H., van der Maas, P., Beemsterboer, r.M.M., Kruger, A.B., Hoedemaeker, R. t 
Rietbergen, J. and Kranse, R., Evaluation of the digital rectal examination as a screening test for 
prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate 
Cancer [see comments]. J Natl Cancer lost, 90, 1817-23 (19981. 
Warmerdam, P.G., de Koning, H.J., Boer, R., Beemsterboer, P.M.M., Dierks, M.L, Swart, E. and 
Robra, B.P., Quantitative estimates of the impact of sensitivity and specificity in mammographic 
screening in Germany [see comments]. J Epidemiol Community Health, 51, 180-6 (1997). 
162 
DANKWOORD 
Na een rustig begin, raakte ik bij het schrijven van dit proefschrift in steeds sneller 
vaarwater. In het begin deed ik onderzoek am te beoordelen of ik wei onderzoeker 
wilde zijn. Vervolgens nam de stroom mij mee en kwamen er nieuwe projecten en 
uitdagende taken bij. Het eindigde als een waterval, door in snel tempo twee artikelen, 
inleiding en discussie van dit proefschrift af te ronden. Hier het resultaat! 
Veel mens en hebben direct of indirect bijgedragen aan het tot stand komen van dit 
proefschrift en aan hen wil ik graag woorden van dank wijden. Ten eerste aan mijn co-
promotor Harry de Koning. Vanaf het begin was jij mijn directe begeleider. De ins en 
outs van de (klinische) screeningspraktijk heb jij me bijgebracht en aile stukjes die ik 
geschreven heb zeker 2 keer gelezen (als het niet meer is). Verder bedank ik je voor 
jouw nooit aflatende optimisme. Vooral in het laatste jaar heeft dat zo nu en dan 
gezorgd voor een flinke oppepper. 
Paul van der Maas wilde meestal op het laatste moment een blik werpen op het 
door mij geleverde werk. Paul, jouw commentaar heeft iedere keer tot een significante 
verbetering van mijn stukken geleid en daarom ben ik erg blij dat je ernaar gekeken 
hebt. 
Met Peter Warmerdam mijn kamergenoot en onderzoeksmaatje van de eerste 
jaren heb ik altijd met veel plezier samengewerkt. De eerste 3 artikelen van dit 
proefschrift zijn een co-productie van jou en mij geweest. Tegen jou kon ik, in het 
wilde weg mijn gedachten spuien en we kwamen tel kens wei tot een aanvaardbare 
oplossing voor de obstakels in het onderzoek. 
Voor de echt moeilijke dingen was daar Rob Boer. Rob, ik bewonder jouw 
onderzoekskwaliteiten en waardeer dat je mijn 'problemen' altijd zeer serieus nam en 
zeer snel een oplossing wist aan te dragen. Ik heb veel van je geleerd! 
Met Mark Wildhagen, m'n kamergenoot gedurende de hele MGZ-periode (bijna 6 
jaar) heb ik heel wat lief en leed gedeeld. Hoewel we erg verschillende personen zijn, 
163 
Dankwoord 
kon ik altijd mezelf zijn en even m'n ei kwijt over het werk, maar ook prive. Dank 
daarvoor. De laatste peri ode hebben we ook samengewerkt aan de prostaatscreening, 
clat na zo'n lange 'inwerkperiode' prima verliep. 
Arry de Bruyn, de duizendpoot voor Harry, maar ook voor de LETB en voor mij. 
Hartelijk dank voor aile klussen die je altijd goedgehumeurd voor me hebt gedaan en 
voor je oprechte belangstelling in mij als persoon. Ik heb dat beide altijd erg 
gewaardeerd. Soms helpt dat om op de been te blijven! 
Met Ries Kranse van urologie heb ik heel wat discussies gevoerd over screening 
en het verloop van het project. Bovenciien kon ik voor ingewikkelde koppelingen en 
andere automatiseringskwesties altijd direct bij jou terecht. Beide zorgden voor nieuwe 
motivatie. 
Professor Schroder bedank ik voor de mogelijkheden om in samenwerking met 
urologie bepaalde deelaspecten van de screening 01' prostaatkanker te onderzoeken. 
Uw snelle en positieve reacties op de manuscripten werkten inspirerend. 
AI mijn co-auteurs (18 in totaai) bedank ik voor het commentaar op m'n artikelen. 
Dat heeft zeker tot verbeteringen geleid! 
Ik bedank ook aile andere collega's van MGl. Aan de periode 01' MGl heb ik vee I 
positieve en leuke herinneringen overgehouden. Bij MGl wordt 01' een of andere 
manier geselecteerd 01' mensen waarmee het prima werken is! Het 25-jarig jubileum 
van MGl was voor mij een hoogtepunt. Ik ben nog steeds blij dat ik voor het cabaret in 
het achtergrondkoor heb mogen optreden. 
Door MGl heb ik zelfs 5 goede vriendinnen overgehouden! Deze 'mutsen' 
hebben bijgedragen aan heel wat 101 tussen de artikelen, analyses en vergaderingen 
door. De wandelvakantie in Wales was een kroon 01' het werk! Helaas laat ik het de 
komende vakantie afweten, maar ik weet zeker dat we elkaar nog heel vaak zullen 
opzoeken om, onder het genot van een flesje wijn, onze ervaringen uit te wisselen! 
Caroline Baan, een van mijn paranimfen (en een van de mutsen), bleef met mij, 
als laatste van de mutsen over op MGl. In die periode heb jij mij heel erg geholpen de 
lijn en voortgang in hel werk te blijven zien. Bovendien wisselden we iedere dag ons 
wei en wee even uit, wat een goed en inspirerend begin van de werkdag was! Hoewel 
niet meer lijfelijk aanwezig hoop ik voor jou ook tot steun te zijn in de laatste fase; 
succes met de laatste loodjes! 
Hester de Melker, mijn andere paranimf, bedankt voor aile steun en aile gezel-
ligheid! Dat wat jij voor mij hebt belekend is moeilijk in woorden uit te drukken. Ais 
vakgenoot weet je precies wat het is om een proefschrift Ie schrijven en als vriendin 
kon ik altijd met alles bij je terecht (en dat was niet gering de afgelopen tijci!). Dat heeft 
me vaak door Illoeilijke tijden gesleept. Door je grote relativeringsvermogen (dat het bij 
164 
Dankwoord 
nog wei eens laat afwetenl zorgde je er vaak voor dat ik het allemaal weer een stuk 
positiever zag. Ook veel succes met de afronding van jouw proefschrift! 
Ik dacht, als ik de dankwoorden van andere promovendi las over verwaarlozing 
van vriendschappen, dat dat mij niet zou overkomen. Een proefschrift schrijven is wei 
belangrijk, maar er zijn ook veel andere belangrijke zaken in het leven. Nu ontkom ik 
zelf toch niet aan het feit dat ik mijn vrienden en familie de laatste tijd wei een stuk 
minder aandacht heb gegeven dan ik zou willen. Ik verwacht dat, nu dit werk er bijna 
opzit, ik weer mijn volle aandacht aan jullie kan besteden. De basis is volgens mij 
zodanig, dat we weer 01' de oude voet verder kunnen gaan! Ik kijk ernaar uit! 
Mijn ouders bedank ik voor de vrijheid die ze me altijd hebben gegeven om te 
doen wat ik graag wilde en voor het onvoorwaardelijke vertrouwen in mijn beslis-
singen en keuzes. Mijn zus, Carolien heeft de voorkant geschilderd en voor dit proef-
schrift bewerkt. Ik be.) heel blij met het resultaat! 
Als laatste bedank ik Reijer, al was hij 'aileen' tot steun bij de laatste loodjes. We 
gaan het avontuur tegemoet; ik heb er zin in! 
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